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Abstract
Quartromicin (QMN), derived from Amycolatopsis orientalis Q427-8, are a complex of novel an-
tiviral antibiotics active against HSV-1, HIV and influenza. Their biosynthesis involves a type I
polyketide synthase (PKS), proposed to implement a module skipping strategy that produces two
different precursors (Figure 1). A series of Diels-Alderase reactions, followed by oxidation and
glycosylation, leads to QMN biosynthesis. Determining how this module skipping mechanism
works would greatly increase the understanding of how modules within PKSs can be relocated to
facilitate PKS engineering.
Figure 1. The final three modules of the biosynthetic PKS pathway for quartromicin PKS and the resulting precursors.
It was shown that module 5 (M5) can accept substrates from the upstream modules’ acyl carrier
protein (ACP) domains (M3 ACP and M4 ACP) and utilise malonyl-CoA to catalyse substrate
extension. Substrate specificity did not appear to be a factor in maintaining pathway fidelity.
M3 ACP was observed to have a quicker rate of acyl transfer to M5 than M4 ACP and stronger
protein-protein interactions (KD: 1.3 v 4.0 µM). Removal of M3 ACP’s C-terminal docking domain
resulted in slower transfer and weakening of protein-protein interactions (KD: 2.6 µM). There was
no significant change in rates of transfer or strength of interactions when the docking domain was
omitted from M4 ACP. Sequence analysis of the docking domains highlighted the omission of a
widely conserved negative residue from M4’s ACP docking domain, perhaps explaining the re-
duced efficiency.
A loss of dimerisation and functionality was noted in M5 constructs lacking an AT-ACP linker
region. Comparison with other spirotetronate PKS modules identified similar regions in ChlA6
and KijS5, predicted to be remnants of KR domains. Creation of truncated constructs allowed
the identification of an α-helix essential in module dimerisation and suggested a dimerisation
motif was located towards the C-terminal of the linker. Cryo-EM of M5 showed a large dimer
interface between the KS domains of two modules and a second contact region, likely to be the
aforementioned dimerisation motif.
xiv
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Chapter 1
Introduction
1.1 Natural products
1.1.1 The history of natural products
Natural products have been used as therapeutic remedies for millennia. Indigenous cul-
tures were able to utilise the remedial properties of many organisms to create the first
crude drugs, although these shamanistic cultures attributed the health benefits to magic.
This primitive belief was held until civilisations began to develop a deeper scientific un-
derstanding of medicine. The Huangdi Neijing, an ancient Chinese text likely originating
from before the Han dynasty (∼ 210 BC), was one of the earliest books to link health and
the progress of disease to the environment, poor diet and hereditary factors.1 In addition,
this text also refers to numerous natural remedies and their benefits in preventing and
curing disease. Thenceforth, the development of pharmaceuticals has been closely linked
to pharmacognosy. This can be seen in Arabic, Greek and Roman medical texts such as
De Materia Medica (1 BC), which documents over 600 medicinal plants and their applica-
tions.2 The dissemination of knowledge throughout Europe led to further developments
by apothecaries, such as Nicholas Culpeper (1616 - 1654), and the establishment of guilds
with the purpose of cultivating plants for medicinal purposes.
It was not until 1817 that an active principle was purified from a natural source when
Friedrich Sertu¨rner isolated morphine from Papaver somniferum (opium poppy).3 Later,
in 1828, Johann Buchner isolated salicin from willow bark,4 which subsequently led to
Bayer deriving the analogous drug, aspirin.5 The first antibacterial natural product was
later discovered when Alexander Fleming accidentally developed mould on plates con-
taining Staphylococcus aureus and noticed that the colonies around the mould had been
destroyed.6 Penicillin was subsequently isolated from the mould and shown to be the
active principle with activity against Staphylococcus aureus. The following period resulted
in a golden age of drug discovery,7 with many natural products being identified and de-
veloped into drugs (Figure 1.1). These natural products and natural product derivatives
include a wide range of antibacterials (colistin, ampicillin, vancomycin, rifamycin),8–11
anticancer agents (vincristine, doxorubicin)12;13 analgesics (morphine, oxycodone)14 and
antimalarials (quinine, proguanil).15
Despite the rise in the number of synthetic drugs entering the market, natural products
2
Figure 1.1. Examples of natural products and natural product derivatives with antibacterial, anticancer, analgesic and
antimalarial properties.
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have remained an important source of novel drug discovery.16 34% of medicines ap-
proved by the US Food and Drug Administration (FDA) between 1981 and 2010 were
natural products or natural product derivatives.17 Furthermore, with less than 1% of the
microbial community estimated to have been cultured in a lab,18 natural products will
remain an abundant source of pharmaceuticals for years to come.
1.1.2 Antimicrobial resistance
Although a large number of antimicrobials are available, antimicrobial resistance (AMR)
is an increasing problem. It is now thought that over 70% of pathogenic bacteria are re-
sistant to at least one antibiotic.19 With globalisation increasing the spread of diseases, it
is now more imperative than ever to produce novel drugs. This has lead to the World
Health Organisation (WHO) categorising AMR as a serious threat to global public health
and stating that it requires action across all sectors of government and society.20
For example, colistin (also known as polymyxin), discovered in the 1940s,8 was rarely
used due to a number of negative side-effects and remained an effective last resort an-
tibiotic. However, over the past few years, numerous cases of genes that confer colistin
resistance through horizontal gene transfer have been found, including cases in the UK
and US.21
1.2 Polyketide synthases
Many pathways exist that contribute towards the production of natural products, in-
cluding non-ribosomal peptide synthetase (NRPS),22–25 fatty acid synthase (FAS)26;27 and
polyketide synthase (PKS).28 The structurally diverse PKSs are a family of multi-enzyme
biosynthetic assembly lines that produce secondary metabolites, known as polyketides.29
4
Figure 1.2. Examples of natural products produced by polyketide synthase pathways. Linear polyketides (top) differ
from macrolides (bottom) as the polyketide does not form a macrocycle.
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1.2.1 Polyketides
Polyketides form one of the largest groups of natural products and have a very diverse
range of biological activities (Figure 1.2).30–32 The first polyketides to be discovered were
linear, such as lovastatin (lowers cholesterol)33 and resveratrol (dietary supplement).34 In
1949, a second class was discovered35 when pikromycin was isolated from Streptomyces
venezuelae.36 Pikromycin was categorised as a macrolide, as it contains a macrocyclic lac-
tone ring. Since pikromycin’s discovery, numerous other macrolides with varying activ-
ities have been isolated, such as gladiolin (activity against Mycobacterium tuberculosis)37
and erythromycin (activity against Staphylococcus aureus and Haemophilus influenzae).38–40
Despite their expansive structural diversity and range of biological activity, polyketides
are all derived primarily from acyl and (methyl)malonyl thioester building blocks that
undergo a series of decarboxylative Claisen condensations catalysed by a polyketide syn-
thase (PKS).
1.2.2 Polyketide synthase classification
Functional differences have led to PKSs being separated into three distinct classes: types
I, II and III.41 Type I PKS are large multifunctional protein complexes that are organised
into modules.42 Each module contains the enzymatic machinery required for one elonga-
tion step, as well as any additional domains such as a ketoreductase (KR),43 dehydratase
(DH) or an enoyl-acyl carrier protein reductase (ER).44;45 Further subdivision of type I
PKSs will be discussed in section 1.2.4. Type II PKS consist of an aggregate of monofunc-
tional proteins that adopt an iterative mechanism.46 Minimal type II PKS modules are
comprised of two ketosynthase (KS) domains and an acyl carrier protein (ACP), with fur-
ther optional reductive domains, cyclases (CYC) and aromatases (ARO) present in non-
minimal modules.47 Type III PKS contains a single protein able to catalyse a series of
condensation reactions directly from an acyl-CoA substrate to generate a polyketide.30;48
Although the vast majority of type III PKSs are found in plants, examples have also been
found in bacteria and fungi.49
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1.2.3 Polyketide synthase domains
ACPs are the central component of both type I and type II PKS modules and contain four
conserved helices that display a high degree of conformational flexibility.50 They play a
vital role in the translocation of polyketide chains between modules and are known to
interact with over thirty different enzymes.51;52 The first ACP was structurally charac-
terised in 1988,53 showing the first long conserved helix to run antiparallel to helix 2 and
3. Further solved structures showed a fourth shorter helix is usually present with varying
orientations (Figure 1.3).54 The second helix and the shorter fourth helix form a hydropho-
bic pocket. A conformational equilibrium was noted for a number of ACPs55, with the
first conformation seeming to allow the polyetide chain to residue in the hydrophobic
pocket to protect the polyketide chain from hydrolysis. The second conformation allows
the polyketide chain to withdraw from the hydrophobic pocket and to be processed by
partern enzymes.56;57
Figure 1.3. Solution NMR structures of ACPs from modular type I PKSs (PDB: 5hv8, 2mvu, 2n98, 2n50, 5hvc, 1acp
and 2ju2). Helices 1, 2 and 3 are labelled.
In nature, each ACP is in its holo-form,58 meaning a phosphopantetheine arm (Ppant) is
attached to the substrate attachment site (serine residue, Figure 1.4 (a)).59 The Ppant arm
is approximately 20 A˚ in length, allowing the ACP to interact with the module’s other
domains, before transferring the nascent chain to a downstream module.60–62
Type I PKS pathways commonly start with a loading module containing an acyltrans-
ferase (AT) and ACP domain.63 A KS domain that does not sequester a polyketide, due to
the replacement of a conserved active site cysteine with a glutamine, may also be present
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(KSQ).64 AT domains (∼ 420 residues) consist of two subdomains: a large hydrolase core,
and a smaller ferredoxin-like subdomain. A catalytic serine residue, located in the chan-
nel between the two subdomains, attacks the thioester bond of a CoA-bound starter unit
before the terminal thiol group of the adjacent ACP’s Ppant arm attacks the resulting ester
bond. This thioester exchange reaction results in the transacylation of a starter unit onto
the ACP’s Ppant appendage (Figure 1.4(b)).65
Downstream of the loading module are a series of modules that extend and modify the
starter unit to produce a polyketide. Theminimal set of enzymes required for a type I PKS
module to extend a polyketide are the KS, AT and ACP domains, which are collectively
responsible for chain elongation.66 The AT catalyses transacylation of an extender unit,
usually (methyl)malonyl, onto the terminal thiol of the ACP’s Ppant appendage using the
same mechanism as in the loading module (Figure 1.4(c)).67 KS domains (∼ 430 residues)
contain a conserved thiolase fold (2α5β2α5β2α) that forms the domains central core.68–70
The thiol of the KS’s catalytic cysteine residue attacks the thioester of the upstream ACP-
bound intermediate, resulting in a new thioester bond to the KS (Figure 1.4(d)). The KS
bound polyketide and the (methyl)malonyl extender unit tethered to the intramodular
ACP then undergo a decarboxylative Claisen condensation, resulting in the transfer of
the polyketide from the KS to the intramodular ACP and an extension of the chain by
two carbons.
The additional presence of optional reductive domains in each module adds diversity to
the produced polyketides. KR domains (∼ 440 residues) contain two subdomains, both
similar to a short-chain dehydrogenase/ reductase.71 One subdomain contains a trun-
cated Rossmann fold and only plays a role in maintaining the structural integrity of the
KR. The second subdomain catalyses the stereoselective NADPH-dependent reduction of
the β-keto group to a β-hydroxy (Figure 1.4(e)). KRs can be categorised into three distinct
subclasses. A-type KRs, containing a conserved tryptophan residue, result in the pro-
duction of a L-3-hydroxyacyl intermediate and B-type KRs, containing a conserved LDD
motif, result in the production of a D-3-hydroxyacyl intermediate. It is proposed that the
different stereochemistry is achieved by the A and B-type KRs guiding the substrates to
the active site from opposite directions.72;73 C-type KRs are catalytically inactive.
DH domains (∼ 280 residues) contain a double hotdog fold (3βα4βα3βα4β)74 that forms
a tunnel that the substrate must enter to access the active site.75 The active site contains
8
Figure 1.4. (a) The conversion of apo-ACP to holo-ACP, (b) the mechanism of a PKS loading module and the function
and mechanism of PKS domains; (c) acyltransferase (AT), (d) ketosynthase (KS), (e) ketoreductase (KR), (f) dehydratase
(DH), (g) enoyl reductase (ER) and (h) thioesterase (TE).
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conserved histidine and aspartic acid residues that catalyse dehydration of the hydroxy-
acyl intermediate to produce an α,β-unsaturated acyl intermediate (Figure 1.4(f)).
The presence of an ER domain (∼ 310 residues), containing both catalytic and struc-
tural subdomains, can catalyse the NADPH-dependent reduction of the C=C bond (Fig-
ure 1.4(g)). This reaction is hypothesised to be reliant on a proton being provided by a
tyrosine residue in the ER active site.76
Other domains may also be present, including a methyltransferase (MT). MTs utilise S-
adenosyl methionine (SAM) to transfer a methyl group onto the α-position of the polyke-
tide (Figure 1.5).77
Figure 1.5. The mechanism of an MT domain loading a methyl group to the α-position of a polyketide chain.
Once all rounds of chain extension have been completed, cleavage of the natural prod-
uct from the PKS enzymes occurs. This is commonly catalysed by a thioesterase (TE, ∼
270 residues) that is present at the C-terminal of the final PKS module, either through
hydrolysis or cyclisation (Figure 1.4(h)). The released chains are often precursors to the
final natural product, with post-PKS tailoring enzymes catalysing further modifications,
such as hydroxylations, glycosylations and methylations.78 In addition, acyltransferase-
like enzymes fulfill housekeeping/proofreading roles by removing abherrant polyketides
from the PKS pathway through hydrolysis.79
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1.2.4 Subdivisions within type I polyketide synthases
Figure 1.6. Mevastatin is produced by an iterative PKS that uses malonyl-CoA extender units. In each catalytic cycle,
different levels of reduction occur depending on which domains act on the nascent chain.
Type I PKS systems may either be categorised as iterative or modular.80 Iterative PKS
systems contain a module with the ability to catalyse repetitive elongations and modi-
fications. In each catalytic cycle, different domains modify the polyketide chain, result-
ing in varying levels of reduction.81 One example of an iterative PKS is the enzyme in
mevastatin production (Figure 1.6), in which the KS, AT and KR domains are utilised
in each of the eight catalytic cycles. The DH domain is employed in all but two cycles,
resulting in the presence of two hydroxyl groups, whilst the ER domain is only utilised
four times, resulting in the presence of C=C bonds82 that undergo a Diels Alder reac-
tion to form the cyclised core.83 In addition, the MT domain creates the methyl-branch of
the α-methylbutyryl ester moiety. A condensation (C) domain, commonly found in non-
ribosomal peptide synthetase (NRPS),22 is also present and likely plays a role in polyke-
tide chain release.
In contrast, modular PKSs utilise numerous modules to extend and modify a polyke-
tide product, with each module typically catalysing one round of chain extensions.85
The archetypal example of a modular PKS is 6-deoxyerythronolide synthase (DEBS),86–89
which utilises six methylmalonyl and one propionyl building block to produce a precur-
sor to erythromycin A (Figure 1.7).84;90
Modular type I PKSs may be further categorised into either cis- or trans-AT systems. In
cis-AT PKS, such as DEBS PKS, every module contains an AT domain, whereas trans-AT
PKS’s modules use stand-alone AT domains which service multiple modules.91;92 Hybrid
PKS systems also exist, such as enacyloxin, with some modules containing an AT domain
and others employing a stand-alone AT.93;94
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Figure 1.7. The DEBS PKS pathway and the post-PKS tailoring enzymes that act upon the resulting precursor,
resulting in the production of erythromycin A.84
1.2.5 Discovering polyketide synthases and product pre-
diction
Type I modular PKSs generally follow the colinearity rule, meaning the domains are
utilised in the order they are encoded in the genome.95 Since sequence similarity is highly
conserved amongst PKS domains, their activities including extender unit selection,96 ste-
rochemistry97 and catalytic functionality,98 can often be predicted by sequence compar-
isons. This makes it possible to identify the PKS likely responsible for the production of
a particular polyketide metabolite by analysis of genomic DNA.99
Although this should mean the product of a PKS can be predicted based on sequence
analysis, in reality, the polyketide product is not necessarily dictated by the order of
the PKS encoding genes in the cluster. This is the case in calcimycin PKS, where the
final module is encoded by a gene located before the gene that encodes the two up-
stream modules in the cluster.100 In addition, domain/module skipping and stuttering
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Figure 1.8. Schematic depiction of possible modular PKS module skipping and stuttering mechanisms.
provide interesting scenarios where modules may either be bypassed or catalytically
modify the polyketide multiple times (Figure 1.8).101;102 An example of module skipping
is in pikromycin/methymycin PKS from Streptomyces venezuelae,103 where two different
ACPs can interact directly with a TE. This creates the possibility of chain termination oc-
curring before the final modification and extension is catalysed by the stand-alone final
module (Figure 1.15).104
1.2.6 Dimerisation interfaces for polyketide synthase sub-
units
Figure 1.9. Schematic representation of porcine FAS
Previously, the understanding of type I PKSs was based upon the organisation of FAS
modules, which shares many of the same domains as PKS due to their intertwined evolu-
tionary history.105;26;106 FAS may either be type I, common in fungi and mammalian cells,
or type II, common in archaea and bacteria. Type I FAS consist of large multifunctional
polypeptides, whereas type II FAS use discrete monofunction enzymes.107 Structural elu-
cidation of FAS domains through X-ray crystallography was successful for all common
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domains, including a 4.5 A˚ structure of a full-length FAS (Figure 1.9). The solving of
crystal structures of a KS-AT didomain, DH, ER-KR and a TE, as well as an NMR struc-
ture of an ACP, provided a vital insight into the boundaries of domains within PKSs, as
well as highlighting common differences between the domain organisation of PKS and
FAS systems. Further acquisition of domain/didomain structures showed AT, KR, ER
and ACP domains to be commonly monomeric, allowing the flexibility for the conforma-
tional changes required for PKS functionality (Figure 1.10).33;71;76;108–117
Figure 1.10. Crystal structures of a KS-AT didomain (PDB: 2HG4), DH (PDB: 3KG7), KR-ER (PDB: 3SLK) didomain,
TE (PDB: 1KEZ) domain and a DE-KR complex (PDB: 4IMP) , and an NMR structure of an ACP (PDB: 2JU2). 118
In archetypal type I PKS systems, the dimerisation of modules is predominantly due to
the KS, which often has a large dimeric interface (Figure 1.11).74 The only other domains
that commonly make contact intramodularly are the DH and TE domains, both of which
have a much smaller interface than the KS domains.75 Each dimerising surface contains
highly conserved accessory motifs.
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Figure 1.11. A schematic representation of a type I multimodular PKS (spinosyn). 76;119 Linkers are shown in grey. 120
An additional dimerisation element (DE) exists in approximately 50% of β-modules.121
Located between the C-terminus of an AT and the N-terminus of a KR, these highly con-
served ∼ 55 residue DEs have been shown to facilitate modular dimerisation.122
1.2.7 The overall architecture of polyketidemegasynthases
Although structures of PKS regions were obtainable through NMR and X-ray crystallog-
raphy, the limitations of both techniques prevent their use in the acquisition of structural
data for an intact module. However, recent advances in cryo-EM technology led to the
first structural insights into the catalytic rearrangement of an intact PKS module, when
models of the penultimate module of pikromycin PKS (PikAIII, β-module) were acquired
for each conformation of its catalytic cycle (Figure 1.12).117;123 The dimeric apo-PikAIII
was observed to be in two varying conformations, both of which showed the KS, AT and
KR domains form a chamber. In both conformations, the ACP was located inside the
chamber and either interacting with the KR domain or in close proximity to the KS and
AT domains.
The structural elucidation of varying constructs allowed a greater insight into the in-
tramodular enzymatic mechanisms and interactions with the upstream ACP. Firstly, a
truncated construct, omitting the ACP (ACP5), was structurally elucidated (PikAIII/-
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Figure 1.12. Cryo-EM models (top) and corresponding schematic representation of substrate processing in PikAIII
(bottom). A pentaketide substrate is transferred from an upstream ACP to the KS domain of holo-PikAIII (state 1),
inducing a rotation of the KR domain and relocation of the intramodular ACP domain to the AT in preparation for loading
with an extender unit (state 2). Loading holo-PikAIII with a methylmalonyl-extender unit results in the repositioning of the
ACP to the KS’s bottom entrance (state 3). Incubation with a β-ketohexaketide results in the relocation of the ACP to
within close proximity of the KR active site in preparation for reduction of the polyketide (state 4) and addition of NADPH
leads to an ejection of the ACP out of the central chamber as a result of a KR-catalysed reduction of the polyketide to a
β-hydroxyhexaketide (state 5). This places the ACP in a position for intermediate transfer to PikAIV (state 6).
∆ACP5). The removal of the ACP resulted in a rotation of the KR domains around the
AT domains by approximately 165◦, suggesting the intramodular ACP plays a role in the
positioning of the KR relative to the AT domain.
Secondly, the intermodular interaction with the upstream ACP of PikAII (ACP4) was ex-
plored. A fused ACP4-PikAIII/∆ACP5 construct was created and the ACP was loaded
with a pentaketide to encourage interactions with PikAIII’s KS domain. The resulting
structure showed that ACP4 binds to the KS domain outside PikAIII’s chamber. The holo-
form of a KS active-site mutated variant (holo-ACP4-PikAIII/C209A/∆ACP5) was used
as a control to confirm that the location of ACP4 was due to the conformational changes
required to facilitate pentaketide translocation.
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Thirdly, the intramodular machinery of PikAIII was studied. Loading of a methylmalonyl
extender unit onto PikAIII resulted in the ACP relocating to a second interaction site on
the KS, this time inside the PikAIII chamber. This provided evidence that the KS has
separate entrances for substrate loading from the upstream ACP (side entrance) and sub-
sequent offloading to the intramodular ACP (bottom entrance).
Incubation of PikAIII with a pentaketide resulted in β-ketohexaketide-PikAIII and the ad-
dition of NADPH yielded β-hydroxyhexaketide–PikAIII. Structural elucidation showed
that, in both cases, the KR and AT domains were in close proximity and the AT domain
occluded the KS’s side-entrance, thus preventing substrate transfer from ACP4 to the KS
of PikAIII. In the case of β-ketohexaketide-PikAIII, ACP5 is docked with the KR’s lid
helix, effectively presenting the β-ketohexaketide to the KR’s active site and allowing re-
duction to β-hydroxyhexaketide in the presence of NADPH. Upon addition of NADPH,
the ACP is released and relocated outside the central PikAIII chamber, facilitating further
interactions with PikAIV.
1.2.8 Docking domains
PKSs require selective intersubunit interactions to ensure the correct biosynthetic route is
maintained for the consistent assembly of products. Interactions between subunits have
been shown to be promoted by docking domains located at the C-terminus of an up-
stream subunit (ACPdd) and the N-terminus of a downstream subunit (KSdd).124 The
ACPdds are connected to the ACP’s four conserved helices via a linker region (30 - 50
residues) that provides a degree of flexibility; whereas KSdds are located directly before
the downstream module’s KS domain. These domains promote intermodular crosstalk
and facilitate the transfer of polyketide intermediates from an upstream ACP to a down-
stream KS. Moreover, the specificity of docking domain interactions plays a vital role in
maintaining the correct order of modules in the PKS biosynthetic pathway, ensuring the
consistent production of the required polyketide.
The structural elucidation of ACP constructs containing docking domains has previously
been unsuccessful, perhaps due to the mobility of the linker region. Furthermore, KS-
dds are often insoluble or overexpress in low quantities when separated from the rest of
the KS domain. However, by creating fused constructs containing the upstream ACPdd
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and downstream KSdd, soluble proteins have been produced.124 This allowed dock-
ing domain complexes to be structurally elucidated from the biosynthetic pathways of
pikromycin125, curacin,126;127, erythromycin,124 and virginiamycin.128 The structural or-
ganisation varies in each case (Figure 1.13). Characterised structures, coupled with se-
quence analysis of identified docking domains has led to cis-AT PKS docking domains
being characterised into three different phylogenetic classes that have been shown to be
mutually incompatible.129
Figure 1.13. Solved structures of interacting docking domains from PKS systems: CurG-CurH (PDB: 4MYY), CurK-
CurL (PDB: 4MYZ), PikAIII-PikAIV (PDB: 3F5H) and VirA-VirFG (PDB: 2N5D).
Existing structures of fused class 1 docking domains, found in actinobacteria PKSs,126
show each ACPdd consists of two dimerisation helices that form a 4-helix bundle with a
second ACPdd130 and a C-terminal docking helix that plays a vital role in facilitating in-
teractions with a downstream KSdd (Figure 1.14). Class 1 KSdds consist of a long α-helix
that dimerises with a second KSdd to form a coiled-coil. The third helices of the ACPdd
dimer then bind to each side of the coiled-coil, interacting with opposite KSdds of the
dimer pair. The specificity of intermodular protein-protein interactions is thought to be
promoted by the location of electrostatically charged residues on the available interface,
with interactions between the ACPdd’s C-terminal helix and the KSdd thought to be of
particular importance.131;132 Interestingly, the upstream ACPs are initially directed away
from the downstream KS domains.126 The presence of a linker region between each ACP
and ACPdd is therefore vital in providing the required mobility for the ACP to relocate
to the KS after intermodular docking has occurred, allowing substrate transfer.
Class 1 docking domains may be further categorised into three distinct subclasses based
upon highly conserved structural motifs. Although domains from different subclasses
sometimes exhibit interactions, they display a significantly weaker affinity than compati-
ble docking domains.125
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Figure 1.14. Homology models of a class 1 ACP docking domain (a, DEBS2) and a class 1 KS docking domain (b,
DEBS3). NMR structures of a fused construct showed dimerisation occurs between helices 1 and 2 of the ACPdd (c,
PDB: 1PZQ) and helix 3 interacts with the coiled-coil formed by two KSdds (d, PDB: 1PZR).
Class 2 docking domains are found in cyano- and myxobacteria PKSs. Crystal structures
for two pairs of class 2 docking domains from curacin PKS showed that, unlike the class
1 docking domains, both the KSdd and ACPdds consisted of two α-helices connected by
a sharp bend.126 The ACPdd was found to be approximately forty residues shorter than
for class 1 ACPdd and the KSdd to be a similar length. Formation of a coiled-coil between
the second helix of a pair of KSdd’s was observed and the first helix of each docking do-
main was seen to extend away from the dimer interface due to the lack of hydrophobic
surface to support the formation of a coiled-coil. The second helix of each ACPdd then
binds to the KSdd’s coiled-coil, interacting with both KSdd’s in the coiled-coil. This is in
direct contrast to class 1 docking domains, where a pair of ACPdd’s third helices bind to
either side of the KSdd’s coiled-coil. This leads to the ACP being directed towards the KS
domain, resulting inmore efficient promotion of acyl-chain transfer between the subunits.
Class 3 docking domains are found in PKS-NRPS hybrids,133 such as tubulysin, and fa-
cilitate interactions between peptidyl carrier proteins (PCP) and the C domain of a com-
patible module.128 The N-terminal docking domain of the C domain has been shown to
adopt an αββαα topology, allowing dimerisation to occur between two C domains.134
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Figure 1.15. The proposed PKS pathways for pikromycin/methymycin PKS36 production and the resulting products.
Docking domains have been shown to retain a high degree of selectivity once discon-
nected from their parent subunit.125 A number of discrete docking domain constructs
were produced and interactions were measured by surface plasmon resonance (SPR), re-
sulting in binding only occurring between compatible pairs. In addition, the fusing of
compatible docking domain pairs onto different parent subunits has been shown to facil-
itate intersubunit acyl transfer, even if the class of the replacement docking domain does
not match the class of the original docking domain.126 Pikromycin PKS produces both
narbonolide (nbl) and 10-deoxymethynolide (10-dml), depending on whether PikAIV is
bypassed (Figure 1.15). To confirm the quantities of each precursor produced, PikAIII
and PikAIV were incubated with thiophenol pentaketide and methylmalonyl-CoA and
10-dml and nbl production were monitored. Production of 10-dml is a result of PikAIV
having not modified the product, whereas nbl is produced if PikAIV has played its pro-
posed role in the pathway. A number of chimeric PikAIII and PikAIV constructs were
then produced with the C-terminal docking domain of PikAIII replaced by the ACPdd’s
from CurG and CurK and the N-terminal docking domain of PikAIV replaced by the
KSdd’s from CurH and CurL (Figure 1.16).
The two module throughput reaction was repeated with each combination of chimeric
construct, resulting in both nbl and 10-dml production for all chimeras containing com-
patible docking domains, with around 50 % of nbl production retained. No nbl was de-
tected for the majority of chimeras containing incompatible curacin docking domains.
The one exception was between PikAIII with the KSdd of CurK (PikAIII-ddCurK) and
PikAIV with the ACPdd of CurH (ddCurH-PikAIV), where around 25 % of nbl produc-
tion was retained.
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Figure 1.16. The curacin PKS pathway (top) contains compatible class 2 docking domains to facilitate intersubunit in-
teractions. Previous work has shown that these docking domains may be fused onto interacting modules from pikromycin
PKS, in place of the natural class 1 pikromycin docking domains, to facilitate acyl transfer (bottom).
The same reaction resulted in an increased level of nbl production (45 %) upon the muta-
tion of CurK (E2224R). The mutation is likely to have created favourable electrostatic in-
teractions between the docking domains, potentially with a glutamine in CurH’s docking
domain, demonstrating the importance of electrostatic interactions in docking domain
selectivity. This highlights the possibility of changing electrostatic interactions through
single point mutations, widening the possibility of engineering docking domains to en-
sure the compatibility of PKS subunits.
1.3 Spirotetronates
A subsection of polyketide metabolites are the spirotetronates. Tetronates contain a 4-
hydroxy butenolide motif and are found in a wide variety of natural products, including
ascorbic acid and terpenes.135;136
Amacrocyclic compound containing a tetronic acid linked to a cyclohexene at a spiroatom
is known as a spirotetronate.137 Since their discovery in 1934,138 over 100 naturally occur-
ring spirotetronates have been identified.28 Abyssomicins (Figure 1.17), a group of small
spirotetronates (central ring system C11), were first discovered in Verrucosispora maris AB
18-032, before the isolation of homologs in land-based soil.139 Abyssomicin C is of partic-
ular interest due to observed bioactivity against Mycobacterium tuberculosis, Methicillin-
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Figure 1.17. Examples of Actinobacter spirotetronates with their spirocompounds and their spiroatoms shown.
Medium spirotetronates (C13) and large spirotetronates (> C13) often contain either a trans-decalin or a tetrahydroth-
iophene moiety.
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resistant Staphylococcus aureus (MRSA) and the para-aminobenzoate pathway in Bacillus
subtilis.140
Examples of medium spirotetronates (C13) include kijanimicin, which is produced by
Actinomadura kijaniata.141 Kijanimicin inhibits the growth of Gram-positive bacteria, show-
ing particularly strong activity against Bacillus subtilis and Propionibacterium acnes. An-
other medium spirotetronate that is closely related to kijanimicin is tetrocarcin A. Tetro-
carcin A was isolated in 1980 fromMicromonospora chalcea NRRL 11289 and exhibits anti-
tumour activity, as well as interfering with anti-apoptotic pathways in lymphomas and
human epithelial cells.142 Tetronothiodin (C19) is a large spirotetronate (> C13), that was
identified in Streptomyces sp. NR0489. Tetronothiodin contains a tetrahydrothiophene
moiety in the position of the decalin-unit found in the medium spirotetronates and is a
highly selective Cholecystokinin B (CCKB) receptor antagonist, making it a valuable tool
in the study of CCK receptors.28
1.3.1 The production of quartromicin precursors through a
polyketide synthase pathway
Figure 1.18. The structure of quartromicin.
Quartromicin (QMN), initially isolated from Amycolatopsis orientalis Q427-8, is a complex
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of novel antiviral antibiotics containing the largest known spirotetronates (C32).143 Each
antibiotic is unique due to the presence of four spirocompounds,144 fused in a head-to-
tail fashion by enone linkers, forming a carbon macrocycle. There are six known QMN
components produced by the strain: A1, A2, A3, D1, D2 and D3 (Figure 1.18), which differ
due to the presence of either an aldehyde or a hydroxymethyl group at R1 and R2 and the
possible presence of galactose moieties. The glycosylated QMNs (QMN A1 - A3) showed
significant antimicrobial activity against herpes simplex virus type I (HSV-1)145 and the
unglycosylated QMNs (QMN D1 - D3) showed significant activity against influenza.
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In addition, QMN A1 and QMN D1 both demonstrated anti-HIV activity due to the inhi-
bition of viral reverse transcription.147;148
As QMN has a wide range of biological activities, creating novel analogues could lead
to the production of more effective pharmaceuticals. This provides the motivation to ac-
quire a greater understanding of the control mechanisms involved in the production of
QMN.
Previous unpublished work by members of the Challis group (Dr. Orestis Lazos and Dr.
Malek Zerikly) had identified genes to encode most of the proposed proteins involved in
the production of QMN. A less detailed gene cluster was subsequently published by an-
other group.147 The creation of genomic libraries for two quartromicin producing strains
(Amycolatopsis orientalis ATCC 53884 and Amycolatopsis mediterraneiNRRL 18815) and the
amplification of a putative gene fragment from within the cluster allowed screening for
the quartromicin gene cluster.149 Shotgun sequencing and bioinformatic analysis of fos-
mids shown to contain the gene encoding an FkbH-like protein from the QMN biosyn-
thetic pathway and overlapping genes led to the identification of genes to encode PKS
modules, proteins to catalyse tetronate biosynthesis, oxidoreductase tailoring enzymes
and a number of regulatory and resistance genes (Figure 1.19).
Figure 1.19. The proposed gene cluster for QMN biosynthesis147, including PKS and tetronate biosynthesis (Ta-
ble 1.1).
24
Table 1.1. The QMN gene cluster and the proposed functions of encoded proteins.
Gene name Length (bp) Proposed function of encoded protein
qmnB 1,413 propionyl-CoA carboxylase
qmnC 753 TE II
qmnD4 966 2-oxoacid dehydrogenase/AT
qmnA1 17,772 PKS (KSQ-AT-ACP-KS-AT-DH-KR-ACP-
KS-AT-DH-KR-ACP-KS-AT-DH-KR-ACP)
qmnA2 5,313 PKS (KS-AT-DH-KR-ACP)
qmnA3 3,876 PKS (KS-AT-KRD-ACP)
qmnE 1,236 unknown
qmnF 1,488 unknown
qmnRg1 255 regulator
qmnG 1,599 PQQ-dependent dehydrogenase
qmnH 1,128 Proposed Diels Alderase
qmnI 1,044 unknown
qmnJ 483 unknown
qmnRs1 1,176 transporter
qmnRs2 681 transporter
qmnK 1,056 unknown
qmnL 456 unknown
qmnM 657 unknown
qmnN 390 unknown
qmnRg2 1,347 regulator
qmnRg1 666 regulator
qmnD5 1,029 3-oxoacyl-ACP synthase III (KS)
qmnD1 1,839 glyceryltransferase/phosphatase
qmnD2 213 ACP
qmnD3 843 2-oxoacid dehydrogenase/AT
qmnO 1,209 cytochrome P450
qmnRg4 2,805 regulator
qmnRg5 2,463 regulator
qmnA1-A3 are proposed to encode three PKS subunits containing a loading and five ex-
tending modules, each containing an ACP, AT and KS domain, with four of the modules
also containing KR and DH domains.150 The loading module contains a KSQ that likely
functions as a malonyl-thioester decarboxylase to procure an acetyl starter unit.147 The
loading module, as well as modules 3 and 5, contains an extender unit binding motif
in the AT domain with specificity towards a malonyl-CoA extender unit (HAFH),72;151
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whilst modules 1, 2 and 4 contain extender unit bindingmotifs specific tomethylmalonyl-
CoA (YASH).Malonyl- andmethylmalonyl-CoA are produced from acetyl- and propionyl-
CoA by a propionyl-CoA carboxylase (qmnB).
Figure 1.20. The proposed biosynthetic pathways for quartromicin PKS147 and the resulting precursors (1 and 2).
Docking domains (*) facilitate intersubunit interactions between modules 3, 4 and 5.
The production of QMN is proposed to require two different precursors.147 Precursor 1 is
the result of each PKS module sequentially extending and modifying the growing natu-
ral product. Precursor 2 is one extension shorter, probably as a result of module 3 being
able to interact directly with module 5 and optionally bypass module 4 (Figure 1.20). The
C-termini of module 3 and module 4’s (M3 and M4) ACPs and the N-termini of the KSs
(M4 and M5) appear to contain class I docking domains.
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1.3.2 Spirotetronate formation
The mechanism for the formation of quartromicin can be predicted by comparison to
the known roles of homologous enzymes in abyssomicin biosynthesis.140;152;153 QmnD1
is proposed to load the 3-carbon glycerol group of 1,3-biphosphoglycerate onto an ACP
(QmnD2), yielding glyceryl-S-ACP (Figure 1.21).147;154 A stand-alone KS domain (QmnD5)
then catalyses bond formation between the glyceryl-S-ACP and the ACP domain-tethered
polyketide chain of the final module. qmnD3 is thought to encode an AT domain that
acetylates the hydroxyl group of the tetronate ring, before the acetic acid is eliminated by
a 2-oxoacid dehydrogenase/AT domain (QmnD4) to form an exocyclic double bond.
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Abyssomicin only contains one spiroatom, as opposed to QMN’s four. Therefore, genes
involved in the subsequent steps of QMN biosynthesis could not be predicted from the
abyssomicin gene cluster. Due to the structure of QMN’s skeleton, is proposed that the cy-
clohexenemoieties attached to tetronic moieties are formed by a two-step reaction involv-
ing two of each precursor. Firstly, an enzyme-catalysed [4+2] endo Diels-Alder reaction is
predicted to occur between a diene (in the tail region of precursor 1) and a dienophile (in
the tetronic ring system of precursor 2) to produce a homodimer. A [4+2] exo Diels-Alder
reaction is then predicted to occur between the diene (in the tail region of precursor 2)
and dienophile (in the tetronic ring system of precursor 1) of two homodimers to produce
the QMN skeleton.156 It is currently not known which protein(s) catalyses this reaction.
1.3.3 Modifications to the quartromicin skeleton
Following biosynthesis of the core QMN ring system, oxidation-glycosylation reactions
further diversify the structure of QMN. A cytochrome P450 (QmnO) hydroxylates the
methyl groups of the exo Diels-Alder adducts (Figure 1.22). QmnG, a pyrroloquino-
line quinone (PQQ) dependent oxidoreductase, then catalyses the dehydrogenation of
the hydroxymethyl groups into aldehydes. The galactose moieties that differentiate quar-
tromicin A from quartromicin D may be transferred from a nucleotide diphosphate to
the hydroxy-methyl groups of the endo Diels-Alder adducts by a glycosyltransferase en-
coded by an unidentified gene.157
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Figure 1.21. The proposed formation of QMN from the PKS precursors.
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Figure 1.22. The proposed modification of QMN’s skeleton to form the six bioactive components of QMN.
1.3.4 Regulatory and unknown genes
Although qmnE shows close identity to a gene encoding a β-lactamase and qmnF to a gene
encoding a pyridoxal phosphate-dependent cysteine desulfurase, both have unknown
roles.155 Five genes (qmnRg1-Rg5) encode putative regulatory proteins. qmnRg1 encodes
a ChlF2-like regulator, qmnRg2 and qmnRg3 encode two-component regulators, qmnRg4
encodes a LuxR family regulator and qmnRg5 encodes a Streptomyces antibiotic regula-
tory proteins (SARP) family activator. qmnC encodes a type II TE that is predicted to be
responsible for removing incorrect PKS intermediates. In addition, qmnRs1 and qmnRs2
encode ATP-binding casette (ABC) transporters and qmnI, qmnJ, qmnK, qmnL, qmnM and
qmnN encode proteins with unknown functions.
1.4 Aims and objectives
The overall aim of this work was to understand the molecular interactions that control
the proposed module skipping in QMN biosynthesis, which allows the KS domain of
module 5 to accept substrates both from the ACP of module 3 and module 4 and catal-
yse a decarboxylative Claisen condensation between either substrate and a malonyl-CoA
extender unit. This is important because experiments that try to incorporate non-natural
PKS domains have often been unsuccessful, likely due to a lack of understanding of how
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protein-protein interactions work within PKSs.
The first aim was therefore to overproduce and purify the ACP domains from modules 3
and 4, with and without their docking domains, as well as module 5, both as a full-length
module and with various truncations. The objective was then to probe the intramodular
interactions within QMNmodule 5. To do this, it would first be necessary to demonstrate
the catalytic activity of the complete module by intact mass spectrometry.158;159 Subse-
quent similar experiments with a variety of substrate analogues were planned to probe
the selectivity of the KS and AT domains160 before intramodular chemical cross-linking
experiments between the intramodular ACP and the KS/AT domains were planned to
identify which domains in module 5 would interact together.161–163
The second aim was to attempt to probe the molecular interactions within module 5
through structural elucidation via techniques such as gel filtration, NMR, X-ray crystal-
lography and cryo-EM.164;165
The third and final aim was to investigate the intermodular interactions between module
5 and the upstream ACP domains of modules 3 and 4, as well as the role of the docking
domains in this interaction. This was intended to be studied by intact mass spectrome-
try assays to monitor the rate of transfer between the upstream ACP domains, both with
and without the docking domains, and module 5. The importance of each domain within
module 5 in facilitating intermodular interactions and the strength of the binding was
intended to be investigated by cross-linking and SPR, respectively. In addition, structural
investigation of the ACP docking domains of module 3 and 4 and the KS docking domain
of module 5 was proposed by NMR and X-ray crystallography.
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Chapter 2
Overproduction, purification and
characterisation of the recombinant
proteins involved in quartromicin’s
unique module skipping mechanism
2.1 Target proteins
Understanding the mechanisms involved in the production of natural products would
provide the possibility of systematically developing synthetic pathways to produce novel
natural products, as well as modifying existing systems or creating hybrids. This would
allow the production of bespoke analogues designedwith specific functionalities inmind.
One way to gain an insight into the enzymatic workings of a PKS pathway is by exam-
ining the intermodular interactions between the subunits, as well as the intramodular
workings of modules. In vitro studies are often used to investigate PKSs due to issues
culturing organisms under in vivo conditions. Prerequisites for studying protein-protein
interactions using in vitro bioassays are to overproduce and purify the relevant recombi-
nant proteins and produce mimics of the proteins’ substrates.
Figure 2.1. QMN module 5 is able to interact with the upstream ACPs from modules 3 and 4, allowing the bypassing
of module 4.
To elucidate information on the module skipping mechanism of QMN PKS, the interac-
tions between the domains and modules involved in the process were studied. The inter-
modular interactions between the ACP domains of modules 3 (M3) and 4 (M4) and the
KS domain of module 5 (M5), as well as the intramodular interactions within M5, may
play key roles in moderating the specificity of the PKS pathway (Figure 2.1). The ACP
domains from M3 and M4 both contain a four conserved helices containing the ACPs
substrate attachment site, as well as a C-terminal docking domain connected to the four
conserved helices by a largely unstructured linker region. The ACP docking domains are
reported to facilitate interactions between the ACP and the KS of the subsequent mod-
ule, which contains an N-terminal docking domain hypothesised to have a specificity to
interacting proteins.124 Two different variations of each ACP were targeted, a full-length
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protein (M3 ACP and M4 ACP) and a truncated variant lacking the docking domain and
linker region (M3 ACPT andM4 ACPT). This would allow the elucidation of information
on the importance of each docking domain in facilitating protein-protein interactions be-
tween the ACP and the downstream KS domain and determine whether the ACP’s four
conserved helices or the docking domain plays the primary role in the specificity of ACP-
KS interactions. Homology models were used to determine the start of the disordered
linker region (Figure 2.2).
Figure 2.2. Homology models (Phyre, PDB: 2ju2, 5hvc) of the QMN ACP domains from the final 3 modules of QMN
PKS. M3 ACPT and M4 ACPT consist of the residues in the 4 conserved helices.
As well as the full-length M5, a number of truncated constructs were planned. The
stand-alone KS domain (M5 KS), KSAT didomain, both with (M5 KSAT) and without
(M5 KSATS) the AT-ACP linker, and the ACP (M5 ACP) were all targeted to allow for
determination of the effects of each region on protein-protein interactions (Figure 2.3).
M5 KS contains the docking domainwith specificity to the upstreamACPs and an archety-
pal KS domain containing the active-site cysteine to which the upstreammodules polyke-
tide substrates are transferred. Therefore, excising the individual domain will allow for
assays to demonstrate that the protein-protein interactions are specific to the KS and ACP.
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Figure 2.3. M5 KS (1,392 bp), M5 KSATS (2,664 bp), M5 KSAT (3,594 bp) and M5 ACP (264 bp) were targetted for
subcloning from M5 (3,876 bp).
Subcloning ofM5 KSATS andM5 KSATwill allow for studies into the importance of both
the AT and AT-ACP linker region (which is predicted to contain structured KR remnants,
including a partial Rossmann fold) in interactions between domains, in particular with
M5 ACP and the upstream ACPs. M5 ACP is at the C-terminal of QMN PKS, and there-
fore only consists of a four conserved helices due to the lack of necessity in interacting
with a downstream KS. Therefore, only one variant of M5 ACP will be targeted.
As well as being useful for determining which regions are important for protein-protein
interactions, the creation of different lengths of truncated constructs will aid structural
studies. Whilst full-length M5 could be studied by cryogenic-electron microscopy, the
resolution of these structures is generally lower than structures obtained from X-ray crys-
tallography or NMR. The creation of the aforementioned truncated variants, specifically
variants lacking flexible regions, will aid analysis using structural biology techniques.
Figure 2.4. Cross-linkable interactions occur between M5 KS and the upsteam ACPs (M3 ACP and M4 ACP), as well
as the intramodular ACP (M5 ACP). Cross-linkable interactions should also be present between M5’s AT and M5 ACP
upon converting the AT’s active-site to a cysteine (S656C).
In addition to the truncated variants of M5, constructs containing active-site mutations
were targeted. Mutation of the KS domain’s active-site cysteine to an alanine (C207A) has
previously been shown to abolish the activity of KS domains,166 thus acting as a vital con-
trol for in vitro bioassays involving M5. A second mutation of the AT’s active-site serine
to alanine (C207A/S656C) was planned in order to facilitate interactions between the AT
and ACP domains and allow in vitro studies to be undertaken (Figure 2.4).
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2.2 Plasmid preparation
Plasmids for the overproduction ofM3 ACP,M4 ACP,M5 KSAT andM5were previously
produced by Dr. Orestis Lazos and Dr. Matthew Jenner. All other plasmids were pre-
pared by PCR amplification of the GOI and ligation into the vector backbone, or through
modification of an existing plasmid.
2.2.1 Plasmid preparation through PCR amplification and
ligation
Each targeted gene of interest (GOI) was amplified by polymerase chain reaction (PCR),
with forward and reverse primers designed to be complementary to 15 - 18 bases at the
5’ and 3’ ends of the GOI. The forward primer also contained additional bases (CACC) at
the 5’ end to facilitate ligation to the complementary sticky end of the host vector (GTGG),
ensuring the correct orientation of the inserted GOI. Where a required stop codonwas not
already present in the GOI, an artificial in-frame stop codon was added to the 5’ end of
the reverse primer (Figure 2.5).
Figure 2.5. Primers encode a CACC overhang on the 5’ end of the replicated region (top) to ensure the PCR product
has the correct orientation after ligation into pET151 (bottom).
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PCR products were visualised by agarose gel electrophoresis and bands corresponding
to the expected sizes were excised and purified (Figure 2.6). Sufficient quantity of PCR
product was produced for the genes corresponding to M3 ACPT, M4 ACPT, M5 ACP
and M5 KS, but reactions were unsuccessful for M5 KSATS and M5 KSAT, perhaps due
to the length of the GOI.
Figure 2.6. Agarose gel electrophoresis following PCR amplification of genes encoding M3 ACPT (a, 247 bp)
M4 ACPT (b, 238 bp), M5 ACP (c, 268 bp) and M5 KS (d, 1,405 bp).
The insertion of the purified GOIs into a pET151 vector was achieved using an expression
kit containing a linearised topoisomerase I-activated pET151-D/TOPO vector. Topoiso-
merase I is an enzyme from Vaccinia virus that cuts a single strand of double stranded-
DNA, facilitating strand relaxation. The 5’ end of the GOI is then able to anneal to the
complementary sticky end of the vector whilst the 3’ end of the GOI anneals to the 5’ end
of the vector. This avoids the necessity of multiple DNA ligation reactions and therefore
can be completed in a relatively short time frame. The ligated product was then used to
transform E. coli and plasmid-containing cells were selected through LB agar ampicillin
plates. Colonies were picked and grown overnight in LB.
Grown cultures were centrifuged to remove the media from the cells, before plasmid
DNAwas extracted and purified. Restriction enzymes with one restriction site in both the
vector and the insert were identified and digests were carried out on the purified DNA
plasmids. Restriction digested clones displaying the correct band sizes following agarose
gel electrophoresis (Figure 2.8) were sent for sequencing to determine their fidelity. This
confirmed successful cloning of the genes encoding M3 ACPT, M4 ACPT, M5 ACP and
M5 KS, respectively.
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Figure 2.7. A gene map of the pET151 D/TOPO vector (SnapGene).
Figure 2.8. Agarose gel electrophoresis following restriction digests of M3 ACPT (a, expected band size: 1,015 and
4,985 bp) and M5 ACP (b, expected band size: 1,120 and 4,880 bp) by PvuI.
2.2.2 Plasmid preparation through site-directed deletion
Due to problems ligating large PCR fragments into the pET151 vector, a new approach
was chosen to subclone the genes encodingM5 KSATS andM5 KSAT by deleting the rele-
vant regions of the plasmid. Non-mutagenic primerswere designed, usingNEBasechanger,
to initiate copying from the flanking regions on either side of the required deletion (Fig-
ure 2.9 (left)).
Primers were designed back-to-back to ensure exponential amplification of the product,
as well as to transform non-nicked plasmids. A series of stop codons were also included
at the 3’ end of the reverse primer to prevent the transcription of extra bases. Clones were
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Figure 2.9. Site-directed mutagenesis and deletion can be carried out on a plasmid. Primers complementary to the
GOI, but with either the omission of (left), or changes (right), a number of bases (a), allow for the production of a PCR
product with the required deletion or base changes, respectively (b). In both cases, the PCR product may be ligated,
producing the modified plasmid (c).
checked by restriction digest and sequenced, confirming the successful deletion of the
relevant regions of the genes encoding M5 KSATS and M5 KSAT.
2.2.3 Site-directed mutagenesis of quartromicin module 5
constructs
All site-directed mutagenesis (SDM) was carried out using a SDM kit that provides the
necessary elements for the successful production of PCR products containing the required
base pair mutation(s) and subsequent ligation of the plasmid (Figure 2.9 (right)). Primers
were designed back-to-back using the NEBasechanger and OligoAnalyzer was used to
confirm no hairpins or dimerisation would occur between the primers. The KS active-site
of the genes encoding M5 and M5 truncations would first be mutated from cysteine to
alanine. Then a mutation on the active-site of the AT domain would be carried out to
produce double mutants of each gene.
The PCR reactions for the C207A mutations were analysed by agarose gel electrophore-
sis and reactions exhibiting bands of the required length were treated with the provided
KLD (kinase, ligase, DpnI) enzyme mix to ensure phosphorylation of the 5’ ends of the
PCR product, circularisation of the plasmid and digestion of methylated template DNA.
The treated plasmids were then transformed, cultured and isolated from the bacteria.
Sequencing confirmed no mutation had occurred for M5 or M5 KSAT. However, the mu-
tation was successful in M5 KSATS (M5 KSATS-C207A). A second mutation (S656C) was
also successful for M5 KSATS-C207A, yielding the double mutant (M5 KSATS-C207A/
S656C). After numerous unsuccessful attempts, it was hypothesised thatM5 andM5 KSAT
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in the pET151 vector were too long to introduce the mutation by this method.
Figure 2.10. PCR products containing restriction sites at both ends may be blunt-end ligated into a pJET vector, allow-
ing for more efficient mutagenesis of the insert. The mutated insert may then be isolated from the vector by restriction
digest and gel purification, before ligation back into pET151.
Two parallel methods were attempted to overcome the inefficacy of the mutations in
M5 KSAT and M5. The first method involved transferring M5 into pJET1.2, a shorter
cloning vector (2974 bp), and carrying out the mutations on the shorter construct (Fig-
ure 2.10). The primers to copy the GOI contained restriction sites at the 5’ and 3’ ends to
allow removal of the mutated GOI from pJET1.2 and ligation back into pET151.
Figure 2.11. The region of M5 KSATS containing the mutations may be restriction digested out of its vector and
purified alongside the complementary region of M5. Ligation of the two regions may be achieved by incubation with T4
ligase, resulting in the production of a plasmid encoding M5-C207A.
The second method involved identifying unique restriction-sites in M5 KSATS (pET151)
that would allow the separation of a region containing the mutations from the rest of the
construct. NdeI was chosen as the only predicted cleavage was in the multiple cloning
site (MCS). XhoI was also identified as cutting the plasmid once, with its restriction-site
located after the second mutation (S656C), but before the end of the AT domain. This
would allow the excision of the area containing the mutated KS and AT active-sites from
M5 KSATS-C207A and M5 KSATS-C207A/S656C. It would also allow the complemen-
tary region of M5 to be excised. This contained the remainder of the AT domain, the
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AT-ACP linker, M5 ACP and the majority of the pET151 vector. Ligation of the regions
containing the mutated KS and AT active sites to the complementary region of M5 would
allow for the creation of M5-C207A and M5-C207A/S656C (Figure 2.11).
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Figure 2.12. An agaorse gel of PCR products for M5-C207A in the pJET1.2 vector (expected band size: 6,706 bp).
PCR of M5 containing 5’ and 3’ restriction sites was successful and the product was in-
serted into pJET1.2 by blunt end ligation (confirmed by sequencing). PCR with the muta-
genic primers yielded a product that was inserted into the vector. Sequencing confirmed
the successful C207A mutation (Figure 2.12).
Figure 2.13. Agaorse gel electrophoresis of a restriction digest of M5 (a), M5 KSATS-C207A (b) and M5 KSATS-
C207A/S656C (c) with NdeI and XhoI. Expected band sizes are 2.0/6.4 kbp for M5 KSATS-C207A and M5 KSATS-
C207A/S656C and 2.0/7.4 kbp for M5.
At the same time, agarose gel electrophoresis suggested successful double restriction of
M5 KSATS-C207A, M5 KSATS-C207A/S656C and M5 had occurred (Figure 2.13). The
required polynucleotides were excised and purified by gel extraction. Ligation of the re-
gion containing the single mutant (C207A) and the double mutant (C207A/S656C) to the
polynucleotide containing most of the vector and the remainder of M5 yielded products
that were confirmed to be of the correct size by restriction digest (Figure 2.14).
Fidelity of M5-C207A and M5-C207A/S656C were confirmed by sequencing. M5 KSAT
variants of both plasmids and a C207A variant of M5 KS were then produced by the ad-
dition of in-frame stop codons and deletion of the relevant regions from M5-C207A and
M5-C207A/S656C (Figure 2.15).
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Figure 2.14. An agaorse gel of a restriction digest of M5-C207A (a) and M5-C207A/S656C (b) with PstI. Expected
band sizes were 1.2 and 8.4 kbp.
Figure 2.15. An agaorse gel of PCR products for M5 KS-C207A (a, 7.2 kbp), M5 KSAT-C207A (b, 9.7 kbp) and
M5 KSAT-C207A/S656C (c, 9.7 kbp).
2.3 Overproduction and purification of
proteins
2.3.1 Overproduction
Plasmids with the correct inserts were used to transform BL21* (DE3), a strain of E. coli
that contains T7 RNA polymerase, allowing transcription of the plasmid’s insert. Single
colonies were selected on LB agar plates containing ampicillin and used to grow LB cul-
tures until the cells reached logarithmic phase.
The addition of an allactose analogue, such as isopropyl β-D-1-thiogalactopyranoside
(IPTG), allosterically released the repressor from the vector’s T7 promoter site, allowing
transcription of the GOI. An advantage of using IPTG over allactose is that it cannot be
metabolised by E. coli, ensuring an invariable rate of expression. The E. coli ribosome was
then able to bind to the RNA transcripts’ ribosome binding site (RBS), allowing transla-
tion to be initiated by the GOI’s start codon (ATG) and ended by a stop codon (TAG, TAA
or TGA). This resulted in heterologous overproduction of the target proteins inside the E.
coli host.167
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Table 2.1. The size (residues) and expected molecular weights (Da) of overproduced His-tagged proteins.
Protein domain M3 ACP (*) M3 ACPT M4 ACP M4 ACPT M5 ACP M5 KS M5 KSATS M5 KSAT
Size (residues) 181 107 181 108 121 497 921 1231
Expected mass (Da) 19,608.83 12,212.79 19,465.05 12,019.77 12,915.41 52,862.21 97,887.79 131,211.28
M3 ACP, M3 ACPT, M4 ACP, M4 ACPT, M5 ACP, M5 KSATS, M5 KSAT and M5 were
all successfully overproduced and were soluble in BL21* TM E. coli (Table 2.1). M5 KS
overproduction initially resulted in a completely insoluble protein fraction, but a reduc-
tion in IPTG concentration (from 500 to 200 µM) resulted in the overproduction of soluble
protein. All mutagenic variants displayed similar levels of overproduction to the corre-
sponding wild type proteins.
2.3.2 Purification by nickel column
Figure 2.16. IMAC chromatogram (left) and SDS-PAGE analysis (right) of M5 (141 kDa).
Immobilised metal affinity chromatography (IMAC) was used as a first purification step
for all soluble proteins (Figure 2.16), resulting in the successful purification of M3 ACP,
M3 ACPT, M4 ACP, M4 ACPT, M5 ACP, M5 KS, M5 KSATS, M5 KSAT, M5 and all mu-
tagenic variants (Figure 2.17). M5 KS also required the addition of a protease inhibitor
(cOmpleteTM, EDTA-free Protease Inhibitor Tablets) to prevent degradation from occur-
ring. M3 ACP co-expressed with a protein of higher molecular weight.
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Figure 2.17. SDS-PAGE analysis of His-tagged M3 ACP (a, 19,608 Da), M4 ACP (b, 19,465 Da), M3 ACPT (c, 12,213
Da), M4 ACPT (d, 12,020 Da), M5 ACP (e, 12,915 Da), M5 KS (f, 52.9 kDa), M5 KSATS (g, 97.9 kDa), M5 KSAT (h,
131 kDa) and M5 (i, 141 kDa) were produced and purified by IMAC. C207A (’) and C207A/S656C mutants (”) are also
shown for constructs containing the KS and AT domains.
2.3.3 Purification by gel filtration
Further purification steps were required for M5 KSATS, M5 KSAT and M5 in order to
achieve a suitable level of purity for high-resolution structural studies. Therefore, size
exclusion chromatography was used on the IMAC purified samples.
A Superdex 200 gel filtration column was calibrated using a number of analytical stan-
dards, producing a calibration curve from which the mass corresponding to each elution
peak could be approximated (Figure 2.18). For all samples, some aggregated protein was
eluted at the dead volume, perhaps as a result of the high protein concentrations prior to
column injection. For M5 KSAT and M5, further peaks were observed, corresponding to
masses of approximately 250 and 280 kDa, respectively, indicating both proteins formed
dimers.
However, for M5 KSATS, a second peak was not visible, suggesting almost complete ag-
gregation of the protein (Figure 2.19 (a)). The addition of protease inhibitor (cOmpleteTM,
EDTA-free Protease Inhibitor Tablets) and increasing the salt concentration (200 mM from
100mM) resulted in the presence of new peaks corresponding to the monomer, dimer and
various oligomers (Figure 2.19 (b)). Further addition of 10 % glycerol resulted in the pro-
duction of mostly monomeric protein (1.7 VeV0 ), but large amounts of aggregation remained
(Figure 2.19 (c)). The amount of aggregate was finally reduced by the addition of 100 mM
EDTA (Figure 2.19 (d)). Calibration predicted a mass of approximately 100 kDa, suggest-
ing M5 KSATS existed as a monomer. The loss of dimerisation in the truncated construct
containing only the KS and AT domains (M5 KSATS) indicates that a dimerisation motif
may be present in the AT-ACP linker region. This observation will be further studied in
section 4.5.
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Figure 2.18. A calibration curve was produced using proteins of known molecular weight (left, S200) and standardised
by the elution time of thyroglobulin (V0). Gel filtration analysis (S200) of M5 KSAT and M5 resulted in elution peaks of
approximately 1.3 VeV0
(top right) and 1.25 VeV0
(bottom right), corresponding to molecular weights of approximately 250
kDa and 280 kDa, respectively.
Figure 2.19. Gel filtration analysis (S75) of M5 KSATS in different buffers: (a) 20 mM Tris, 100 mM NaCl, pH 7.4, (b)
+ 100 mM NaCl and protease inhibitors, (c) + 10 % glycerol and (d) + 100 mM EDTA.
2.3.4 Estimating protein concentration
In order to ensure all assays were quantitatively accurate, the concentration of proteins
must be accurately measured. To predict the concentration of each protein, a spectropho-
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tometer was used to measure the absorbance of the sample at 280 nm. The protein con-
centration (C, mg/mL) was then estimated using the Beer-Lambert law:
C =
A280
ϵl
,
where A280 is the absorbance of the sample at 280 nm, ϵ is the protein’s extinction coeffi-
cient and l is the path length of the cell. The extinction coefficient was calculated from the
number of each aromatic residue (tryptophan, tyrosine, phenylalanine) and corresponds
to how strongly the protein attenuates to light at 280 nm. Molarity was calculated by di-
viding the concentrations by the expected molecular weight of the protein.
All proteins were diluted to 0.5 mg/mL and a Bradford assay was used to confirm the
accuracy of the measurement. A Bradford assay predicts protein concentrations based
upon the absorbance shift of an anionic dye upon protein binding.168 The absorbance
shift can then be compared to the shift of a protein of known concentration, often bovine
serum albumin (BSA). The anionic dye forms a non-covalent complex with the protein’s
carboxyl groups by donating its free electrons to the protein’s ionisable groups. This
causes disruptions to the proteins native state, exposing hydrophobic pockets that then
bind non-covalently to the dye via Van der Waals forces. The proteins positively charged
primary amines may then interact and bond to the negatively charged dye, causing the
neutralisation of the dye and a change in colour that can be measured by the absorbance
reading (595 nm). An advantage of this method is that it is not susceptible to various
chemical compounds often found in protein samples, such as salts.
A calibration curve was measured with varying concentrations of BSA (Figure 2.20), be-
fore the absorbance was measured for each protein. Comparisons with the calibration
curve predicted concentrations of 0.476 and 0.501 mg/mL for M3 ACP and M5 (as ex-
pected), and concentrations of 0.188, 0.284 and 0.359 mg/mL for M3 ACPT, M4 ACP and
M4 ACPT, respectively. This variance in predicted concentration could be due to a lack
of residues with absorbance at 280 nm, resulting in an inaccurate extinction coefficient
leading to an overestimation of concentration by nanodrop. As a result of this disparity
in ACP protein concentrations, it was decided to lyophilise samples of each ACP, thereby
allowing for accurate resuspension to the required concentration.
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Figure 2.20. A calibration curve was acquired using Bradford reagent and BSA as a standard. All samples were
measured in triplicate and errors correspond to one standard deviation.
2.4 Protein characterisation
2.4.1 Characterisation by mass spectrometry
Although the molecular weight of the proteins had previously been estimated by SDS-
PAGE, the exact mass was yet to be determined. Liquid chromatography-mass spectrom-
etry (LC/MS) is a common analytical tool used to isolate proteins, or molecules, from
a sample or assay and measure their molecular weight.101;169 High-performance liquid
chromatography (HPLC) first separates the components of the protein sample depending
on their retention time on a reverse phase HPLC column. Electrospray ionisation (ESI)
mass spectrometry (MS) then ionises the sample and a magnetic or electric field sorts the
ions into different charge states based on their mass-to-charge ratio (m/z). Each of these
ions (I) are from a single intact protein with mass Mr = n(I − N+), where N+ is the
mass of a proton and n is a positive integer. The mass of the intact protein is then cal-
culated through a maximum entropy deconvolution algorithm with defined mass range
boundaries. In essence, this method maximises the entropy (H):
H = −K
n
∑
i=1
pi log(pi),
where K is a constant and pi is the probability of a system being in cell i of its phase space.
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By selecting the mass spectra corresponding to the retention time of the protein, and se-
lecting a mass range in which the protein is expected to lie, a deconvoluted spectrummay
be acquired.
Figure 2.21. UV chromatogram of QMN module 5 (a) and the corresponding mass spectra at t = 13− 14 minutes (b).
LC/MS was used to confirm each protein had the expected molecular weight. The LC
component allowed all purified proteins to be separated from contaminants. The peak
with the retention time corresponding to the eluted protein was selected (Figure 2.21 (a)).
All mass spectra of samples eluted during this time period were combined with the re-
sulting spectra consisting ofmultiple peaks corresponding to different charge-states of the
protein (Figure 2.21 (b)). The spectra were then deconvoluted using Compass DataAnal-
ysis 4.1’s (Bruker) maximum entropy deconvolution algorithm to provide the measured
mass of each protein (Figure 2.22).
As can be seen in Table 2.2, the measured molecular weights were within 50 ppm for all
purified proteins. As noted in the SDS-PAGE analysis, a second peak was observed with
a higher molecular weight (22,107 Da) for M3 ACP. This peak had approximately 20 %
of the intensity of the peak corresponding to the predicted molecular weight of M3 ACP.
The nature of this species is discussed in section 2.4.3.
2.4.2 Characterisation by circular dichroism spectroscopy
Ultraviolet (UV)-circular dichroism (CD) is an analytical technique commonly used to
analyse the secondary structure of proteins. It measures the differential absorption of left
and right polarised light caused by passing through an optically active medium, such
as the protein sample. Each secondary structure element will impart a distinct spectral
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Figure 2.22. Deconvoluted mass spectra for all overproduced proteins (from spectra in Figure 8.4). Expected and
measured masses are displayed in Table 2.2.
Table 2.2. The measured and expected molecular weights of overproduced proteins.
Protein domain M3 ACP (*) M3 ACPT M4 ACP M4 ACPT M5 ACP M5 KS M5 KSATS M5 KSAT
Expected mass (Da) 19,608.83 (unknown) 12,212.79 19,465.05 12,019.77 12,915.41 52,862.21 97,887.79 131,211.28
Measured mass (Da) 19,609.32 (22,105.90) 12,213.42 19,464.17 12,020.02 12,914.3875 52,861.13 97,886.15 131,209.80
Protein domain M5 M5 KS-C207A M5 KSATS-C207A M5 KSATS-C207A/S656C M5 KSAT-C207A M5 KSAT-C207A/S656C M5-C207A M5-C207A/S656C
Expected mass (Da) 141,079.29 52,830.15 97,855.73 97,871.79 131,179.22 131,195.28 141,047.23 141,063.29
Measured mass (Da) 141,077.17 52,829.10 97,854.56 97,870.43 131,178.57 131,193.36 141,047.10 141,059.78
signature. For instance, α-helices have negative maxima at 208 and 222 nm, as well as a
positive maximum at 190 nm. In contrast, β-strands display a negative maximum at 218
nm and a positive maximum at 195 nm.
Spectra were obtained for all wild type protein constructs (Figure 2.23) and Dichroweb
was used to calculate the percentage of α-helix, β-strand and disordered region (Table 2.3)
in the protein complex. Phyre2 was then used to predict the expected percentages of α-
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Figure 2.23. CD spectra of purified wild type proteins from the QMN PKS pathway.
helices, β-strand and disordered region of each protein/complex and comparisons were
made between the calculated and expected values for each type of structure. The exper-
imental and predicted values displayed contiguousness for the percentage of α-helix in
each protein. For the ACPs, the percentage of β-strand predicted byDichrowebwas lower
than for the experimental data. However, low percentages of β-strand can be predicted by
Dichroweb for proteins with solved crystal structures showing they contain no β-strands
(e.g. concanavalin). Therefore, the values obtained are indicative of correct folding of
M3 ACP, M3 ACPT, M4 ACP, M4 ACPT, M5 ACP, M5 KS, M5 KSATS, M5 KSAT and
M5.
2.4.3 Characterisation of the glycosylated M3 ACP
Other strains of E. coli were used to confirm the higher mass protein co-expressed with
M3 ACP (M3 ACP*) was not just an artefact of BL21* overproduction (Figure 2.24). Three
BL21* derivatives were used; RosettaTM 2 (DE3) singles, which is designed to enhance
the expression of rare codons, C43, which is designed for the overproduction of toxic pro-
teins and NiCo21, which is engineered to minimise the co-expression of endogenous E.
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Table 2.3. Measured (and predicted) secondary structures of purified wild type proteins based on Dichroweb predic-
tions (and homology models).
Protein domain α-helix (%) β-strand (%) Disordered (%)
M3 ACP 60 (60) 3 (0) 26 (34)
M3 ACPT 69 (69) 3 (0) 12 (14)
M4 ACP 61 (61) 2 (0) 34 (32)
M4 ACPT 71 (69) 7 (0) 0 (14)
M5 ACP 66 (69) 7 (0) 14 (16)
M5 KS 40 (42) 18 (16) 24 (8)
M5 KSATS 43 (42) 12 (16) 25 (9)
M5 KSAT 34 (37) 13 (16) 26 (10)
M5 38 (41) 12 (13) 27 (10)
colimetal-binding proteins, therefore allowing for superior IMAC purification.
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Figure 2.24. SDS-PAGE analysis following IMAC M3 ACP overproduction in different E. coli (DE3) strains.
Visualisation by SDS-PAGE gel electrophoresis indicated that the higher mass band was
still present for each sample, with the exception of protein overproduced in NiCo21.
However, MALDI (matrix-assisted laser desorption ionisation) analysis of the protein
sample showed the protein with higher molecular weight was still present (Figure 2.25).
A range of chromatographic techniques were utilised in an attempt to separate the pro-
teins (Figure 2.26). Neither a gradient of increasing imidazole nor the use of cobalt in place
of nickel (due to its higher selectivity towards His-tagged proteins)170 resulted in sepa-
ration. Anion exchange chromatography and gel filtration were then attempted, again
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Figure 2.25. MALDI analysis of M3 ACP confirmed the presence of two proteins with mass of approxi-
mately 19.5 and 22 kDa.
resulting in both proteins being eluted together.
Figure 2.26. Chromatograms of attempts to separate M3 ACP from the protein with higher molecular weight.
The continued co-elution of the proteins suggested interactions were occurring between
them, possibly because the protein with higher molecular weight is a posttranslationally
modified (PTM) variant of M3 ACP.
One possibility was that the His-tag was being glycosylated. Cleavage of the His-tag
resulted in bands corresponding to cleaved M3 ACP and a higher mass band, either cor-
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responding to uncleavedM3 ACP or the higher mass PTM-ACP after cleavage. Complete
disappearance of the higher mass His-tagged PTM-ACP suggests it is likely to be the lat-
ter. Therefore, it is probable that the PTM does not occur on the His-tag.
Peptide mass fingerprinting (PMF) was used to see if both proteins contained sequence
similarity in order to confirm that the higher mass band corresponds to a PTM M3 ACP.
PMF is a technique in which a protein is enzymatically digested, usually by trypsin, be-
fore the resulting peptides’ masses are measured using MS. Therefore, if the higher mass
protein is a PTM M3 ACP then it would likely yield a number of peptides with the same
mass as M3 ACP after such treatment, confirming that both proteins share a sequence
similarity.
Figure 2.27. MALDI analysis of peptides resulting from tryptic digests of M3 ACP (top) and a proposed posttransla-
tionally modified M3 ACP (bottom).
The protein mixture was analysed by SDS-PAGE and both proteins’ bands were excised
separately from the gel. Tryptic digests were carried out on both gel pieces and the result-
ing peptides were analysed using MALDI (Figure 2.27). The expected peptide fragments
were observed for both proteins, with 82 % sequence coverage for M3 ACP and a 68 %
sequence coverage for the protein with the higher molecular weight. This shows that the
higher molecular weight protein has high sequence similarity to M3 ACP and is likely to
be a posttranslationally modified M3 ACP.
The modification was proposed to be an N-linked glycosylation based on the identifica-
tion of an NGT motif within M3 ACP. An N-linked glycosylation is the attachment of an
oligosaccharide, known as a glycan, to the amine group of an asparagine residue, result-
ing in the production of a glycoprotein. 72.2 % of reported N-linked glycosylations occur
at the asparagine of an NxT motif, with NGT being the most common motif (12.6 %).171
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Furthermore, the location of the NGT motif in the docking domain region would explain
why M3 ACPT did not contain the second protein. A peptide with an increased mass of
2.5 kDa could not be seen in the MALDI spectra for the digested higher molecular weight
protein, perhaps due to glycopeptides not ionising completely due to the microhetero-
geneity of attached glycans.
Figure 2.28. MALDI analysis of (a) M3 ACP, (b) the isolated higher mass band (22 kDa) and (c) the isolated higher
mass band after deglycosylation (19.6 kDa).
In order to confirm this hypothesis, and attempt to remove the potential mutation, an in-
gel deglycosylation kit was used. The kit allows peptides to be extracted from SDS-PAGE
gel pieces and for an amidase (PNGase F) to cleave all N-linked oligosaccharides. The
successful N-deglycosylation of the higher molecular weight protein to a protein of the
expected molecular weight of M3 ACP was observed (Figure 2.28), thereby confirming
the higher molecular weight protein to be a N-linked glycosylation of M3 ACP.
2.5 Conclusions
M3 ACP, M3 ACPT, M4 ACP, M4 ACPT, M5 ACP, M5 KS, M5 KSATS, M5 KSAT and
M5 were recombinantly overproduced in a soluble form. Each construct contained an
N-terminal His-tag, enabling purification by IMAC. Mutations of the KS and AT active-
sites were also introduced in M5 KSATS, M5 KSAT and M5, allowing for the probing
of intramodular AT-ACP interactions as well as providing controls. In addition, M5 KS-
C207Awas produced to provide a control for M5 KS. M5 KSATS, M5 KSAT andM5were
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further purified by gel filtration to enable high-resolution structural studies. Comparison
to a range of protein markers showed a loss of dimerisation betweenM5 KSATS (residues
1 - 888) and M5 KSAT (residues 1 - 1198), suggesting the structure of the AT-ACP linker
region must play a vital role in module dimerisation.
The purity of all proteins was checked by SDS-PAGE and the molecular weight charac-
terised by mass spectrometry before the correct secondary structure was confirmed using
circular dichroism spectroscopy. Nanodrop estimates of protein concentration did not
agree with estimates from Bradford assays for M3 ACPT, M4 ACP and M4 ACPT, per-
haps due to the lack of residues with absorbance at 280 nm. To ensure accurate concen-
trations, all ACPs were lyophilised, weighed and resuspended.
In addition, IMAC purified M3 ACP was shown to contain a second protein with an in-
creasedmolecular weight of approximately 2.5 kDa. The larger protein was not present in
the truncated M3 ACPT and the two proteins could not be separated by a variety of chro-
matographic techniques. PMF analysis confirmed the higher mass protein was likely to
be a PTMmodified version of M3 ACP. The PTM was predicted to be an N-glycosylation
due to the presence of an NxT motif in M3 ACP’s docking domain. This was confirmed
by the successful deglycosylation of the higher mass protein to regenerate a protein with
the expected molecular weight of M3 ACP.
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Chapter 3
The intramodular interactions of
quartromicin module 5
3.1 Confirming the catalytic activity of
module 5
M3 ACP,M3 ACPS,M4 ACP,M4 ACPS,M5 ACP,M5 KS,M5 KSATS,M5 KSAT andM5
were all previously overproduced and purified (Table 2.1), along with KS active-site mu-
tants (C207A) and KS/AT active-site mutants (C207A/S656C).
The proposed role of M5 in the PKS pathway is to sequester an 8-carbon substrate (from
M3 ACP) or a 10-carbon substrate (fromM4 ACP) and to utilise a malonyl-CoA building
block to catalyse chain extension by two carbons.155 A series of in vitro bioassays were
planned to confirm the intramodular catalytic activity of M5 and also to explore the mod-
ule’s ability to utilise different extender units and substrates.
Figure 3.1. A LC/MS-QTOF chromatogram of apo-M5 (top left) and a chromatogram confirming the successful phos-
phopantetheinylation of M5 (bottom left). Deconvoluted mass spectra corresponding to the intact proteins are also shown
(right).
An extension assay172 was then designed to confirm the ability of the KS to sequester a
pantetheine-bound polyketide, the AT to utilise a malonyl-derived extender unit and the
modules’ ability to successfully catalyse the translocation of an extender unit to M5 ACP
and subsequent extension of the KS-bound polyketide by incubation with intact M5, a
CoA-bound extender unit and a pantetheine-bound substrate mumic. Successful conver-
sion from apo- to holo-M5 was confirmed by LC/MS (Figure 3.1). Holo-M5 was then in-
cubated with malonyl-CoA and octanoyl-SNAC. Octanoyl-SNAC was chosen as a mimic
of the polyketide transferred from M3 ACP to M5 KS. Malonyl-CoA was chosen as it
is the predicted extender unit utilised by M5. LC/MS analysis of the assay mixture
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showed a peak in the deconvoluted mass spectra at 141,588 Da, corresponding to 3-
keto-decanoyl-holo-M5. Collision-induced dissociation (CID) provided confirmation the
change had occurred on the pantetheine moiety, due to the presence of ejected 3-keto-
decanoyl-pantetheine (429.24 Da, Figure 3.2).
Figure 3.2. Schematic representation of an SNAC-bound polyketide subunit being extended by a malonyl extender
unit, resulting in the extension of the polyketide chain by one keto group (top). Deconvoluted spectra (bottom left)
and corresponding EICs (bottom right) from LC/MS analyses of holo-M5 incubated with octanoyl-SNAC or decanoyl-
pantetheine. Assay components are shown on the left of each EIC. Ejected pantetheines and m/z are displayed on the
right (± 0.05 Da).
CID results in a proportion of the phosphopantetheinyl moiety being ejected from holo-
ACPs, leaving a phosphate ion attached to the ACP’s PTM serine residue. In single do-
main ACPs, this dissociation has to be forced by supplying energy, but due to the large
molecular weight of M5, it occurs spontaneously during ionisation. A five-membered
tetrahydrofuranol ring with a protonated imine is formed when the carbonyl of an amide
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displaces the pantetheinyl unit (Figure 3.3). The simplicity of detecting relatively small
fragment ions through extracted ion chromatograms (EIC), compared to the mass change
of an intact protein, is particularly practical in analysing whether a large protein complex,
such as M5, has successfully extended a polyketide substrate.
Figure 3.3. The mechanism of CID induced pantetheine ejection from a holo-ACP.
The experimentwas then repeatedwith decanoyl-pantetheine, in place of octanoyl-SNAC,
as a mimic of the substrate transferred from M4 ACP. A pantetheine substrate was used
because longer chain SNAC substrates are likely to be insoluble. Although deconvolution
of the spectra resulted in a peak corresponding to 3-keto-dodecanoyl-holo-M5 (141,616
Da), no ejected 3-keto-dodecanoyl-pantetheine (457.27 Da) was detected.
Combined, these experiments confirm the ability of the AT domain of module 5 to load
malonyl-CoA and for the KS domain to accept either 8-carbon or 10-carbon chains and
catalyse chain extension, fulfilling the predicted role of M5 in the biosynthetic pathway.
3.1.1 Exploring module 5’s ability to utilise different
malonyl-derived extender units
To produce the predicted polyketides necessary to form the skeleton of quartromicin, M5
is proposed to only use malonyl-CoA extender units. Furthermore, the AT domain con-
tains a conservedHAFHmotif in the active-site which is proposed to control themodule’s
extender unit specificity, meaning it can only catalyse the sequestering of malonyl exten-
der units.173 ATs with a conserved YASH motif are reported to utilise methylmalonyl
extender units. This is proposed to be because the limited room in the binding pocket of
ATs containing a HAFH motif, due to the extra molecules of the phenylalanine residue
(as opposed to a serine), prevents the methylmalonyl extender unit from entering the
binding pocket. This would prevent the AT domain from catalysing the sequestering of a
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methylmalonyl extender unit and result in no extended product.
Figure 3.4. Schematic representations of M5 extending an octanoyl-SNAC with a methylmalonyl extender unit (left)
and EICs from LC/MS analyses following incubation of octanoyl-SNAC with holo-M5 and methylmalonyl-CoA (top) and
methylmalonyl-holo-M5 (bottom). Components of the assays are displayed on the left. Ejected pantetheines and m/z are
displayed on the right (± 0.05 Da).
Holo-M5 was incubated with octanoyl-SNAC and methylmalonyl-CoA. LC/MS analy-
sis showed no peaks corresponding to ejected pantetheine containing an extended prod-
uct (Figure 3.4). This suggests that M5 is only able to utilise a malonyl extender unit
due to the AT’s inability to catalyse the sequestering of a methylmalonyl extender unit
for the ACP. To confirm whether an elongated product could be produced if a methyl-
malonyl extender unit was loaded directly onto the ACP, M5 was directly converted to
methylmalonyl-holo-M5 by incubation with methylmalonyl-CoA, Sfp and MgCl2, before
incubation with octanoyl-SNAC. A peak was observed with m/z 443.26 Da, which was
absent in the control, corresponding to the successful extension of the octanoyl substrate
with a methylmalonyl extender unit. This indicates that the extender unit selectivity of
M5 is due to the AT domain’s inability to sequester a methylmalonyl extender unit.
3.1.2 Systematically probing the substrate specificity of
module 5
The second consideration in the intramodular functionality of M5 was which substrates
M5 could sequester and elongate with a malonyl-extender unit. PKS modules have pre-
viously been shown to have a wide substrate tolerance, with a range of tested polyketide
59
substrates successfully elongated.174 Confirming the substrate tolerance of M5 will help
elucidate whether it plays a role in ensuring the PKS pathway’s fidelity.
A number of SNAC/pantetheine-bound substrates were synthesised by Matthew Beech,
Christian Hobson, Dr. Joleen Masschelein and Dr. Shan Shan Zhou (Figure 3.5).175 Whilst
the shorter chain substrates were synthesised as SNAC derivatives, the dodecanoyl sub-
strate was coupled to pantetheine. This was due to potential solubility issues when cou-
pled to SNACs, as discussed for decanoyl-pantetheine previously.
A number of substrates were used to determine whether the length of the carbon chain
has any effect on substrate tolerance. The previous elongation assays were repeated with
propionyl-SNAC (3-carbon chain) and dodecanoyl-pantetheine (12-carbon chain). Suc-
cessful elongation was seen in both cases (Figure 3.6, 359.19 and 485.30 Da, respectively),
suggesting substrate length has no role in selectivity. Next, a tert-butanoyl-SNAC was
utilised to test whether additional methyl groups would have an effect on substrate toler-
ance, resulting in detection of extended product (387.19 Da). Unsaturated-hexanoyl was
also tested to determine whether double bonds in the carbon chain had an effect, with
extended product detected (397.18 Da). Furthermore, 3-keto-octanoyl-SNAC was also
successfully loaded and extended (443.22 Da), although in significantly reduced quanti-
ties (< 5 %). This potentially suggests that M5 less efficiently extends polyketides with a
3-keto group, although the reduction in detected product could potentially be due to an
increased level of hydrolysis of the β-keto thioester.
Studying substrate selectivity has shown that M5 tolerates a wide range of substrates.
Therefore, it is unlikely that M5’s substrate tolerance plays a significant role in maintain-
ing the selective promiscuity of the QMN PKS module skipping mechanism.
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Figure 3.5. S-N-acetylcysteamine (top left) and pantetheine (top right) thioesters.The SNAC and pantetheine-bound
substrates used to probe M5’s substrate tolerance (bottom).
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Figure 3.6. EICs for LC/MS analyses following incubation of holo-M5 with malonyl-CoA and various SNAC/pantetheine-
bound substrates. Components of the assays are displayed on the left. The ejected pantetheines and m/z are displayed
on the right (± 0.05 Da).
3.2 Intramodular cross-linking of
quartromicin module 5
The ability to structurally characterise protein-protein interactions within PKS systems is
severely limited due to their transient nature. In order to study such interactions, a site-
specific enzymatic cross-linking approach may be utilised.176 A pantetheine cross-linker
(Matthew Jenner, pantetheine chloroacrylamide), containing a terminal chlorine leaving
group, may be loaded onto an ACP’s PTM serine through incubation with CoA synthase
enzymes. The ACP-loaded linker should then be delivered to the active-site of a com-
patible KS domain, where the thiol of the active-site cysteine may attack the terminal
chlorine of the cross-linker. This would result in the formation of a stable covalent linker
between the KS and ACP domains of approximately the same length as a Ppant arm, en-
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suring the KS and ACP domains are proximal to their positions during the elongation
of a polyketide product. In addition to being a useful structural biology tool, the extent
of cross-linking between two domains has been reported to correspond to the strength
of protein-protein interactions occurring.177 Therefore, not only does enzymatic cross-
linking allow the presence of interactions to be identified, it also allows the estimation of
affinity between two proteins.
Figure 3.7. Schematic representation of the intramodular cross-linking between the KS and ACP of M5 (top). LC/MS
chromatograms of apo-M5 and intramodularly KS-ACP cross-linked M5 (KS-ACP, bottom).
M5 was incubated with the cross-linker and the enzymes required for loading the cross-
linker to the ACP’s PTM serine, resulting in successful KS-ACP cross-linking as deter-
mined by an increase in molecular weight of 413 Da in the deconvoluted mass spectra of
M5 (Figure 3.7).
M5 contains KS, AT and ACP domains, as well as a 310 residue linker region between
the AT and ACP (AT-ACP linker). To determine the importance of each domain and the
linker region, M5’s ACP (M5 ACP) was incubated with pantetheine chloroacrylamide
and either M5 KS, M5 KSATS (without linker region) or M5 KSAT (with linker region).
Analysis by SDS-PAGE (Figure 3.8) showed successful cross-linking to the KS domain of
M5 KSAT as a new band was present at 140 kDa, compared to the control in which no
cross-linker was added.178 Neither of the constructs lacking the AT-ACP linker (M5 KS
and M5 KSATS) showed any sign of cross-linking.
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Figure 3.8. SDS-PAGE analysis following attempted cross-linking of M5 ACP with (i) M5 KS, (ii) M5 KSATS and (iii)
M5 KSAT variants. Variants in each lane are (a) WT control (in which cross-linker was omitted), (b) WT, (c) C207A
mutants and (d) C207A/S656C mutants.
C207A variants of each construct had previously been produced to prevent cross-linking
to the KS active-site. These constructs acted as negative controls in order to show the
specificity of the cross-linking interactions was to the KS domain. SDS-PAGE analysis of
each C207A variant incubated with cross-linker loaded M5 ACP displayed no bands of
increased mass, indicating no cross-linking had occurred and confirming the increased
mass band seen for M5 KSAT corresponds to KS-ACP cross-linking.
C207A/S656C variants were also available where the serine of the AT active-site had
been mutated to a cysteine. This would allow cross-linking between the AT and ACP
domains, as well as ensuring no KS-ACP cross-linking occurred. SDS-PAGE analysis of
M5 KSAT-C207A/S656C with cross-linker loaded M5 ACP resulted in a band of ∼ 140
kDa, confirming AT-ACP cross-linking. Constructs omitting the AT-ACP linker region
(M5 KS-C207A/S656C and M5 KSATS-C207A/S656C) showed no sign of cross-linking.
3.3 Conclusion
The ability of M5 to sequester and elongate different extender units and polyketide sub-
strates was studied. An 8-carbon substrate mimic andmalonyl-extender unit successfully
produced an elongated product, confirming the catalytic functionality of the construct.
Probing of extender unit specificity indicated that M5 could only utilise a malonyl ex-
tender unit. M5 was able to extend a polyketide chain when a methylmalonyl extender
unit was loaded directly onto the ACP, suggesting the module’s extender unit specificity
was due to the AT being unable to catalyse the sequestering of a methylmalonyl extender
unit. This agrees with previous experimental data that suggests modules containing a
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conserved HAFH motif are only able to utilise malonyl extender units.
M5 was shown to have a wide substrate tolerance, with elongated products detected for
a number of different substrates. Varying lengths of substrate were successfully extended
(3, 8, 10 and 12-carbons), as well as saturated chains and chains containing extra methyl
groups and a 3-keto group. This suggests that the modules’ substrate tolerance is ex-
tremely wide and that the fidelity of the pathway is likely governed by other factors.
The next step is to probe M3 and M4’s intramodular catalytic functionality through the
range of substrates and extender unit assays. Cloning and overproduction of constructs
containing various regions of M3 and M4 would allow further cross-linking assays to de-
termine the importance of each region in both modules’ intramodular functionality. This
will be discussed in chapter 5.
Interactions between M5 ACP and both the KS and AT domain of M5 were shown via
chemical cross-linking, with no preference given for a specific domain. The ability to
cross-link KS and AT domains to ACPs could be of significant advantage in structurally
studying polyketide modules and domain complexes. Being able to ensure the proximity
of KS or AT active-sites to the ACP’s PTM serine could allow the study of transient con-
formational states, as well as potentially reducing structural mobility. This would allow
techniques such as X-ray crystallography to be considered, possibly providing greater in-
sights into the PKS system. The locking of M5 in both intramodular conformations, as
well as with upstream and downstream modules, would also be potentially beneficial in
obtaining cryo-EM maps of the module in each stage of its catalytic cycle.
KS-ACP and AT-ACP interactions were only observable for constructs containing the AT-
ACP linker region, suggesting the region plays a vital role in ensuring the module’s func-
tionality. The importance of the AT-ACP linker region will be explored in chapter 4.
65
Chapter 4
Structural studies on module 5 of
quartromicin
4.1 Introduction
Constructs containing various regions of M5 had previously been overproduced and pu-
rified (chapter 2, Figure 4.1).
Figure 4.1. Available constructs containing various domains and regions of M5 (A) and homology models for M5 ACP
(B), M5 KS (C), M5 KSAT (D) and M5 (E).
There are various ways of obtaining structural information on a biological system. The
most basic is gel filtration, in which proteins are separated according to size, allowing the
determination of the protein’s oligomerisation state. To obtain more detailed information
about the molecular interactions within proteins, a variety of methods may be used de-
pending on the size and flexibility of the construct of interest.
Relatively small proteins (< 20 kDa) may be structurally elucidated by NMR. The fact
that over 10,000 NMR structures can be found on the PDB (including numerous ACP
domains) attests to the technique’s capabilities, with protein complexes containing over
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1,000 residues being structurally elucidated by solution-state NMR.179–181;55;182 Other do-
mains that are too large to be solved by NMR, but less structurally mobile, may poten-
tially be crystallised, opening up the possibility of utilising X-ray crystallography. Do-
mains which have been structurally solved by X-ray crystallography include KR,110;111
DH,112;113 ER33 and TE domains,114;115 as well as KS-AT108;116;117 andKR-ER didomains,76
commonly to resolutions of below 2 A˚.
Entire modules or complexes that are too structurally mobile to crystallise may be struc-
turally elucidated by cryogenic-electron microscopy (cryo-EM).117;123 However, the re-
duced resolution (5 - 10 A˚) requires modelling in of high-resolution homologous struc-
tures for each domain to acquire information on a residue level.
4.2 Structural elucidation of module 5’s
ACP domain
Circular dichroism (CD) was used to determine conditions in which M5 ACP was well
folded. Variable pH-CD indicated that M5 ACP (pI = 5.08) was structurally stable be-
tween pH 5.5 and 8.0, with a reduction in absorbance at 208 nm (indicative of unfolding)
observed only for pH 5.0 (Figure 4.2). Variable-temperature CD showed a reduction in
absorbance at 208 nm between 35 and 40oC.
[U-15N]-M5 ACPwas overproduced (usingminimalmedia containing 15NH4 Cl) and pu-
rified, and HSQCs were acquired in phosphate buffer. A range of different temperatures
and pH values in which the protein had previously been shown to be stable were inves-
tigated (Figure 4.3). The HSQC’s showed a wider dispersion of peaks at pH 6.5 than pH
7.0, and for 15oC compared to higher temperatures. This is indicative of higher levels
of folding and would likely provide spectra that are easier to assign. Promisingly, the
sample retained structural integrity for 24 hours, allowing a larger number of scans to be
undertaken. However, due to the number of solved ACP structures and high similarity
between ACPs, other structural work was prioritised until a cryo-EM map of the entire
module could be elucidated.
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Figure 4.2. Variable-pH (a) and temperature CD spectra for M5 ACP. The variable-temperature correspond to raising
(b) and reducing temperatures (c).
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# #
Figure 4.3. HSQC spectra of [U-15N]-M5 ACP. pH 6.5 (top left) at 15, 20 and 25 oC, and pH 7.0 (top right) at 10, 15, 20
and 25 oC. An HSQC of M5 ACP obtained at 15 oC (bottom left) displays pH 6.5 and pH 7.0 and pH 6.5 (bottom right) on
the day the sample was prepared and a day later at 15 oC. NS = 32 (top left, top right and bottom left) and 132 (bottom
right).
4.3 Structural elucidation of quartromicin
module 5’s KS-AT didomain
As discussed in section 4.1, crystallisation of intact M5 would likely prove challenging
due to the presence of the structurallymobile ACP domain and its largemolecular weight.
Initial trials were therefore carried out with M5 KSATS, which does not contain the flex-
ible ACP domain or the linker region between the AT and ACP domains.
4.3.1 Crystallisation of module 5’s KS-AT didomain
M5 KSATS was overproduced and purified as described in section 7.3. Screening in 96-
well sitting drop crystal trays, containing JCSG Core I and II screens, produced a number
of crystals (Figure 4.4). Cryogenic freezing and diffraction on beamline I06 at Diamond
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NeedlesSpindlesSmall globular crystals
Figure 4.4. Crystals obtained for M5 KSATS.
Light Source showed the crystals obtained from conditions E9 and H2 of Core I contained
protein (Figure 4.5). Unfortunately, the small crystals only diffracted to 6 - 8 A˚, meaning
further optimisation would be required for the crystals to be of sufficient quality to obtain
a high-resolution structure.
Figure 4.5. Diffraction pattern of a M5 KSATS crystal produced under condition H2 of Qiagen Core I.
Further optimisation, based upon the conditions containing protein crystals was then
planned. The trials were based extensively around 4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid (HEPES) and sodium citrate buffers, with Polyethylene glycol (pEG) 3350,
due to their presence in a number of promising conditions. Crystal trials were set up in
sitting drop wells with 1:1, 2:1 and 3:1 (sample to buffer) ratios. Wells contained either
0.1 M HEPES or 0.1 M sodium citrate, both at pH 6.5, with 20% pEG 3350 and a range of
71
different salts (NaCl, CaCl2, HK2O4P, MgSO4, ClK, H2KO4P and HNa2O4P, all 0.2 M).
Further optimisation of salt levels (0.05 - 0.5 M) and pEG 3350 concentrations (17 - 23 %)
were carried out around the most promising conditions at both room temperature and
4◦C, at a range of protein to buffer concentrations (1:2, 1:1, 2:1 and 3:1) and in sitting and
hanging drop trays. pH was also adjusted for some conditions (pH 6.0 - 8.5) and sample
concentration was varied (2 - 10 mg/mL). However, no significant improvements upon
the original crystals were seen, potentially due to unfavourable entropy.
Since M5 KSATS was unexpectedly monomeric, crystallisation trials were repeated using
full-lengthM5 KSAT, which is dimeric and contains the KS-AT didomain and the AT-ACP
linker region. Crystallisation trials were set up using all four cores of JCSG Core suite in
96-well sitting drop plates, but no improvements on the crystals produced for M5 KSATS
were found.
4.4 Probing the interactions between
M5 KSAT and M5 ACP using
carbene footprinting
All work in section 4.4 was done by Dr. Matthew Jenner using the previously produced
homology models. Carbene footprinting was used in an attempt to map interactions
onto homology models of M5 KSAT and M5 ACP as previous work had failed to pro-
vide structural information on the domains of M5.
Carbene footprinting is a recently developed technique that provides information on
which residues are involved in protein-protein interactions.183 Protein labelling is achieved
via incubation with an aryl diazirine reagent, which upon laser irradiation at 350 nm lib-
erates the N2 and yields a highly reactive carbene species in situ. The carbene has the
ability to insert into C-H bonds of non-polar amino acid sidechains, such as in trypto-
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phan, and the O-H, N-H or S-H of polar amino acid sidechains, such as in lysine and argi-
nine, thereby providing a wide labelling coverage of the solvent-exposed surface. Protein
samples are then enzymatically digested, using trypsin, and the resulting peptides are
examined by mass spectrometry. Comparison of the isolated domain with labelled com-
plexes will then allow the deciphering of interaction surfaces from the disappearance of
visible peptides (Figure 4.6).
Figure 4.6. The workflow process of carbene footprinting for hen egg white lysozyme (HEWL, top). 183 Carbene
footprinting allows the identification of residues masked as a result of protein-protein interactions (bottom).
M5, M5 KSAT and M5 ACP were diazirene labelled and enzymatically digested. No la-
belling was observed on the KS or AT domains for both M5 KSAT as a stand-alone con-
struct, or as part of the complete module. This indicates that the corresponding residues
were inaccessible, perhaps due to aggregation. In contrast, labelling was observed on the
three peptide fragments of the ACP domain for both the standalone M5 ACP construct
and the entire M5, suggesting that the ACP domain was not aggregated.
Residues 114-121 of the ACP domain exhibited similar levels of labelling in the presence
and absence of the rest of M5 (Figure 4.7), suggesting that they were not involved in any
intramodular protein-protein interactions. Due to its location at the C-terminus of the
ACP’s final helix, it perhaps plays more of a role in interactions with the downstream
post-PKS enzymes. Diazirine labelling of the peptides corresponding to residues 53 - 66
and 101 - 113 of the ACP domain was significantly masked in M5, compared to M5 ACP,
suggesting these regions were involved in intramodular protein-protein interactions or
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were involved in the module’s aggregation.
Figure 4.7. The fractional labelling seen for M5 ACP peptides after AspN digests (left). A homology model (Phyre)
highlighting the two peptides (53 - 66 and 101 - 113) significantly masked in M5 (right), along with the substrate attach-
ment site (DSL).
M5 was also diazirene-labelled in its holo, malonyl-holo and acetyl-acetyl-holo forms, all
resulting in no labelling of the KS-AT regions and no statistically significant deviation
from the labelling of apo-M5.
4.5 Structural motifs involved in the
dimerisation of module 5
As mentioned in section 2.3.3, although M5 and M5 KSAT are dimeric, M5 KSATS (with-
out the AT-ACP linker region) is monomeric. This is surprising as module dimerisation is
virtually reliant on interactions between KS domains, which have large interaction inter-
faces. Although in this system, KS domain dimerisation is certain to play a role in module
dimerisation, it is probable that a second dimerisation motif exists in the linker region.
There are other systems in which the KS domain is not solely responsible for modular
dimerisation. DH domains, for example, also usually purify as dimers and can play roles
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in modular dimerisation.123 Additionally, it was also recently suggested that the ACP
domain in PikAIII contains a second dimerisation motif since the removal of the ACP
domain results in a loss of dimerisation.117 Although ACP docking domains have previ-
ously been shown to dimerise124 and could therefore play this role, M5 ACP has no such
docking domain as there is no need to facilitate interactions with a downstream KS.
Figure 4.8. A homology model of M5’s AT-ACP linker region (left) and crystal structures of a KR (top right) and ER
(bottom right) domain. The highlighted α-helix of M5-KRD is essential for module dimerisation and the β-strands are not.
A homology model was created for the AT-ACP linker region to search for the presence
of known structural motifs (Figure 4.8). One identified motif was a partial Rossmann fold
that formed an extended β-sheet, suggesting the linker region may contain remnants of a
historical KR or ER domain. One of the most common super-secondary structures, Ross-
mann folds consist of a nucleotide-binding βαβ fold, with the possible addition of extra
β-strands to create an extended β-sheet. Rossmann folds show a low level of sequence
similarity between families, with the only widely conserved motif being a GxGxxG/A
motif located in the tight bend between the first β-strand and α-helix. Dimerisation has
been noted between Rossmann folds in a number of solved structures, such as dehy-
drogenases (PDB: 1a71, 1A4I),184;185 indicating the regions could play a role in module
dimerisation.
In order to investigate the boundaries of the dimerisation interface, three C-terminal (Fig-
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Figure 4.9. Sequence (top) and a homology model (bottom left) showing the termination points of various truncated
M5 constructs (bottom right).
ure 4.9) and four N-terminal truncated constructs were overproduced. Of the three C-
terminal truncated constructs, M5 KSAT∆283 (residues 1 - 915, 100,970 Da) andM5 KSAT
∆136 (residues 1 - 1062, 117,115 Da) almost completely aggregated and M5 KSAT∆72
(residues 1 - 1126, 123,947 Da) corresponded to a monomeric eluted protein (Figure 4.10).
As this construct omits 72 residues from the C-terminal of M5 KSAT, this suggests that
these residues were essential for module dimerisation. Three further intermediate con-
structs were overproduced, with M5 KSAT∆38 (residues 1 - 1160, 127,548 Da) and M5
KSAT∆21 (residues 1 - 1177, 129,231 Da) being soluble andM5 KSAT∆60 insoluble (residues
1 - 1138, 125,285 Da). M5 KSAT∆38 and M5 KSAT∆21 both corresponded to dimeric pro-
tein complexes, suggesting the loss of dimerisation occurs between residues 1126 and
1160. As this region only contains an α-helix, it can be assumed that the α-helix plays a
vital role in module dimerisation. It can also be concluded that the final three β-strands
that are proposed to form part of an extended β-sheet are not essential to module dimeri-
sation. The α-helix in question is located within a hydrophobic pocket, meaning the large
amount of aggregation seen for M5 KSAT∆38 could be due to the removal of the β-sheet
exposing the helix, resulting in the protein unfolding.
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Figure 4.10. Gel filtration chromatograms of Superdex 200 calibration (top left), SDS-PAGE analysis of overproduced
truncated M5 constructs (top right) and corresponding gel filtration (bottom) that formed either monomers (*) or dimers
(**) of M5 (141 kDa), M5 KSAT ((i), 131 kDa), M5 KSAT∆38 ((ii), 128 kDa), M5 KSAT∆72 ((iii), 124 kDa) and M5 KSATS
((iv), 98 kDa).
Sequence analysis indicated that the linker region contained significant structural similar-
ity to known KRs (e.g. from spinosyn module 3), with several domain finding algorithms
labelling the linker region as a KR domain. Although M5’s linker region is too short to be
a complete KR, and no reduction of the β-keto group occurs, the region contains a con-
served tryptophan, indicative of an A-type KR, and an active-site tyrosine. The proposed
role in module dimerisation has led to the region being termed a KR dimerisation motif
(KRD).
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Figure 4.11. A homology model showing the predicted structure of overproduced constructs containing various lengths
of M5’s AT-ACP linker region.
N-terminal truncations (Figure 4.11) showed M5 KRD-A (residues 960 - 1198, 29,036 Da),
M5 KRD-B (residues 1014 - 1198, 23,319 Da) and M5 KRD-C (residues 1063 - 1198, 17,825
Da) to be homodimers (54, 42 and 34 kDa, respectively), whereas M5 KRD-D (residues
1103 - 1198, 13,526 Da) completely aggregated (Figure 4.12). Each dimerising construct
contained at least two α-helices, one of which was previously shown to be essential for
module dimerisation, and a β-sheet that could potentially provide an interaction interface
with the corresponding β-sheet of a dimeric partners’ KRD.
X-ray crystallography of the AT-ACP linker region was then attempted. M5 KRD-A was
chosen as the ideal construct for crystallisation due to a low level of aggregation. To
increase the chances of crystallisation, the His-tag was cleaved with TEV (tobacco etch
virus)-Sfp (surfactin phosphopantetheinyl transferase) before removal of the TEV-Sfp and
uncleaved proteins by reverse NTA column. The cleaved protein was then further puri-
fied by gel filtration and the fractions containing the protein were transferred into a buffer
of 20 mM Tris, 50 mMNaCl, pH 7.4 by PD10 column. The protein was concentrated to 10
mg/mL and crystallisation conditions were tested using Qiagen cores I and II. Unfortu-
nately, no crystals were obtained.
Spirotetronate producing PKS pathways ubiquitously end with standalone modules re-
sponsible for a non-reductive elongation. Sequence alignments with the final modules of
other spirotetronate PKSs were carried out (Figure 8.3), with a number of these modules
shown to contain significantly shorter AT-ACP linker regions (< 100 residues) and no
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Figure 4.12. Calibration of the Superdex 75 (top left), SDS-PAGE analysis of overproduced KRD proteins (top right)
and gel filtration chromatograms of constructs containing varying lengths of M5’s AT-ACP linker region (bottom) that
formed dimers (**) or completely aggregated (Ve/V0 = 1). KRD-A (A, 29 kDa), KRD-B (B, 23 kDa), KRD-C (C, 17 kDa)
and KRD-D (D, 14 kDa).
remnants of Rossmann folds. However, the final modules of the chlorothricin and kijan-
imicin PKS pathways (ChlA6 and KijS5) contain AT-ACP linkers that display significant
sequence similarity/identity to M5 (71/60 and 59/50 %, respectively). Although the link-
ers for ChlA6 and KijS5 are substantially longer (∼ 510 and 390 residues, Figure 4.13),
they also contain regions predicted to be Rossmann folds.
KijS5 has previously been reported to contain a non-elongating KR andChlA6 to be amin-
imal module.147;186 Although the regions were too short to contain an entire KR, several
domain picking algorithms predicted the linker regions as KR domains. ChlA6 also con-
tained a conserved LDDmotif, indicative of a B-type KR, and a GGxGxxGNADP-binding
motif (GGPGVTG),187 further suggested it was a KR remnant. Further sequence analysis
showed that ChlA6 and KijS5’s AT-ACP linker regions contained a dimerisation element
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Figure 4.13. Homology models of the AT-ACP linker region of ChlA6 (left) and KijS6 (right). α-helices and β-strands
are displayed. Models were based upon the following structures: 2vz8, 6fik, 6c9u (ChlA6 and KijS5)
found between the AT and KR domains of various PKS systems,122 followed by the rem-
nants of a KR, leading to the regions also being labelled as KRDs. The same dimerisation
element was not present in M5, suggesting the presence of a novel dimerisation motif
within M5-KRD.
4.6 The morphology of module 5
Cryo-EMwas first successfully applied to the study of PKSs in 2014, when cryo-EM struc-
tures were obtained for the penultimate module of pikromycin PKS (PikAIII, β-module)
in each conformation of its catalytic cycle.123;188
4.6.1 Sample optimisation of module 5
The folding of M5 under various conditions was first confirmed using circular dichroism
(CD), before further examination at varying temperatures showed a significant reduction
in absorbance at 208 nm between approximately 35oC and 50oC. This indicates that M5
is stable at room temperature over a short time period (2 hours) and starts to unfold at
approximately 35oC (Figure 4.14).
Negative-stain EM was used to obtain preliminary images to assess the quality of the
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Figure 4.14. Variable-temperature CD spectra of M5 at pH 6.5.
sample. The advantage of negative-stain EM is that the background is stained with a
heavy metal, creating a contrast between the sample and the background without stain-
ing of the sample. This ensures that the conformation of the protein is not affected by the
staining procedure, whilst providing the required contrast for images of the sample to be
collected. Although negative-stain is suitable for gaining a base level understanding of
the sample, cryo-EM would be needed to reach the levels required to gain any significant
structural information.
Figure 4.15. Gel filtration chromatograms for M5 (S200, 20 mM Tris, 150 mM NaCl and varying levels of glycerol).
Gel filtration was used to assess the level of aggregation of M5 under various buffer con-
ditions, with optimal conditions found to be 20 mM Tris, 150 mM NaCl, 10 % glycerol,
pH 7.4. To acquire cryo-EM pictograms, it is advantageous to have lower glycerol levels
to prevent a loss of contrast. Therefore, further optimisation was carried out in which
lower glycerol levels were tested (2 % and 5 %). Both resulted in significant aggregation
(Figure 4.15). Therefore, 10 % glycerol was used in all buffers.
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Figure 4.16. Negative-stain electron microscopy image of M5 (left, light areas). A cryo-EM visualisation of M5 with
Ni-NTA-Au (right, Daniel Griffiths). Each black dot corresponds to an M5 homodimer with Au bound to each of the KS
docking domains.
Figure 4.17. 2-D cryo-EM reconstructions of individual M5 dimers.
Negative-stain EM highlighted M5’s propensity to aggregate (Figure 4.16 (left)). As a re-
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sult, other work was prioritised and acquisition of a morphological map for M5 was fol-
lowed up by Dr. Daniel Griffiths, a postdoctoral researcher in the group, based at Monash
University. Cryo-EM images were obtained of unconcentrated fresh protein samples,
directly off the gel filtration column, in an attempt to limit aggregation. These images
showed aggregation had decreased significantly (Figure 4.16 (right)) and 2-D particle av-
eraging indicated the observed particles were of approximately the same size in different
orientations (Figure 4.17), highlighting the homogeneity of the sample. However, the im-
ages acquired were not of high enough quality to consider producing a 3-D morphology
model of M5.
Examination of the 2-D reconstructions led to some interesting observations. A significant
number of the reconstructions showedM5 to form a central chamber, similar to what was
noted for PikAIII. One end of the observed chamber is wider in each case, likely corre-
sponding to two KS domains with a large interaction interface (Figure 4.18). Either side of
the reaction chamber is likely to be the AT domains, which are proposed not to associate
in PKS systems, followed by the KRD region with a contact region corresponding to the
dimerisation motif (section 4.5). The ACP is likely to be omitted from these reconstruc-
tions due to its structural mobility. The other reconstructions are likely to correspond to
various orientations of the same structural conformation.
Figure 4.18. A 2-D cryo-EM reconstruction of a M5 dimer (left) and a schematic representation (right).
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4.7 Conclusion
Structural elucidation ofM5’s componentswas attempted through a variety of approaches,
including NMR, X-ray crystallography, cryo-EM, carbene footprinting and gel filtration.
Most of these approaches were hindered due to the high propensity of M5 to aggregate.
Sample optimisation of M5 ACP resulted in suitable samples for further structural elu-
cidation and sample optimisation of the KS-AT didomain prevented aggregation and al-
lowed the obtaining of small crystals. Although diffraction was observed for two crystals,
they did not provide the necessary resolution to acquire a structure (6 - 8 A˚).
Carbene footprinting of M5, using homology models, identified two regions on the ACP
that interact with the rest of the module. However, no labelling was observed in the KS
and AT domains, suggesting aggregation had occurred. This is possibly indicative of the
formation of a higher order structure involving the KS and AT domains, leaving the ACP
free to interact with the post-PKS enzymes.
Analytical gel filtration showed that the removal of a linker region between the AT and
ACP domains resulted in a loss of dimerisation. Further intermediate constructs showed
dimerisation was lost between residues 1126 and 1160, a region containing a long α-helix,
suggesting this region plays a vital role in module dimerisation. N-terminal truncated
constructs were also produced to determine the start of the region essential for mod-
ule dimerisation. Analytical gel filtration of three different constructs showed they were
dimers. Importantly, each of these three constructs contained the α-helix shown to be es-
sential for module dimerisation, as well as a β-sheet. It was subsequently hypothesised
that the linker regions long β-sheet was able to pair to a dimerisation partner to provide
an interaction interface, supporting a dimerisation element formed by the intermodular
linking of α-helices.
Sequence analysis of the linker region suggested it contained the remnants of a KR do-
main. AT-ACP linker regions were also noted in ChlA6 and KijS5, both of which con-
tained the conserved residues of a previously noted dimerisation element not present in
M5-KRD.122
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Finally, cryo-EM images showed single particles of M5 were observed from various ori-
entations. A chamber was observed in a significant number of the reconstructions, with
what appears to be a large KS-KS dimerisation interface on one side and a smaller contact
region on the other side. This was proposed to be the hypothesised dimerisation motif
located towards the end of the AT-ACP linker region.
4.8 Future Work
Structural elucidation of the AT-ACP linker region would provide information on the
dimerisation motif. Both X-ray crystallography and NMR would be potentially viable
ways to understand the linker region functions. The homologous region of ChlA6 could
also be targeted, allowing comparisons with M5’s linker.
Using cryo-EM to elucidate the structure of M5 in its varying conformations will be the
second priority. Further optimisation may provide a suitable sample to allow this. Acqui-
sition of approximately two hundred 2-D class averages representing a range of particle
orientations would allow for the creation of a de novo 3-D model, before refinement of
the resulting structure could provide a morphology map of M5.
Successful acquisition of a morphology model would provide motivation to resume the
acquisition of a high-resolution structure of M5 ACP. 3-D spectra (cbcaconh, cbcanh, . . . )
would first be acquired, allowing complete backbone assignment. Distance restraints
could then be acquired through a 15N Nuclear Overhauser Effect Spectroscopy (NOESY)
HSQC from which an experimental 3-D structure of M5 ACP could be acquired and
mapped into M5. Any solved structure of the AT-ACP linker region and a homologous
KS-AT didomain could then be mapped into M5, creating a pseudo-atomic level structure
of the entire module in each step of its catalytic cycle.
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4.9 A homologous gene cluster in Amy-
colatopsis albispora
A blast search of the QMN biosynthetic gene cluster highlighted close similarities with
a region of Amycolatopsis albispora’s gene cluster (Figure 4.19). Homologues of all genes
known to play a role in the production of QMNwere present (Figure 4.20, 83 - 96 % iden-
tity), with qmnM and qmnN the only genes without identified homologues. Homologous
genes to those encoding the QMN PKS pathway were present (88 - 93 % identity), with all
docking domains completely conserved. Genes predicted to encode a number of NRPS
domains were present. Modification of the QMN precursors by the NRPS domains could
result in the production of modified precursors with the potential to formQMN skeletons
with attached functional groups.
Figure 4.19. A comparison of a gene cluster from Amycolatopsis albispora (top) and the homologous quartromicin
biosynthetic gene cluster (bottom).
As the structural elucidation of M5 was problematic, the homologous protein from Amy-
colatopsis albispora could be studied instead. Homology models predicted the protein to
be structurally very similar to M5 (91 / 86 % similarity/identity) and to contain a similar
AT-ACP linker region (Figure 4.21). Sequence alignments of both AT-ACP linkers (77 / 68
%) highlighted the strong similarity and led to the region of Amycolatopsis albispora being
categorised as a KRD.
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Figure 4.20. Proteins hypothetically encoded by the Amycolatopsis albispora (left) and the QMN gene cluster (right).
The resulting predicted precursors for quartromicin (A) and the Amycolatopsisnalbispora gene cluster (B) are also shown.
Figure 4.21. Homology models of QMN module 5 (top left), the homologous module from Amycolatopsis albispora
(top right) and a sequence alignment between the two modules (bottom). Homology models were produced using 2vz8,
6gik and 6c9u in both cases.
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Chapter 5
The intermodular interactions of
quartromicin module 5
5.1 Acyl transfer between upstreamACPs
and quartromicin module 5
An important aspect of the QMN PKS pathway is the intermodular interactions between
M3/M4 and M5. The ability of M5 to successfully accept, extend and modify nascent
polyketides from two different ACPs provides an interesting opportunity to study the in-
teractions between the domains. Understanding the promiscuous selectivity of M5’s KS,
as well as M3’s ACP, may help understand how pathway fidelity is ensured.
Figure 5.1. Schematic representation of acyl transfer from an upstream ACP to a downstream module (a). Deconvo-
luted LC/MS chromatograms (b) monitoring the protein in the box (left). ACPs used were (i) M3 ACP, (ii) M3 ACP, (iii)
M3 ACPT and (iv) M4 ACPT.
Since M3 ACP and M4 ACP appear to contain a C-terminal docking domain, we first
set out to determine whether these docking domains are essential for acyl transfer from
the ACP domains to the KS of module 5. The full-length (M3 ACP and M4 ACP) and
truncated (M3 ACPT and M4 ACPT) upstream ACPs were loaded with acetyl-CoA, as
previously described (chapter 3), before being incubated overnight with buffer (control)
or equimolar quantities ofM5. Intact proteinmass spectrometrywas then used tomonitor
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the loss of an acetyl group from the ACPs. A small amount of holo-ACP can be detected
in all the control experiments due to hydrolysis of the acyl chain. A significant difference
was noted in the presence of M5. Almost complete acyl transfer was observed for each
full-length ACP (Figure 5.1), indicating that both ACPs could transfer a substrate to M5.
Truncation of the docking domain resulted in a decrease to approximately 80 % substrate
transfer, suggesting that whilst the docking domains may play a role in intermodular in-
teractions, they are not essential for substrate transfer.
5.1.1 Calculating the rate of acyl transfer
Assays were then repeated with aliquots taken over a series of time points to better un-
derstand the impact of the docking domain on the rate of transfer (Figure 5.2). The rate
of transfer was noticeably quicker for M3 ACP than M4 ACP. Interestingly, whilst the re-
moval of the docking domain had a significant effect on the rate of transfer fromM3 ACP,
the rate of transfer from M4 ACP was unaffected. In fact, transfer from M4 ACP and the
ACP constructs only containing the four conserved helices (M3 ACPT, andM4 ACPT) all
proceeded at a similar rate. This suggests M3’s ACP docking domain (M3 ACPdd) more
efficiently facilitates acyl transfer than M4’s (M4 ACPdd). For example, after 3 hours of
monitoring the reaction, approximately 15 % transfer was seen from M3 ACP and 10 %
transfer was noted from M3 ACPT, M4 ACP and M4 ACPT.
5.1.2 The stoichiometry of intermodular acyl transfer
Assays were repeated over 90 minutes with varying concentrations of M5 to ACP. Con-
trols were run with equimolar quantities of M5-C207A. Increased levels of transfer off
each ACP was observed as the concentration of M5 increased and more acyl transfer was
observed from M3 ACP than M4 ACP for each concentration (Figure 5.3). Significantly,
the amount of transfer for 1:1 ratios of each ACP to M5 were as expected given previous
results (section 5.1.1).
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Figure 5.2. A graphical representation of acyl transfer to M5 over time (top) and corresponding deconvoluted spectra
for M4 ACP (bottom). Experiments were run in triplicate and errors correspond to one standard deviation.
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Figure 5.3. Graphical representation of acyl transfer to M5 for varying equimolar ratios (top) and corresponding
deconvoluted spectra for M4 ACP (bottom). Experiments were run in triplicate and errors correspond to one standard
deviation.
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5.2 Transfer of 8- and 10-carbon chains
from upstream ACPs to module 5
Although the availability of acetyl-CoA makes it convenient to use acetyl groups to mon-
itor transfer, the substrates accepted by M5 KS in the biosynthesis of QMN are 8- and
10-carbon long chains for M3 ACP and M4 ACP, respectively. Transfer of octanoyl and
decanoyl substrates from the upstream ACPs to M5 was therefore investigated to confirm
the proteins are able to undergo their proposed functions and to determine whether M5
preferentially accepts a specific chain length. An additional advantage is that the increase
in mass corresponding to the transfer of larger substrates onto M5 should be detectable
by LC/MS, confirming the transfer of acyl groups.
M3 ACP andM4 ACP were loaded with octanoyl- or decanoyl-CoA (mimics of their nat-
ural substrates), before incubation with M5 for 12 hours. Controls were run for octanoyl
and decanoyl-holo-ACPs with M5-C207A, an M5 variant containing a mutation to the KS
active-site. No significant levels of conversion to holo-ACPwere seen in each case, indicat-
ing that any substrate transfer seen in the presence of M5 must be to M5 KS’s active-site.
Complete conversion to holo-ACP can be observed for both ACPs with either substrate
in the presence of M5 (Figure 5.4). Furthermore, a corresponding increase in mass was
detected for M5 in each case, confirming the transfer of both 8- and 10-carbon chains oc-
curred. The present results do not indicate a clear substrate tolerance, as both reactions
proceed to completion. Further kinetic analysis would be required to investigate this fur-
ther.
Having established that the KS domain of M5 can accept the proposed 8- and 10-carbon
chains from M3 ACP and M4 ACP, we sought to more accurately replicate the natural
system by allowing module 5 access to both ACPs concurrently. Initially, both ACPs were
loaded with octanoyl- or decanoyl-CoA and incubated together in equimolar quantities
with twice the amount of M5. LC/MS analysis of 1:1:2 ratio samples (M3 ACP: M4 ACP:
M5) confirmed almost complete transfer of both substrates from each ACP and onto M5
(Figure 5.5 (left)). Two M5 variants were observed for each assay, corresponding to both
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Figure 5.4. Deconvoluted LC/MS chromatograms showing the transfer of octanoyl and decanoyl substrates from
M3 ACP and M4 ACP to M5. The box shows the protein being monitored. ACPs used were (i) octanoyl-holo-M3 ACP, (ii)
decanoyl-holo-M3 ACP, (iii) octanoyl-holo-M4 ACP and (iv) decanoyl-holo-M4 ACP. Controls were run with M5-C207A.
octanoyl- and decanoyl-M5. However, as the peaks were not resolved, it was not possi-
ble to accurately determine the proportion of each component. The ratio of transferred
product was not affected by which ACP was loaded with octanoyl-CoA and which was
loaded with decanoyl-CoA.
The experiment was repeated with a 1:1:1 ratio (M3 ACP: M4 ACP: M5) to ensure both
reactions could not be completed. Although LC/MS analysis showed a large proportion
of M3 ACP was deacylated at the end of the reaction, as would be expected given pre-
vious studies on the rate of transfer from M3 ACP and M4 ACP, the difference with the
amount of deacylated M4 ACP was relatively small and is not reflected in the ratio of
octanoyl-M5 to decanoyl-M5 produced (Figure 5.5 (right)). This is perhaps due to the in-
accuracy of ACP concentration.
Although these results correspond with what would be expected given the occurrence of
no significant levels of inhibition, time course or kinetic assays are required to confirm
whether any inhibition is occurring.
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Figure 5.5. Deconvoluted LC/MS chromatograms of the upstream ACPs and M5 incubated together in a 1:1:1 (left)
and a 1:1:2 ratio (right). The box shows the protein being monitored.
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5.3 Intermodular cross-linking of
module 5
Figure 5.6. A chemical representation of a crypto-ACP (left) and deconvoluted LC/MS spectra (right) of crypto-M3 ACP
(expected mass, 20,019 Da), crypto-M4 ACP (19,879 Da), crypto-M3 ACPT (12,621 Da) and crypto-M4 ACPT (12,429
Da).
Having established acyl transferase activity of the KS domain, the protein-protein in-
teractions between the upstream ACPs and the KS of M5 were investigated using the
previously described chemoenzymatic cross-linking approach (section 3.2). M3 ACP,
M3 ACPT, M4 ACP and M4 ACPT were first loaded with the pantetheine chloroacry-
lamide cross-linker (Figure 5.6) and incubated with M5. SDS-PAGE analysis (Figure 5.7)
showed that in both cases a new band appeared, relative to the controls lacking any ACPs.
These bands correspond to mass increases of approximately 20 kDa, 15 kDa, 20 kDa and
15 kDa, respectively, indicating successful cross-linking. Incubation with M5-C207A re-
sulted in no observable cross-linking, indicating that the site of cross-linking is specific
to the active-site of the domain. Interestingly, incubation with M5-C207A/S656C did not
result in cross-linking, suggesting that the upstream ACPs cannot interact with the AT
domain in the same way as M5 ACP. The occurrence of cross-linking in the truncated
ACPs again suggests the docking domains are not essential in facilitating protein-protein
interactions.
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Figure 5.7. Schematic representation of cross-linking between M5 and an ACP (top) and an SDS-PAGE analysis of
cross-linking between M5 (i), M5-C207A (ii) and M5-C207A/S656C (iii) to M3 ACP (a), M3 ACPT (b), M4 ACP (c) and
M4 ACPT (d, bottom). Controls (CTL) correspond to M5 without an ACP.
5.3.1 Exploring the effects of each region of module 5 on
facilitating intermodular interactions
To determine whether all of M5 was essential in facilitating protein-protein interactions
with the upstreamACPs, the cross-linking assays were repeated withM5 constructs omit-
ting various domains and structural motifs. SDS-PAGE analysis showed successful cross-
linking between the upstream ACPs and M5 KSAT, but no cross-linking to M5 KS or
M5 KSATS (Figure 5.8), suggesting the AT-ACP linker region is vital for facilitating up-
stream interactions with M3 ACP and M4 ACP. As previous work has shown that the
constructs lacking a linker region between the AT and ACP domain are unable to func-
tion intramodularly and exist as monomers (chapter 4), this highlights the importance of
the AT-ACP linker region in both the intra- and intermodular functionality of M5.
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Figure 5.8. SDS-PAGE analysis of cross-linking of M3 ACP (a), M3 ACPT (b), M4 ACP (c) and M4 ACPT (d) to
the WT (i), C207A (ii) and C207A/S656C (iii) variants of M5 KS (A), M5 KSATS (B) and M5 KSAT (C) Controls (CTL)
correspond to the truncated M5 constructs.
5.4 Calculating the strength of intersub-
unit interactions
The cross-linking experiments (section 5.3) give an indication of where protein-protein
interactions are occurring, but not about the strength of the interactions. One possible
reason for the higher levels of acyl transfer from M3 ACP to M5 may be due to a higher
binding affinity betweenM5 andM3 ACP than is the case forM4 ACP. The stronger bind-
ing affinity would increase the likelihood of the upstream ACPs binding to the module
and therefore being in close enough proximity to transfer their polyketide substrate.
Attempts to understand the rate of protein-protein interactions using cross-linking proved
unsuccessful (Figure 5.9). Surface plasmon resonance (SPR) was therefore used to study
the binding and dissociation of M5 with both full-length and truncated versions of the
upstream ACPs.
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Figure 5.9. SDS-PAGE analysis of cross-linking at varying time intervals between M5 and M3 ACPT (left) and M3 ACP
(right).
5.4.1 The principles of surface plasmon resonance
When light hits an electrically conducting layer on the interface between materials with a
high and a low refractive index (RI) at the resonance angle, a drop in intensity of the re-
flected light can be detected as a result of an evanescent wave. In SPR, the low RI material
is a liquid channel, the high RI material is a glass prism and the gold layer is inside a flow
channel of a sensor chip, to which a protein (ligand)may be attached. For this to occur, the
surface of the chipmust first be activated using 1-ethyl-3-(3-dimethylaminopropyl)carbodi-
imide (EDC) and N-Hydroxysuccinimide (NHS) before a ligand is immobilised onto the
chip through amine coupling and the remaining sites deactivated using ethanolamine-
HCl (Figure 5.10). Changes in the aqueous layer close to the chip can be monitored by
measuring the RI, allowing confirmation of the ligand binding. The concentration of
protein bound to the surface can be varied to adjust the strength of the binding signal,
independent of the ligand-analyte affinity.
Figure 5.10. The chemical process behind SPR ligand immobilisation. NHS and EDC activate the surface by the
modification of a carboxymethyl group to a N-hydroxysuccinimide ester (a). The primary amine of a lysine residue is
covalently attached to the surface (b) before the remaining EDC-NHS complexes are deactivated by ethanolamine (c).
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Figure 5.11. Schematic dipicting the immobilisation of M5 to an SPR chip and interactions with an ACP analyte189
An analyte may then be passed through the channel containing the surface-bound ligand
and the response of the surface may be measured (Figure 5.11). The level of response,
comparative to an immobilised blank channel, indicates the amount of ligand-analyte
binding. A buffer is then run through the channel and dissociation of the analyte from
the ligand is measured. Association and dissociation constants may then be calculated by
repeating the experiments for a range of concentrations. Kinetic equilibrium association
(KA) and dissociation (KD) constants are defined as follows:
KA =
ka
kd
=
[AB]
[A].[B]
KD =
kd
ka
=
[A].[B]
[AB]
,
where A and B are the ligand and analyte concentrations, respectively, and ka/kd are the
on- and off-rates. The KD is the analyte concentration at which half of the binding sites of
the surface-bound ligand are occupied. Therefore, a lower KD value signifies the occur-
rence of stronger protein-protein interactions.
Immobilisation conditions were tested for a range of sodium acetate buffers (pH 3.5 -
6.3), with pH 6.3 exhibiting the strongest interactions between M5 and the surface (Fig-
ure 5.12). pH 6.3 also had the additional advantage of providing the conditions most
suitable for amine coupling and was therefore chosen as the immobilisation buffer.
100
Figure 5.12. SPR chromatograms of interactions between M5 and the surface in various buffers (left) and successful
immobilisation of M5 (right, 3,000 RU).
5.4.2 Confirming the specificity of the observed interactions
M5 was successfully immobilised (20,000 RU, sodium acetate, pH 6.3) and responses to
20 µM samples of each ACP in its apo form were measured (Figure 5.13). Successful re-
generation of M5 to its unbound state was observed in each case with a regeneration
solution of 10 mM glycine pH 9.0. Maximum RUs were similar for each upstream ACP,
with M5 ACP having a slightly lower level of interaction. The responses from a number
of apo-carrier proteins (CPs) from other systems were also measured, in each case result-
ing in significantly weaker responses than those observed with the compatible upstream
ACPs. AerA is a peptidyl carrier protein (PCP) involved in aeruginosin biosynthesis and
contains a short linear motif docking domain. GbnD6 (I) and GbnD6 (II) are both ACPs
from the final module of gladiolin PKS. Neither construct contains a docking domain.
Gbn constructs were chosen as GbnD6 (I) is proposed to require interactions with a KS,
whereas GbnD6 (II) is not.
5.4.3 Elucidating the binding and dissociation constants of
module 5 with the upstream ACPs
Binding and dissociationmay bemore accurately elucidated from curves exhibiting smaller,
but still measurable responses (∼ 200 RU). A smaller quantity of M5 was successfully im-
mobilised (3,000 RU, sodium acetate, pH 6.3) andmeasurable protein-protein interactions
were observed with each ACP. Successful regeneration of M5 to its unbound state was ob-
served with a regeneration solution of 10 mM glycine pH 9.0.
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Figure 5.13. Maximum RU (blank subtracted) for each apo-carrier protein (20 µM) with surface-immobilised M5.
Experiments were repeated in triplicate with the displayed errors corresponding to one standard deviation. HBS (HEPES
buffered saline) was used as a control.
Response curves for varying concentrations of each ACPwere then acquired (Figure 5.14).
Fitting of the data to a number of models resulted in 1:1 binding resulting in the closest
fit. This model was used to calculate association and dissociation constants (Table 5.1).
Table 5.1. Dissociation constants calculated from SPR data of M5 with the upstream ACPs (Figure 5.14).
Protein KD (µM)
M3 ACP 1.3 ± 0.0
M4 ACP 4.0 ± 0.5
M3 ACPT 2.6 ± 0.1
M4 ACPT 4.3 ± 0.7
The data shows that the KD for M3 ACP is three times lower than for M4 ACP. Fur-
thermore, in the case of M3 ACP, excising the docking domain noticeably weakens the
strength of protein-protein interactions (∼ 50 %). This was expected based on previous
work suggesting docking domains play a vital role in facilitating intramodular interac-
tions between ACPs and KSs and on our observation that the rate of acyl transfer is faster
from M3 ACP than M3 ACPT. Interestingly, in the case of M4 ACP, no statistically sig-
nificant change in KD is observed upon removal of the docking domain. This suggests
that M4 ACP’s docking domain is not effectively facilitating interactions with M5 and ex-
plains why M3 ACP was found to have a higher rate of substrate transfer than M4 ACP.
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Figure 5.14. SPR spectra of the upstream ACPs binding to a surface-bound QMN M5. Experiments were run in
triplicate with the displayed errors corresponding to one standard deviation.
5.4.4 Elucidating the binding and dissociation constants of
module 5’s KS domain with the upstream ACPs
SPR experiments were repeated with M5 KS as the immobilised ligand in order to check
whether the other domains in M5 were significantly affecting the intermodular binding
and dissociation, and that protein-protein interactions with the upstream ACPs were spe-
cific to the KS domain. M5 KS was immobilised (2,000 RU, Figure 5.15) to establish the
presence of protein-protein interactions with each ACP. The previously used regeneration
conditions were again shown to be suitable.
Kinetic binding experiments were repeated for each ACP (Figure 5.16). A 1:1 binding
model was sufficient to calculate kinetic values for M3 ACP and M4 ACP, showing the
KD for M3 ACP to be around four times lower than for M4 ACP (Table 5.2). All math-
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Figure 5.15. An SPR spectra showing immobilisation of M5 KS (1,800 RU).
Figure 5.16. SPR spectra showing interactions between the upstream ACPs and surface-bound M5 KS. Experiments
were run in triplicate and the errors correspond to one standard deviation.
ematical models for the data between M5 KS and the truncated ACPs resulted in large
residual errors. The poor fits obtained for the data could perhaps be due to unspecific
binding to the KS in areas previously inaccessible due to the presence of an AT domain.
Furthermore, the KS construct expressed as a monomer, meaning the residues usually
forming an interface between the two KS domains of the homodimeric module are likely
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Table 5.2. Dissociation constants calculated from SPR data of M5 KS with the upstream ACPs (Figure 5.16).
Protein KD (µM)
M3 ACP 0.9 ± 0.0
M4 ACP 3.5 ± 0.1
to be exposed. The increased level of unspecific interactions could interfere with the site-
specific interactions seen in section 5.4.3.
No cross-linking had been observed betweenM5 KS and the upstreamACPs (section 4.4),
suggesting any site-specific interactions would be significantly weaker and a high pro-
portion of interactions observed between M5 KS and the upstream ACPs may not be
specific to functional interactions. The fact a discernable difference between M3 ACP
and M4 ACP was seen could be due to M5 KS’s immobilisation to the surface, perhaps
through reducing aggregation or presenting the KS domain a more more favourable ori-
entation for interactions.
5.4.5 The effect of malonating module 5 on protein-protein
interactions with the upstream ACPs
It had previously been hypothesised that a module conformationally prepares for sub-
strate transfer from an upstream ACP if it is loaded with an extender unit.190 This would
therefore suggest M5 would be more likely to be in a conformation to promote interac-
tions between the KS and the upstream ACPs after the loading of a malonyl-extender
unit to M5 ACP. Plans to repeat SPR experiments with immobilised malonyl-holo-M5
were made to test this hypothesis. Unfortunately, attempts at malonating M5 (as in sec-
tion 3.1.2) in the HEPES buffer used for SPR led to instantaneous aggregation upon the
addition of MgCl2. M5 was repurified in 50 mM sodium acetate, pH 6.3, and the mal-
onation assay was repeated. Ligand immobilisation was unsuccessful with this sample,
with approximately 1 % of the immobilisation levels obtained for similar concentrations
of apo-M5.
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5.5 Structural dynamics of the upstream
ACPs
Figure 5.17. HSQC spectra of [U-15N]-apo-M4 ACP (top left), [U-15N]-apo-M3 ACP (top right), [U-15N]-apo-M3 ACP
(bottom left) before and after titration with M5 and [U-15N]-apo-M3 ACP compared with [U-15N]-apo-M3 ACPT (bottom
right). The HSQC of [U-15N]-M3 ACP before and after M5 titration displays a magnified insert in the bottom right corner.
An insert from a chemical shift of approximately 10 ppm is also shown in the top left. The HSQC comparing M3 ACP and
M3 ACPT contains a box that highlights peaks not present in the M3 ACPT spectra.
Solution NMRwas used in an attempt to determine which residues of the upstreamACPs
were involved in intermodular interactions with M5. [U-15N]-M3 ACP and [U-15N]-
M4 ACP were overproduced and 1H-15N HSQC spectra were acquired for both ACPs
(Figure 5.17). Unstructured regions were noted due to the cluster of peaks around 8.1
ppm (F2). However, a reasonable number of peaks were well-defined, suggesting parts
of the proteins were well-folded. Titration of M3 ACP with equimolar M5 resulted in a
number of observable peak shifts, indicating the occurrence of protein-protein interac-
tions between M3 ACP and M5.
The disordered regions were perhaps due to the constructs containing largely unstruc-
tured linker regions between the four conserved helices and the docking domains, giving
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the impression that the proteins were partially unfolded. Other reported NMR struc-
tures omit the docking domain and linker region, suggesting solution NMR could be a
more feasible approach on the ACP constructs containing just the four conserved helices
(M3 ACPT and M4 ACPT).
[U-15N]-M3 ACPT was overproduced, purified and a 1H-15N HSQC was acquired in
potassium phosphate buffer. A number of peaks disappeared in comparison with full-
length M3 ACP and the dispersion of peaks significantly improved, suggesting removal
of disordered regions. The area highlighted contains numerous peaks only visible in the
spectrum for M3 ACP, likely to correspond to residues of the docking domain. Some of
the missing peaks were previously shown to shift upon titration of M5 and somewere un-
affected. In addition, a number of peaks observed to shift upon titration of M3 ACP with
M5 were still present, suggesting residues in the docking domain and the four conserved
helices interacted with M5.
5.6 Structural elucidation of the docking
domains
Figure 5.18. Homology models of the ACP docking domains from M3 and M4 fused to the KS docking domain of M5
(112 and 111 residues, respectively).
Structural elucidation of the upstream ACP’s docking domains in complex with the KS
docking domain of M5 (M5 ddKS) could help understand how they interact together (Fig-
ure 5.18). NMR has the ability to determine the spatial placement of each residue, thereby
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determining how electrostatic interactions form between the helices. Mutation of key
residues could also allow the elucidation of which residues are essential for facilitating
and maintaining interactions.
Figure 5.19. SDS-PAGE analysis of His-tagged M4 ACPdd-M5 ddKS (15,790 Da, left) and a CD spectra (right).
A fused complex between M4’s ACP docking domain (M4 ACPdd) and M5 ddKS was
overproduced and purified, before structural integrity was confirmed by CD (Fig-
ure 5.19). No linker region was present, with the KSdd starting immediately after the end
of the ACPdd. Production of 13C/15N labelled protein could allow structural elucidation
of the interacting docking domains, helping to understand how the electrostatic interac-
tions play a role in intermodular interactions. A similar approach could be applied to a
fused M3/M5 docking domain construct.
5.7 Conclusion
It has been established through a series of transfer assays that both upstream ACPs are
able to transfer various substrates and that M3 ACP more efficiently transfers substrates
to M5 than M4 ACP. Acyl transfer assays with truncated constructs omitting a docking
domain resulted in transfer being seen for both ACPs. M3 ACPT had a significantly
slower rate of transfer than M3 ACP. However, no significant difference in the rate of
transfer was seen between M4 ACP and M4 ACPT. Interestingly, the rate of transfer for
both M4 constructs was comparable to the rate seen for M3 ACPT.
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SPR data indicated this was due to M3 ACP’s docking domain more efficiently fa-
cilitating protein-protein interactions than M4 ACP’s docking domain and therefore
preferentially transferring substrates to M5. Such a bias in module preference is likely to
be due to M3 ACP being able to transfer a substrate to both M4 KS and M5 KS. Efficient
QMN biosynthesis requires an equal number of precursors 1 and 2 to be produced. As
nature usually produces extremely efficient pathways, it is reasonable to hypothesise
that approximately 50% of the substrates bypass M4.
Structural elucidation of M3 ACPT and M4 ACPT would be completed by acquir-
ing HSQC, cbcaconh and cbcanh spectra for both constructs. Acquisition of HSQC
spectra for M3 ACP and M4 ACP and both ACPs titrated with M5 would then al-
low the identification of which residues of the ACPs’ four conserved helices interact
with M5. Structural elucidation of the fused docking domain constructs would also
provide detailed information about molecular interactions between the docking domains.
Figure 5.20. A homology model of M3 ACP’s docking domain (top left), a homology model of the M5 KS docking
domain (top right), sequence comparison of the final helix of the ACPs with other Class 1 Type 1 docking domains
(bottom left) and a schematic representation of the domains involved in QMN module skipping (bottom right).
Sequence alignment of M3 ACP and M4 ACP with other known T1 docking domains
(Figure 5.20) showed the widely conserved negative charged aspartic or glutamic
acid residue at the start of the third helix was replaced by a glycine in M4 ACP. The
electrostatic pattern of the third helix is widely reported to be essential in facilitating
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docking interactions with KS docking domains.131 Therefore, the absence of a negatively
charged residue in M4 ACP could interfere with the electrostatic pattern and disrupt the
occurrence of protein-protein interactions between the two docking domains. Mutation
of M4 ACPdd’s glycine residue (G126) to either an aspartic or glutamic acid could
potentially create a mutant with greater affinity for protein-protein interactions with
M5’s KS domain, hence providing evidence to support this hypothesis. In addition,
mutation of the aspartate in M3 ACP would allow further studies to determine if its
ability to facilitate interactions with M5 had decreased, demonstrating the importance of
this negative residue in intramodular interactions.
Finally, to gain a complete picture of how the QMNmodule skipping mechanism works,
interactions between M3 ACP and M4 must also be studied. Many of the experiments
described in this chapter could be repeated to probe the acyl transfer and protein-protein
interactions betweenmodule 3 and 4 and how this compares to their interactionswithM5.
When combined together, these approaches would provide the site-specific interactions
of all the domains involved in the two different pathways and create a better under-
standing of the module skipping mechanism present in QMN PKS. This information will
prove invaluable in the possible creation of synthetic module skipping PKSs with the
ability to produce multiple natural products.
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Chapter 6
Conclusions and future work
6.1 Activity and substrate tolerance of
quartromicin module 5
A series of assays, monitored by intact ESI mass spectrometry, showed QMN module 5
is capable of accepting a substrate from the ACP domains of either module 3 or mod-
ule 4 and of catalysing chain extension of the substrates with a malonyl-CoA extender
unit, thus confirming the predicted role of module 5 in the biosynthesis of quartromicin.
Successful transfer of 2, 8 and 10-carbon chain substrate mimics from both M3 ACP and
M4 ACP to the KS domain, as well as successful chain extension of a wide range of sub-
strate analogues (including those with shorter, longer, saturated and branched carbon
chains) with a malonyl-CoA extender unit indicated that the substrate tolerance of mod-
ule 5 is not a key factor in governing pathway fidelity. M5 was, however, unable to catal-
yse chain extension using methylmalonyl-CoA. Direct loading of a ppant-methylmalonyl
group to the ACP and incubation with an octanoyl substrate led to the detection of ex-
tended product, showing that the extender unit specificity of M5 is ensured by the AT
domain. These results indicated that the pathway’s fidelity is more likely ensured by
the specificity of protein-protein interactions between module 5 and the ACP domains of
modules 3 and 4.
Although attempts were made to investigate the structure of module 5 by NMR, X-ray
crystallography, carbene footprinting and cryo-EM, nonewere particularly successful due
to the propensity of module 5 to aggregate. Future work could involve repetition of these
studies with homologous modules from the potential quartromicin producing Amyco-
latopsis albispora to help understand the architecture and mechanistic rearrangements of
each module throughout its catalytic cycle.
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6.2 Importance of docking domains in fa-
cilitating protein-protein interactions
between module 5 and the ACP do-
mains of modules 3 and 4
In addition to confirming the ability of M5 to catalyse acyl-transfer from M3 ACP and
M4 ACP, the presence of corresponding protein-protein interactions was confirmed by
intermodular cross-linking. These experiments indicated that whilst the upstream ACPs
can interact with the KS of M5, they can not interact with the AT domain. Analysis of
acyl-transfer rates showed that M3 ACP more efficiently transfers a substrate to M5 than
M4 ACP. Removal of the docking domains had no significant effect on the rate of transfer
from M4 ACP, whereas a significant reduction was noted in the case of M3 ACP.
SPR analysis with chip-immobilised M5 confirmed the occurrence of protein-protein in-
teractions between M5 and both full length and truncated M3 ACP and M4 ACP. Kinetic
studies suggested that M3 ACP had a lower KD than M4 ACP (1.3 v 2.6 µM). In compari-
son, truncated versions had KD values of 4.0 and 4.3 µM for M3 ACPT and M4 ACPT, re-
spectively, suggesting that M3’s ACP docking domain more efficiently facilitates protein-
protein interactions than M4’s. This is perhaps because a substrate attached to M4 may
only be transferred to M5, whereas a substrate attached to M3 has the potential to be
transferred to M4 or M5.
Whilst both ACP docking domains are structurally similar, the reduced efficiency of M4’s
could be due to the presence of a glycine residue, in place of a widely conserved neg-
atively charged residue, interfering with the electrostatic pattern required for facilitat-
ing interactions. Mutation of M3 ACP’s conserved negative residue to a glycine and
M4 ACP’s glycine to a negative residue, followed by the repetition of the in vitro assays
and SPR experiments would test the aforementioned hypothesis. However, it is impor-
tant to note that the creation of mutated constructs has previously had undesirable effects
in other fused docking domain systems.124
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Initial solution state NMR experiments indicated that residues within both the main 4-
helix bundle and the docking domain of M3 ACP were involved in protein-protein inter-
actions with M5. This work could be completed by carrying out more extensive titration
experiments following HSQC assignment of both M3 ACP and M4 ACP. Furthermore,
structural elucidation of the fused docking domain complexes (section 5.6) would show
how the docking domains interact on an atomic-level.
A canonical understanding of docking domain interactions could lead to the production
of synthetic docking domains to facilitate specific intersubunit interactions. Understand-
ing how numerous precursors can be created by a pathway and how quantities are con-
trolled is vital in creating novel PKS pathways that produce numerous precursors.
6.3 Identification of a dimerisation mo-
tif essential formodular dimerisation
and catalytic functionality
A loss of dimerisation was noted when the AT-ACP linker region was omitted from M5
constructs, leading to the hypothesis that this region contains a dimerisation motif. Ho-
mologymodels predicted the region to bemostly structured and to contain an extended β-
sheet and a partial Rossmann fold. Comparisonwith other finalmodules of spirotetronate
PKSs was carried out as they are all proposed to end with a stand-alone non-reductive
module. The majority of modules contained a significantly shorter unstructured AT-ACP
linker region. However, ChlA6 and KijS5 were identified as containing long, highly struc-
tured linker regions with similarities to M5. Sequence analysis indicated they are likely
to contain the remnants of a KR domain. In addition to the expected large interaction in-
terface between the KS domains, 2-D cryo-EM reconstructions of M5 also depicted what
seemed to be a contact region at the other end of the complex. This is likely to be formed
by the dimerisation motif present in the linker region.
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Analytical gel filtration of both C-terminal and N-terminal truncated M5 constructs indi-
cated that a dimerisationmotif existed, with a loss of dimerisation noted between residues
1126 - 1160. A chemoenzymatic cross-linking approach demonstrated this dimerisation
motif, which we have termed a KRD domain, was essential for facilitating interactions
between both the upstream ACPs and M5’s ACP domain, thus ensuring modular func-
tionality.
Successful crystallisation and subsequent structural elucidation of the linker regionwould
help explain the region’s role in module dimerisation. Although initial crystal trials
proved unsuccessful, various lengths of construct and a wider range of conditions may
still allow crystals to be obtained. Acquiring atomic-level resolution information on the
dimerisation motif would highlight which residues are essential in the formation of a
dimerisation bridge, as well as understanding the structure of the formed bridge. This
could potentially allow the identification of similar motifs in other PKS systems. Similar
structural studies could be carried out on ChlA6, KijS5, the M5 homologue from Amyco-
latopsis albispora and any other systems found to contain dimerisation motifs, to provide
a deeper understanding of how these motifs function.
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Chapter 7
Experimental Procedures and Methods
7.1 Materials and Instruments
7.1.1 Chemicals and reagents
All chemicals and reagents used in this thesis were of molecular biology grade and pur-
chased from the stated suppliers. All guidelines were closely followed. dH2O was pre-
pared by autoclaving H2O (121◦C, 20 minutes) and used to dilute all chemicals to the
required working concentration (unless otherwise stated).
7.1.2 Stock solutions
Table 7.1. The solvent for all stock solutions was dH2O. All solutions were sterilised by autoclave.
Stock solution Concentration Manufacturer
Trisaminomethane-hydrochloride (Tris-HCl) 0.2 M Thermo Fisher
Sodium Chloride (NaCl) 0.1 M Thermo Fisher
Imidazole 1.0 M Sigma-Aldrich
Ethylenediaminetetraacetic acid (EDTA) 0.1 M Sigma-Aldrich
Isopropyl β-D-1-thiogalactopyranoside (IPTG) 1.0 M VWR Chemicals
Magnesium chloride (MgCl2) 0.1 M Thermo Fisher
Calcium chloride (CaCl2) 0.1 M Thermo Fisher
Potassium phosphate (KH2PO4) 0.1 M Scientific Laboratory Supplies
10 % ammonium persulfate (APS, Thermo Fisher), 10 % sodium dodecyl sulfate (SDS,
Sigma-Aldrich), 100 mg/mL ampicillin (Sigma-Aldrich), 50 % glycerol (Sigma-Aldrich)
and 70 % ethanol are made up by dilution with dH2O and filtered using MF-MilliporeTM
membrane filters (0.2 µm, Merck Millipore). All other buffers were prepared as described
in Table 7.1.
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7.1.3 Instruments and equipment
PCR reactions were performed using the Eppendorf Mastercycler® nexus GX2 thermo-
cycler. Negative-stain images were acquired on a Jeol 2010F transmission electron mi-
croscope. LC-QTOF was performed using the maXis IITM (Bruker) and MALDI using an
Autoflex speed MALDI-TOF/TOF spectrometer (Bruker). An AmaZon X (Bruker) was
also used for LC/MS. Circular dichroism spectra were acquired using a JASCO 1500 in-
strument and HSQCs were acquired using a Bruker Avance II 700 MHz spectrometer.
Surface plasmon resonance data was acquired on Biacore T2000 and Biacore T200 instru-
ments (GE Healthcare Life Sciences).
Other instruments used: Astell compact top autoclave, NewBrunswick Scientific Innova®
44 refrigerated incubator shaker, A¨KTA Pure 25 L (GEHealthcare Life Sciences) fast liquid
protein chromatography (FPLC) system, Thermo Electron Corporation Heraeus® Func-
tion Line incubator, an Eppendorf® Centrifuge 5804 R, HI-VAC® vacuum valve (Sigma-
Aldrich) and a VirTis BenchTopTM K lyopholiser.
7.1.4 Escherichia coli strains
Table 7.2. Strains of Escherichia coli used in this thesis.
Strain Manufacturer Description Genotype
One Shot® TOP 10TM Invitrogen Plasmid holding
F-mcrA ∆(mrr-hsdRMS-mcrBC) Φ80lacZ∆M15 ∆lacX74
nupG recA1 araD139 ∆(ara-leu)7697 galE15 galK16 rpsL(StrR) endA1 λ-
One Shot® BL21 StarTM (DE3) Invitrogen Protein overproduction
B F-ompT gal dcm lon hsdSB(rB?mB?)
λ(DE3 [lacI lacUV5-T7p07 ind1 sam7 nin5]) [malB+]K-12(λS)
NiCo21 (DE3) New England Biolabs Protein overproduction
can::CBD fhuA2 [lon] ompT gal (λ DE3) [dcm] arnA::CBD slyD::CBD glmS6Ala
∆hsdS λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5
OverExpress C43 (DE3) Lucigen Protein overproduction F-ompT gal dcm hsdSB(rB- mB-)(DE3)
RosettaTM 2 (DE3) SinglesTM Novagen Protein overproduction
F-ompT gal dcm lon? hsdSB(rB-mB-) λ(DE3 [lacI lacUV5-T7p07 ind1 sam7 nin5])
[malB+]K-12(λS) pLysSRARE[T7p20 ileX argU thrU tyrU
glyT thrT argW metT leuW proL orip15A](CmR)
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7.1.5 Buffers and gels
All buffers used with an FPLC were vacuum filtered using a sterile 500 mL Steritop-GP
45 mm threaded bottle top filter (0.22 µm pore size, polyethersulfone (PES) Express PLUS
membrane, Merck Millipore).
Wash buffer
• 20 mM Tris-HCl
• 100 mM NaCl
• 20 mM Imidazole
• Add dH2O up to 1 L
• pH 8.0
Elution buffer
• 20 mM Tris-HCl
• 100 mM NaCl
• 500 mM Imidazole
• Add dH2O up to 1 L
• pH 8.0
Benchtop elution buffers
• 20 mM Tris-HCl
• 100 mM NaCl
• 50, 100, 200 and 300 mM Imidazole
• Add dH2O up to 1 L
• pH 8.0
Storage buffer
• 20 mM Tris-HCl
• 100 mM NaCl
• Add dH2O up to 1 L
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• pH 8.0
Anion exchange (AEX) buffers
• 20 mM Tris-HCl
• 200, 300, 400, 500 mM and 1 M NaCl
• Add dH2O up to 1 L
• pH 8.0
10x SDS-PAGE (protein gel) running buffer
• 30 g Tris-HCl
• 144 g Glycine
• 10 g Sodium dodecyl sulfate
• Add dH2O up to 1 L
6x SDS-PAGE loading dye
• 2 mL 1 M Tris-HCl pH 6.8
• 2 mL Glycerol
• 0.4 mL β-mercaptoethanol
• 0.02 g Bromophenol blue
• 0.4 g Sodium dodecyl sulfate
• 2 mL dH2O
IMAC column stripping buffer
• 10 mM Tris-HCl
• 100 mM NaCl
• 100 mM EDTA
• Add dH2O up to 1 L
0.1 M Nickel(II) sulfate (NiSO4)
• 1.55 g NiSO4
• 100 mL dH2O
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0.1 M Cobalt(II) sulfate (CoSO4)
• 1.55 g CoSO4
• 100 mL dH2O
10x Tris-borate-EDTA (TBE) elecrophoresis running buffer
• 108 g Tris-HCl
• 55 g Boric acid
• 20 mL 1 M EDTA
6x gel loading dye
• 2 mL Glycerol
• 0.02 g Xylene cyanol FF
• 0.02 g Bromophenol blue
• 4 mL dH2O
1 % agarose gel
• 1 g agarose
• 10 mL 10x TBE buffer
• 90 mL dH2O
• Dissolved in microwave and cooled
• Add 5 µL of GelRedTM Nucleic Acid Stain (Biotium)
• Set in gel plate with gel comb (20 minutes)
Circular dichroism (CD) buffer
• 10 mM potassium phosphate
• 20 mM NaCl
Nuclear magnetic resonance (NMR) buffer
• 2.5 mL of 0.1 M Potassium phosphate
• 5 µL of 0.1 M DSS
• 250 µL D2O
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• Up dH2O up to 5 mL
• pH 6.0, 6.5 or 7.0
Liquid Chromatorgraphy/ Mass Spectrometry (LC/MS) buffer A
• dH2O (99.9 %)
• 0.1 % Formic acid
LC/MS buffer B
• Acetonitrile (99.9 %)
• 0.1 % Formic acid
7.1.6 Culture media
Lysogeny Broth (LB)
• 25 g Lysogeny Broth, Miller (Thermo Fisher)
• Add dH2O up to 1 L and autoclave
• 1 mL Ampicillin (100 mg/mL)
Lysogeny Broth Agar
• 25 g Lysogeny Broth (Thermo Fisher)
• 15 g Bacto agar (Sigma-Aldrich)
• Add dH2O up to 1 L and autoclave
• 1 mL Ampicillin (100 mg/mL)
5 x M9 salt solution
• 32 g Na2HPO4 · 7H2O
• 6 g KH2PO4
• 2.5 g NaCl
• Add dH2O up to 500 mL and autoclave
M9 minimal media
• 200 mL 5 x M9 salt solution
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• 2 mL 1 MMgSO4
• 100 µL 1 M CaCl2
• Add dH2O up to 1 L and autoclave
• 20 mL 100 x BME vitamins (Sigma-Aldrich)
• 0.5 g 15NH4Cl (dilute in 2.5 mL H2O and use 0.2 µm filter)
Autoinduction media
• 10 g Tryptone
• 5 g Yeast extract
• 3.3 g (NH4)2SO4
• 6.8 g KH2PO4
• 7.1 g Na2HPO4
• 0.5 g Glucose
• 2.0 g α-Lactose
• 0.15 g MgSO4
• Add dH2O up to 1 L and autoclave
7.1.7 Plasmids and primers
The plasmids for quartromicin M5 (KS-AT-ACP), M3 ACP and M4 ACP were produced
by Dr. Orestis Lazos (Challis group) using fosmid libraries previously produced byMalek
Zerikly from the following strains:
• Amycolatopsis orientalis ATCC 53884 (American Type Culture Collection)143
• Amycolatopsis mediterranei NRRL 18815 (Agricultural Research Service Patent Cul-
ture Collection).143
Further constructs were subcloned from M3 ACP, M4 ACP and M5 using primers or-
dered from IDT (Table 7.3). Primer suitability was checked using OligoAnalyzer 3.1 (IDT).
Stocks of primers were diluted to 100 µM (dH2O) and stored at −20 ◦C. Small aliquots of
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primers were further diluted to 10 µM before use (dH2O).
Table 7.3. Primers for all constructs used in this thesis. Bases shown in red correspond to stop codons and bases
shown in blue allow the ligation of the PCR product into a TOPO vector. Site-directed mutations are also highlighted.
Protein Plasmid name Origin gene Length (bp) Vector Forward primer Reverse primer
M3 ACP pTG5000 qmnA1 444 pET151 CACC TTG CTG GAC CTG GTC CTA TCT TCT CCC GTT GCC
M3 ACPT pTG5001 qmnA1 240 pET151 CACC TTG CTG GAC CTG GTC CTA GTC GGT GGG TTC CGG
M4 ACP pTG5002 qmnA2 444 pET151 CACC CTG CTC ATC GAC GT CGG TGC TCA TGC GGT TT
M4 ACPT pTG5003 qmnA2 231 pET151 CACC CTG CTC ATC GAC GTG CTA CGG GGC CAG TTC GG
M5 ACP pTG5004 qmnA3 261 pET151 CACC ACG GGT GCC GAG CA CTA GGA TGG TTC GGC GGC
M5 KS pTG5005 qmnA3 1,377 pET151 CACC ATG AGC ACC GGC CCG AC CTA CCG TTC CAG TAT CAC GTG CGC GTT
M5 KSATS pTG5006 qmnA3 2,664 pET151 TAA TAA CGG GTC GAC CTG CCG ACG CCT GGC CCC GCT GAA CCC
M5 KSAT pTG5007 qmnA3 3,594 pET151 TAA AAG GGC GAG CTC AGA TCC GG TTA CGG CAC GCT CGC GCT CAG
M5 pTG5008 qmnA3 3,876 pET151 CACC ATG AGC ACC GGC CCG AC CTA GGA TGG TTC GGC GGC
C207A pTG5008-11 qmnA3 3,876 pET151 CGT CAC CAT CGA CAC CGC AGC CTC GTC CTC GCC GGT CCC TCC AGG CCG AAG GTG TAG G
S656C pTG5012-16 qmnA3 3,876 pET151 GCC GGT CAT TGC ATC GGC GAG C ACA AAG GAC GGT CGA ACG C
M5 KSATS-A pTG5017 qmnA3 2,761 pET151 TAA TAA CTC GCC GCC GAA CCA TCC CAG GTC GAC CTG CGC CGA
M5 KSATS-B pTG5018 qmnA3 3,202 pET151 TAA TAA CTC GCC GCC GAA CCA TCC CAG GTC GAC CTG CGC CGA
M5 KSATS-C pTG5019 qmnA3 3,382 pET151 TAA TAA CTC GCC GCC GAA CCA TCC GAG TTC CGC GCG CTC CAG
M5 KSATS-D pTG5020 qmnA3 3,418 pET151 TAA TAA GCC TGG GAC GGC GTC GCT GAC CAC CAC CGC ACC CCG
M5 KSATS-E pTG5021 qmnA3 3,480 pET151 TAA TAA GCT GCG GCA GGG CGC ACC AGG CCG ACC GCG CTC G
M5 KSATS-F pTG5022 qmnA3 3,531 pET151 TAA TAA CTC GCC GCC GAA CCA TCC CAA CGG CGC CAA CGC CTC
M5 KRD -A pTG5023 qmnA3 717 pET151 CTG GCT GGT CCC GTC CGG GTG AAG GGA TCA ATT CCC TGA AAA TAC AGG TTT TC
M5 KRD -B pTG5024 qmnA3 555 pET151 GTA CGC CTG CGA CCA CCT GTG AAG GGA TCA ATT CCC TGA AAA TAC AGG TTT TC
M5 KRD -C pTG5025 qmnA3 408 pET151 CGA CGG CGA CTG GTG GCC GTG AAG GGA TCA ATT CCC TGA AAA TAC AGG TTT TC
M5 KRD -D pTG5026 qmnA3 288 pET151 ACT GGC GGC GGT TGT CCA GTG AAG GGA TCA ATT CCC TGA AAA TAC AGG TTT TC
A ChampionTM pET151Directional TOPO® host-expression vector (pET151, Figure 7.1)191
was used for the overproduction of all proteins. Plasmids in pET151 undergo low-copy
replication due to the presence of the basis of mobility (bom) region from pBR322 origin
(origin of replication) and repressor of primer (ROP) genes. The presence of a β-lactamase
gene (AmpR) ensures the production of an enzyme that inactivates β-lactam antibiotics,
such as ampicillin, thus conferring an antibiotic resistance to E. coli cells containing the
plasmid. This allows selection through lysogeny broth (LB) agar ampicillin plates of
plasmid-containing cells, minimising the chance of selecting an empty vector.
The vector also contains genes encoding a T7 promoter site to which T7 RNA polymerase
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Figure 7.1. A gene map of the pET151 D/TOPO vector (SnapGene).
must bind to allow transcription of the GOI to occur. This transcription is regulated by
the lactose (lac) operon, which encodes a repressor of the lac operator (lacI), preventing the
binding of the T7 RNA polymerase to the T7 promoter site. As a result, overexpression of
the gene cannot occur whilst the repressor is present, preventing leaky expression of the
gene.
In addition, the presence of 6xHis encodes an in-frameHis-tag at the protein’s N-terminus.
A TEV site (ENLYFQG) is also encoded to allow the cleavage of a His-tag from the pu-
rified recombinant protein, leaving an N-terminal tag of only 6 residues attached to the
protein. A gene encoding a V5 epitope tag on the protein’s N-terminus is also present (V5
tag), allowing the tagged protein to be analysed by immunochemical methods, such as
Western blot.
pJET1.2 also used to allow successful site-directed mutagenesis of longer constructs due
to its significantly shorter backbone. The inclusion of restriction sites allowed the mu-
tated inserts to be transferred back into the original pET151 vector.
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7.2 Molecular Biology
7.2.1 Preparation of chemically competent E. coli
All proteinswere recombinantly overproduced using either One Shot® BL21 StarTM (DE3),
NiCo21 (DE3), OverExpress C43 (DE3) or RosettaTM 2 (DE3) SinglesTM strains of E. coli
(Table 7.2). Plasmids were produced in the One Shot® TOP 10TM strain. All strains of
E. coli were produced in the lab from commercially available stocks and all solutions,
Eppendorfs® and pipette tips were sterile.
10 µL of frozen E. coli glycerol stocks were used to inoculate LB (10 mL) and grown
overnight (37 ◦C, 180 rpm). 1 mL of the overnight culture was then used to inoculate
LB (100 mL) and grown (37◦C, 180 rpm) to OD600 ∼ 0.4 (3 - 4 hours). Cells were recov-
ered by centrifugation (3000 rpm, 15 minutes, 4 ◦C) and the supernatant decanted. The
pellet was resuspended in 10 mL of ice-cold wash buffer (0.1 M MgCl2) and left on ice
(20 minutes). The cells were then centrifuged (3,000 rpm, 15 minutes, 4 ◦C) and the su-
pernatant was decanted, before the pellet was resuspended in 2 mL of ice-cold buffer (0.1
M CaCl2). After being left on ice (20 minutes), glycerol was added (final concentration
of 10 %), the cells were aliquoted (50 µL) and flash frozen (liquid nitrogen). Cells were
immediately stored at −80 ◦C.
7.2.2 Transformation of chemically competent E. coli
1 µL of plasmid DNA was added to 50 µL of chemically competent cells. The suspen-
sion was gently mixed and left on ice (30 minutes). The suspension was heat shocked (1
minute at 42 ◦C, then 2 minutes on ice), before the addition of 950 µL of LB and incuba-
tion (37 ◦C, 180 rpm, 1 hour). Transformants were then plated on LB agar plates with the
relevant antibiotic resistance and incubated overnight (37 ◦C).
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7.2.3 Plasmid isolation
The following method was used to prepare all plasmids used in protein overproduction.
After transforming plasmids into TOP10 E. coli and growing on antibiotic plates a result-
ing colony was picked and used to inoculate 10 mL of LB. The culture was incubated
overnight (37 ◦C, 180 rpm) and harvested by centrifugation (4,000 rpm, 15 minutes).
Plasmid isolation was then carried out using a GeneJET Plasmid Miniprep Kit #K0502,
#KO503 (Thermo Scientific) according to the manufacturer’s instructions, with the excep-
tion that dH2O was used to elute the DNA in place of the provided elution buffer. The
concentration of the purified DNA solution was determined by a NanoDrop Lite spec-
trophotometer (Thermo Scientific) and stored at -20◦C.
The pellet was resuspended in 250 µL of resuspension solution and transferred to a mi-
crocentrifuge tube where 250 µL of lysis solution was added. 350 µL of neutralisation
solution was then added and mixed, before centrifugation (14,000 rpm, 5 minutes). The
supernatant was transferred to a GeneJET spin column and centrifuged (14,000 rpm, 1
minute). 500 µL of wash solution was added, before again centrifuging (14,000 rpm, 1
minute). The wash and centrifuge steps were repeated and the GeneJET spin column
was transferred into a fresh Eppendorf® tube. 50 µL of dH20 was added and the solution
left for 2 minutes, before being centrifuged (14,000 rpm, 2 minutes). The flow-through
was discarded and the concentration of the purified DNA solution was determined by a
NanoDrop Lite spectrophotometer (Thermo Scientific). The purified DNA solution was
stored at −20 ◦C.
7.2.4 Polymerase chain reaction
All polymerase chain reactions (PCR) were done using the Mastercycler® nexus X2 (Ep-
pendorf). Q5 polymerase (New England Biolabs) was used to ensure high-fidelity copy-
ing. Each reaction contained between 4 and 8 % DMSO due to the high GC-content of
the template DNA. Other reagents and conditions are listed in Table 7.4. A temperature
gradient was used to find the most suitable annealing temperature (10 µL of PCRmix at 5
different temperatures) before 50 µL of PCR mix was run with the annealing temperature
that produced the optimal results.
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Table 7.4. PCR components and conditions.
PCR components Amount (µL) Final concentration
Q5 reaction buffer (5x) 4 1x
Q5 high-GC enhancer (5x) 4 1x
Q5 polymerase (2000 u/mL) 0.5 1 unit
Forward primer (10 µM) 2.5 500 µM
Reverse primer (10 µM) 2.5 500 µM
Template DNA (100 ng) 0.5 2.5 ng/µL
Dimethyl sulfoxide (DMSO) 4 - 8 % 58 - 68
Total volume 20
Step Temperature (◦C) Time
1. Initial denaturing 98 2 minutes
2. Denaturing 98 15 seconds
3. Annealing 55-68 30 seconds
4. Extension 72 1 minute per kbp
Return to step 2 (30 cycles)
5. Final extension 72 10 minutes
7.2.5 Site-directed mutagenesis
Mutants and a number of truncated constructs were created using the Q5 site-directed
mutagenesis kit (New England Biolabs). Primers were designed using NEBaseChanger
(New England Biolabs) and PCR was carried out as per manufacturer’s guidelines, with
extended extension steps set to 8 minutes. PCR products were incubated with a kinase-
ligase-Dpn1 (KLD) enzyme mix (10 minutes, room temperature, followed by 20 minutes
at 37 ◦C) to allow complete digestion of the template plasmid by Dpn1 (Table 7.5).
7.2.6 Analysis of PCR products
To analyse the PCR products either 10 or 50 µL of sample was mixed with 2 or 10 µL of
6x DNA loading dye, respectively. The samples were then loaded onto a 1 % agarose gel
with a ladder (GenerRulerTM 1kb or high range, Thermo Fisher) and run in a BioRad tank
containing 1x TBE buffer, powered by a Power PAC 300 (80V, 1 hr). Gels were visualised
and photographed using a UVP imaging system UV transilluminator.
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Table 7.5. PCR components and conditions used to produce mutants and truncated constructs using the NEB-SDM
kit.
Components Amount (µL)
2x Q5 HF master mix 10
Forward primer (10 µM) 1
Reverse primer (10 µM) 1
Template DNA 1
Nuclease free H2O 7
Total Volume 20
Step Temperature (◦C) Time
1. Initial denuturing 98 2 minutes
2. Denaturing 98 15 seconds
3. Annealing 55 - 72 30 seconds
4. Extension 72 1 minute per kbp
Return to step 2 (30 cycles)
5. Final extension 72 10 minutes
Components Amount (µL)
PCR product 2
KLD reaction buffer (10x) 1
KLD enzyme mix 1
NF–H2O 6
Total Volume 10
7.2.7 Gel extraction of PCR products
DNA of the appropriate size was excised from the agarose gel using a GeneJet™ Gel Ex-
traction Kit #K0691 #K0692 (Thermo Scientific). All buffers were provided in the kit and
centrifugation was done at 11,000 rpm. The gel slice containing the DNAwas cut out and
incubated (50 - 60 ◦C, 10 minutes) with a 1:1 volume of binding buffer. The gel was then
vortexed. 800 µL of solubilised gel was transferred into a GeneJet column and centrifuged
(1 minute). The flow-through was decanted and 100 µL of binding buffer was added, fol-
lowed by centrifugation (1 minute) and decantation of the flow-through. 700 µL of wash
buffer was added, followed by centrifugation (2 minutes), before the GeneJet columnwas
transferred to a fresh Eppendorf® and left to stand in 50 µL of 60 ◦C dH2O (5 minutes)
before a final centrifugation step (2 minutes) was carried out. The concentration of the
extracted PCR product was determined by a NanoDrop Lite spectrophotometer (Thermo
Scientific) and stored at −20 ◦C.
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7.2.8 Ligation of amplicons into a pET151 vector
The gel extracted PCR product was ligated into a pET151 vector using a ChampionTM
pET Directional TOPOTM Expression Kit (Table 7.6). Reactions were incubated (20 min-
utes, room temperature) and transformed, plated and grown overnight in LB with 100
µg/mL ampicillin.
Table 7.6. Components of the ligation reaction between the PCR product and the pET151 vector.
Component Volume (µL)
Purified PCR product 0.5 - 4
Salt solution 1
dH2O up to 5
pET151 vector 1
Final volume 6
7.2.9 Blunt-end ligation of amplicons into pJET1.2
Gel extracted PCR products were blunt-end ligated into pJET1.2 using the CloneJET PCR
Cloning Kit (Thermo Scientific). The reaction mix (Table 7.7) was vortexed (5 seconds)
and incubated (22 ◦ C, 30 minutes). 5 µL of ligated product was transformed into TOP10
(as previously described), selected by ampicillin plates, grown and miniprepped.
7.2.10 Restriction digests
8 µL of mini-prepped DNA was digested with 1 µL of the relevant restriction enzyme
and 1 µL of the corresponding buffer. Double digests were either done sequentially or
through a double digest where an appropriate buffer was available.
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Table 7.7. Components of the blunt-end ligation reaction between the PCR product and the pJET1.2 vector.
Component Volume (µL)
Purified PCR product 1
2 x Reaction Buffer 10
dH2O up to 17
DNA blunting enzyme 1
pJET1.2 blunt cloning vector 1
T4 DNA ligase 1
Final volume 20
Samples were incubated (37 ◦C, 1 hr) before 2 µL of 6x loading dye was added. The sam-
ples were then loaded onto a 1 % agarose gel with a high range ladder and run in a BioRad
tank, powered by a Power PAC 300 (80V, 1 hr). Gels were visualised and photographed
using a UVP imaging system UV transilluminator. Extraction of digested DNA was car-
ried out as previously described (7.2.7).
7.2.11 Sequencing
All sequencing was done through GATC-biotech’s SUPREMERUN (Sanger sequencing)
service. The T7 and pET-RP primers were utilised to sequence the start and end of each
construct, with further primers designed to sequence the inner regions of the construct
where necessary (Table 7.8).
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Table 7.8. Forward sequencing primers for qmnA3.
Start point of primer (bp) Primer sequence
760 GCC GAC GGC CGG TGC AAG
1551 GCG CAC CTC GTT CTC CCA C
2344 CCG GTG GTG TCC ACG GTG A
3140 TCC GTG GTC CGG AGG TGT TC
7.3 Overproduction and purification of
proteins
The following steps were used to successfully overexpress and purify all proteins used in
this thesis. All steps after lysis were either carried out in a cold room (4 ◦C) or on ice.
7.3.1 Overproduction of recombinant protein in LBmedia
Plasmids were transformed into an overproduction strain of E. coli, plated overnight
(37◦C) on ampicillin plates and the resulting colonies were used to inoculate 10 mL cul-
tures of LB with ampicillin (100 µg/mL). The culture was grown overnight (37 ◦ C, 180
rpm) and was used to inoculate 1 L of LB with ampicillin (100 µg/mL) which was grown
(37 ◦C, 180 rpm) to OD600 ∼ 0.6 (3 - 4 hours). IPTG (500 µM) was then added and the
culture was incubated overnight (15 ◦C, 180 rpm).
Autoinduction media was also used as a growth media in place of LB for less soluble
proteins. 10 mL overnight cultures were grown in LB (as above) and used to inoculate 1
L of autoinduction media with ampicillin (100 µg/mL). The culture was then grown (37
◦C, 180 rpm) to OD600 ∼ 1− 2 (∼ 5 hours), before the temperature was dropped to 20 ◦C
for a further 24 hours of incubation (180 rpm).
Isotope labelling of proteins was essential for facilitating 2D-NMR experiments. To iso-
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tope label proteins, 10 mL overnight cultures were grown in LB (as above) and used to
inoculate 1 L of LB with ampicillin (100 µg/mL). The culture was then grown (37 ◦C,
180 rpm) to OD600 ∼ 0.6 (2 - 4 hours) and centrifuged (5000 rpm, 15 minutes, 4 ◦C). To
produce [U-15N] proteins, the pellet was resuspended in 200 mL of M9 salt solution and
the cells were centrifuged as before and resuspended in 1 L minimal media (100 µg/mL
ampicillin, 0.5 mM IPTG). The culture was then incubated overnight (20 ◦C, 180 rpm).
7.3.2 Sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis
Table 7.9. Recipe for SDS-PAGE gels (6 %, 8 % and 15 %).
Constituents (mL) 6 % resolving gel 8 % resolving gel 15 % resolving gel 5 % stacking gel
Distilled water 2.6 2.3 1.1 0.68
29:1 (30 %) Acrylamide:Bisacrylamide 1.0 1.3 2.5 0.17
Tris buffer 1.3 (pH 8.8, 1.5 M) 1.3 (pH 8.8, 1.5 M) 1.3 (pH 8.8, 1.5 M) 0.13 (pH 6.8, 1.0 M)
10 % SDS 0.05 0.05 0.05 0.01
10 % Ammonium persulfate 0.05 0.05 0.05 0.01
N,N,N,N-Tetramethylethylenediamine 0.003 0.002 0.002 0.001
Total volume 5 5 5 1
Samples were prepared by mixing 10 µL of protein samples with 2 µL of 6x SDS-PAGE
loading dye. 10 µL of sample was then loaded into each lane of the gel. 6 % SDS-PAGE
gels were used for the analysis of M5 (141 kDa), 8 % gels for the analysis of the KSAT
didomain and 15 % gels for the analysis of ACP and KRD domains. Constituents were
mixed in proportions as shown in Table 7.9, before being set in the gel mould (20minutes).
70 % ethanol was used to ensure the level of the gel was consistent, before a stacking layer
was prepared and added to the top of the gel. The comb was immediately inserted into
the gel and it was again left to dry (20 minutes). The gel was then clamped and placed
in a Mini-PROTEAN® Tetra Cell System (BioRad) containing 1x protein running buffer.
Samples were then loaded into each lane, with PageRuler Plus prestained protein ladder
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(Thermo Scientific) as a marker. The gel was run (180 V, 1 hr) and then stained for several
hours using InstantBlue Protein Stain (Expedeon). Gels were then destained overnight in
H2O with 1 % ethanol.
7.3.3 Purification of His-tagged proteins by immobilised
metal affinity chromatography
Figure 7.2. The His-tagged protein binds to the Ni-NTA Sepharose of the HisTrap column.
The presence in the pET151 vector of a gene encoding an N-terminal polyhistidine (6x)
tag (His-tag) allowed the purification of overproduced proteins by immobilised metal
affinity chromatography (IMAC). IMAC is a widely used method of His-tagged protein
purification. It utilises columns coated with chelating agents that are able to bind and
immobilise metals such as nickel, copper and cobalt, through coordinate covalent bonds.
The His-tag’s consecutive histidine residues have a strong affinity to the immobilised
metal’s ions, resulting in coordinate bonds forming and the immobilisation of the protein
on a nitrilotriacetic acid (NTA) Sepharose column (Figure 7.2). The positioning of the His-
tag at the N-termini minimises the possibility of interference in the protein’s functionality.
Proteins that had bound non-specifically to the column were removed by washing the
column with a buffer containing a low concentration of imidazole, a strong metal ion lig-
ating compound. Imidazole is a compound that is structurally similar to histidine and
as a result, is able to form complexes with Nickel (II) ions (Ni(II)). Buffers containing in-
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creasing concentrations of imidazole were then passed through the column. Once the
imidazole concentration is high enough, stable coordinate bonds are formed between the
metal ion and imidazole, resulting in the breaking of the bond between the His-tag and
Ni(II). The eluted protein was then collected in fractions.
Overnight cultures of media containing overproduced proteins were centrifuged (11,000
rpm, 20 minutes) and the pellets resuspended in 10 mL of wash buffer. The cells were
then lysed using a cell disruptor (Constant Systems E1061), centrifuged (11,000 rpm, 20
minutes) and filtered using aMF-MilliporeTM membrane filters (0.2 µm,MerckMillipore)
syringe filter.
The cells were purified by using a 1 mL or 5 mL HisTrap™ HP affinity column (Nickel
Sepharose High Performance, GE Healthcare Life Sciences). A 5 mL HiTrap chelating HP
(GE Healthcare Life Sciences) containing cobalt was used for some M3 ACP samples to
improve sample purity. Columns were regenerated before each use (5 mL of stripping
buffer, 10 mL of wash buffer and 5 mL of 0.1 M NiSO4 or CoSO4, followed by 20 mL of
wash buffer) using a 5 mL syringe. An A¨KTA Pure 25 L (GE Healthcare Life Sciences) fast
liquid protein chromatography (FPLC) system was used to pass the sample through the
column and the unbound sample was washed off using wash buffer (20 mL). The sam-
ple was eluted by a linear gradient with increasing imidazole content (20 mM to 300 mM)
and collected in 1.5 mL fractions which were visualised by the A¨KTA’s inbuilt UV-system.
The length of the gradient varied between 20 mL and 50 mL, depending on whether other
proteins coexpressed with a similar affinity to the chelating metal.
A second method of purifying the protein through IMACs was also utilised, with a sy-
ringe being used to inject sample to a 1mLHisTrap column (as used above). The unbound
sample was then washed out by wash buffer and buffers containing 50 mM, 100 mM, 200
mM and 300 mM (5 mL of each) were run through the column, in order of increasing con-
centration, and collected separately. Each fraction was then checked for protein purity by
an SDS-PAGE gel.
In both cases, the fractions containing the protein were then concentrated by centrifuga-
tion (4,000 rpm, 1 hour) in a Vivaspin® 20 Ultra Centrifugal Filters (5,000, 10,000 or 30,000
MWCO). Glycerol was then added to a final concentration of 10 % before proteins were
aliquoted and frozen with liquid nitrogen. Samples were stored at −80 ◦C.
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7.3.4 Prediction of protein concentrations using a Bradford
assay
The following assays were run in triplicate. Errors corresponded to one standard devia-
tion.
Proteins were serially diluted to 0.25, 0.5, 0.75, 1.0, 1.25 and 1.5 mg/mL using protein
running buffer. BSA was also diluted to the same concentrations. 30 µL of each concen-
tration were then pipetted into separate Eppendorfs, before 1.5 mL of Bradford reagent
was added. A blank containing no protein was also prepared. Samples were incubated
(15 minutes, room temperature) and absorbance was measured at 595 nm. The BSA re-
sults were then used to produce a calibration curve fromwhich the proteins concentration
could be estimated.
7.3.5 Cleaving His-tags from proteins
Green fluorescent protein tobacco etch virus (GFP-TEV) protease was used to cleave the
His-tag from purified proteins. Assays contained protein and GFP-TEV protease in an ap-
proximately 100:1 ratio and were incubated (2 hours, room temperature). TEV digested
proteins were run through a nickel-affinity column to remove all remaining His-tagged
proteins and the GFP-TEV protease. The flow-through was then collected and examined
on an SDS-PAGE gel against the uncleaved protein. Samples were then concentrated and
stored (as above).
7.3.6 Tryptic digestion of proteins
Trypsin digests were carried out using the Trypsin Profile IGD Kit For In-Gel Digestions
(PP0100, Sigma-Aldrich). All buffers and reagents mentioned are part of this kit. An SDS-
PAGE gel was run and the band of interest was cut out using a razor blade. The gel piece
was then placed in a prewashed Eppendorf® tube (100 µL of Peptide Extraction Solution)
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and covered in 200 µL of Destaining Solution. After incubation (30 minutes, 37 ◦C), the
solution was discarded and this step was repeated. The gel piece was then dried (30 min-
utes) in a desiccator attached to a HI-VAC® vacuum valve (Sigma-Aldrich).
20 µL of Trypsin Solution (0.4 µg of trypsin) and 50 µL of Trypsin Reaction Buffer was
then added to the gel piece, followed by incubation (37 ◦C, overnight). The solution was
then removed from the gel piece, concentrated using a C18 ZipTip® (Merck Millipore, see
below) and examined for extracted tryptic peptides by matrix-assisted laser desorption
ionisation-time of flight(MALDI-TOF).
7.3.7 Deglycosylation of proteins
Glycan analysis was carried out using the GlycoProfileTM I Enzymatic In-Gel N-Deglycosy-
lation Kit (Sigma-Aldrich) and all buffers used are from this kit.
An SDS-PAGE gel was run and the band of interest was cut out using a razor blade. The
gel piece was then washed and dried (7.3.6). 10 µL of PNGase F solution was then added
to the gel piece, followed by a brief centrifugation and incubation (37 ◦C, 30 minutes).
20 µL of dH2O was added to the gel piece, which was then incubated (37 ◦C, overnight).
The sample was then briefly centrifuged and the solution was removed and retained for
glycan analysis (MALDI).
The gel piece was incubated (37 ◦C, 30 minutes) in 200 µL of dH2O to remove excess
PNGase. The solution was then discarded and the previous step repeated. The deglyco-
sylated protein may then either be extracted from the gel piece for analysis or digested
using the above trypsin protocol. The intact deglycosylated protein was extracted from
the gel using the following method. The gel piece was dried in a desiccator attached to
a vacuum pump (HI-VAC, 45 minutes). 50 µL of Peptide Extraction Solution was added
and the sample was incubated (37 ◦C, 30 minutes). The supernatant was separated and
concentrated using the ZipTip® protocol (7.3.8). Samples were analysed by MALDI.
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7.3.8 Concentrating proteins and peptides using ZipTip®
The ZipTip was wet with 10 µL of the elution solution (50 % acetonitrile (ACN): 50 %
dH2O), was then dispensed to waste (repeated several times). Equilibrated was carried
out by washing three times with 10 µL of wash solution 1 (0.1 M triethylammonium ac-
etate (TEAA), pH 7.0). The sample was bound to the ZipTip by aspirating the sample 10
times, before being washed several times with 10 µL of wash solution 1 followed by wash
solution 2 (dH2O). The wash solution was discarded after each wash. 2 µL of the elution
solution was then aspirated and dispensed into a fresh Eppendorf®. Aspiration of the
eluted solution was repeated several times to obtain an adequate volume of sample for
further analysis (MALDI).
7.3.9 Size exclusion chromatography
Gel filtration columns contain a porous matrix of differing sizes to which the proteins
have varying access depending on their size and steric conformation (Figure 7.3). By
passing protein samples through a calibrated column and monitoring the elutants using
a UV spectrophotometer, it is possible to collect fractions containing the desired purified
product. This removes the majority of proteins of incorrect size and any unfolded pro-
teins, as well as confirming the oligomerisation states of the eluted protein.
Gel filtration 
column
Eluted 
fractions
Figure 7.3. Size exclusion chromatography utilises a porous matrix to separate proteins based upon their size and
steric conformation. The protein sample passes through the column at a different rate, depending on the number of pores
entered, resulting in larger proteins being eluted before smaller proteins.
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A SuperdexTM 200 10/300 GL gel filtration column (GE Healthcare Life Sciences) was
washed with 150 mL of storage buffer at 0.5 mL/min on an A¨KTA Pure 25 L (GE Health-
care Life Sciences) FPLC system. The column was then calibrated using protein markers
(Table 7.10, 2 mg of each marker, 150 mL of wash buffer), before up to 1 mL of protein
was injected. The column was then washed with a further 150 mL storage buffer and the
eluted volumewas collected in 5mL fractions. The chromatogramwas recorded and used
to determine which fraction contained the eluted protein and the corresponding fractions
were concentrated and stored (as above). Calibration of a SuperdexTM 200 10/300 GL
gel filtration column (GE Healthcare Life Sciences) was carried out in the same way with
the Gel Filtration Markers Kit for Protein Molecular Weights 6,500 - 66,000 Da (Sigma
Aldrich). Elution times of each marker are displayed in Table 7.11.
Table 7.10. Protein markers used to calibrate the GE Healthcare Life Sciences SuperdexTM 200 10/300 GL gel filtration
column.
Protein marker Molecular weight (kDa) Elution volume (mL)
Thyroglobulin 660 46
Apoferritin 481 50
β-amylase 200 64
Bovine serum albumin (BSA) 66 76
Lysozyme 14.3 109
Table 7.11. Protein markers used to calibrate the GE Healthcare Life Sciences SuperdexTM 75 10/300 GL gel filtration
column.
Protein marker Molecular weight (kDa) Elution volume (mL)
Blue Dextran 2,000 45.2
Bovine serum albumin (BSA) 66 54.3
Carbonic Anhydrase 29 68.5
Cytochrome C 12.4 80.6
Aprotinin 6.5 96.5
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7.3.10 Anion exchange chromatography
A HiTrap Q HP (Q Sepharose®, GE Healthcare Life Sciences) was used to further pu-
rify proteins. A 5 mL syringe was used to pass samples through the column, before 10
mL of storage buffer was used to wash off the sample not bound to the column. AEX
buffers were then passed through the column (5mL)with increasingNaCl concentrations.
Each fraction was collected separately and the location of the protein was determined by
SDS-PAGE gel electrophoresis, before the corresponding fractions were concentrated and
stored (as above).
7.3.11 Buffer exchange and lyophilisation
A PD10 desalting column (GE Healthcare Life Sciences) was used to transfer protein to a
new buffer. The column was washed with 10 mL of the new buffer before up to 2.5 mL of
sample was embedded in the column. 10 mL of the replacement buffer was then washed
through the column and 0.5 mL fractions were collected. The absorbance of the fractions
were then measured using a NanoDrop Lite Spectrophotometer (Thermo Scientific) and
peaks were run on an SDS-PAGE gel to confirm which contained the protein. Fractions
containing the proteins were then concentrated using a Vivaspin® 20 Ultra Centrifugal
Filter column (3, 5, 10, 30, 50 or 100 kDa MWCO, GE Healthcare Life Sciences).
Samples requiring lyophilisation were first transferred into dH2O. Fractions were con-
centrated (as above) to a volume of less than 1 mL and transferred to a 1.5 mL Eppendorf
tube. The lid was opened and a layer of parafilm placed over the opening. The parafilm
was then pierced several times and the sample was flash frozen in liquid nitrogen. All
flasks connected to the VirTis BechTopTM K were then isolated and a 600 mL VirTisTM
flask containing the Eppendorf was connected to a free valve. All flasks were then recon-
nected to the instrument and the sample was left overnight to freeze-dry.
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7.3.12 Homologymodelling of domains, structural features
and protein complexes
All homologymodels in this study were constructed using the Phyre2 server. The utilised
templates were chosen by Phyre2’s algorithms.
7.4 Analytical techniques
7.4.1 MALDI-TOF
MALDI-TOFwas used to confirm themasses of proteins and peptides. A saturated sinap-
inic acid solution was prepared in 50 % acetonitrile and mixed (1:1) with the sample. A
target on a plate (Bruker MTP 384 target plate ground steel T F) was spotted with 0.5 µL
of the solution. Samples were then examined using an Autoflex speed MALDI-TOF/TOF
spectrometer (Bruker, see manual for settings).
7.4.2 Identifying the location of posttranslational modifi-
cations using peptide mass fingerprinting
Intact proteins were trypsin digested (7.3.6) and the resulting peptides were examined us-
ing MALDI-TOF (7.4.1). The masses of both the digested protein and the digested protein
with PTMswere then compared with the theoretical masses of the enzymatically digested
protein (ExPaSy PeptideCutter) to confirm the location(s) of PTMs.
7.4.3 Liquid Chromatography Quadrupole Time Of Flight
(LC-QTOF) of intact proteins
All mass spectrometry measurements described in this study were performed using a
maXis II superscriptTM (Bruker Daltronics) or an amaZon X (Bruker Daltronics) LC/MS.
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Both instruments utilise electrospray ionisation (ESI) to produce ions by applying a high
voltage to a liquid to produce an aerosol.
Samples were diluted to 4 µMwith sterile water and 100 µL was placed inside an LC/MS
vial (Agilent). The protocol was run with the following conditions:
Table 7.12. LC/MS running conditions.
Time (minutes) Buffer A Buffer B
0 95 % 5 %
10 95 % 5 %
30 0 % 100 %
40 0 % 100 %
40 95 % 5 %
50 95 % 5 %
Parameter MaXis II AmaZon X
Column type C4 C3
Prerun (minutes) 15 5
Injection volume (µL) 2 50
Flow rate (mL/min) 0.05 1.0
LC wavelength (nm) 190 - 400 254
MS range (m/z, Da) 195 - 3,000 100 - 3,000
The MaXis IITM (Bruker) was used with an ACE 3 C4-300 column (2.1 x 100 mm) and the
amaZon X with a ZORBAX 300SB-C3 column (4.6 x 150 mm). A blank sample containing
LC/MS buffer A was run before and after each set of samples.
The LC chromatogram was then used to identify the retention time of the proteins. The
relevant peak was selected and the corresponding MS spectra were deconvoluted using
Compass DataAnalysis 4.1’s (Bruker) maximum entropy deconvolution algorithm.
7.4.4 LC-QTOF of ejected ions
Samples were diluted to 10 µMwith sterile water and 100 µLwas placed inside an LC/MS
vial (Agilent) before 1 µL was injected into the maXis IITM (Bruker). Running conditions
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were as above (Table 7.4.3). Compass DataAnalysis 4.1 (Bruker) was to produce an ex-
tracted ion chromatogram (EIC) for the expected mass of the ejected ion (± 0.05 Da).
7.4.5 Circular dichroism
Circular dichroism (CD) was used to examine the secondary structure of proteins and to
determine at which temperatures and pH they were stable. A 450 µL sample was pre-
pared (approximately 0.1 mg/mL of protein) by diluting in CD buffer. Samples were
then placed inside a 1 mm cuvette. The spectra were taken from 260 - 190 nm using the
JASCO-1500 spectrometer with a Peltier type cell holder (PTC-423L) to allow for variable-
temperature measurements. D.I.T was set to 1 second and the bandwidth as 1.0 nm, with
a data pitch of 0.2 nm and a scanning speed of 100 nm/min. For each sample, 8 acquisi-
tions were taken. The spectra were then accumulated, with a reference sample containing
only buffer subtracted for calibration.
7.4.6 Variable-temperature CD
Samples were prepared (as above) and a small amount of oil was added to prevent evap-
oration upon heating. Four spectra were taken for each temperature in 10 ◦C increments
from 10 ◦C to 70 ◦C and back down to 10 ◦C. The spectra for each temperature were then
accumulated, with a reference sample containing only buffer subtracted for calibration.
7.4.7 Solution NMR spectroscopy
Nuclear Magnetic Resonance (NMR) was independently developed by Felix Bloch and
Edward Mills Purcell,192;193 resulting in their sharing of the 1952 Nobel Prize in Physics.
It uses the fact that all nuclei have a charge and most have an intrinsic property, known
as spin, that causes them to behave as a magnet and therefore align under a static mag-
netic field. The spin of each proton and neutron within an atomic nucleus contribute to
its overall spin. If the spins are paired against each other, such as in 12C, then the atomic
nucleus does not possess an overall spin. However, if the spins are unpaired, such as in
1H, 13C and 15N, then the atomic nucleus possesses an overall spin and can produce a
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dipole moment (⃗µ):
µ⃗ =∑
i
qi⃗ri,
where qi is the magnitude of the i
th charge and r⃗i is the position of the i
th charge.
If a magnetic field, B0, is applied to a sample containing isotopes of odd nucleon mass
(spin = 12) then each nucleus aligns with or against the magnetic field. The ratio of nuclei
aligning with the field is described by the Boltzmann distribution:
pi =
exp(−ϵi/kT)
∑
M
j=1 exp
(
−ϵj/kT
) ,
where pi is the probability of the system being in state i, T is the temperature, M is the
number of accessible states, k is the Boltzmann constant and ϵi is the energy state of i.
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The direction of B0 is designated as z and no NMR signal is generated whilst B0 is in
equilibrium along the z-direction. To generate an NMR signal, the equilibrium must be
perturbed by the application of a second magnetic field in the form of a radio frequency
(RF) pulse. The frequency of the RF pulse is known as the Larmor frequency and the
direction of the pulse is designated as the x-direction. This causes the magnetisation to
precess around the z-direction and move towards the y-direction (Figure 7.4). The angle
at which the magnetic field perturbs is dependent on both the strength and length of the
RF pulse.
Figure 7.4. A magnetic field may be perturbed by an RF pulse.
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Upon termination of an RF pulse, the magnetic moment relaxes towards the z-direction.
This results in NMR signals becoming weaker and broader over time. The NMR signal in-
tensity may be plotted over time (free induction delay, FID), resulting in the signals being
displayed by overlapping sine curves. This may be resolved by Fourier transformation
of the FID, resulting in a spectrum in which each peak represents a Larmor frequency of
a single nucleus. Modern-day NMR programmes use sequences of pulses to manipulate
the nuclei and elucidate the required information.195
The RF pulse also causes an energy transition from the base energy to a higher energy
level. The spin then returns to the base level, emitting energy at the resonant frequency
(v), which is dependent on the effective magnetic field at the nucleus. This can be affected
by proximal electrons shielding the nucleus from magnetism. The effect of the shielding
leads to a perturbation in the frequency. This is measured against the Larmor frequency
(v0) to give the chemical shift (δ):
δ =
(v− v0)
v0
· 106.
The concentrated proteins were prepared to 100 - 500 µM in 50 mM phosphate buffer pH
6.5, 5 % D2O and 0.6 µL of 0.1 M DSS. 600 µL of the solution was pipetted into an NMR
tube. An Avance II-700 NMR (AV TwinBay 5 Channel 700) spectrometer was used to
acquire all spectra with a 16.45 Tesla ultra-shielded superconducting magnet (700 MHz)
and triple resonance cryoprobe (Bruker). The proton resonance frequency was 700.24
MHz and the operating temperature for each experiment was 298 K, unless otherwise
stated.
Samples were locked against the deuterium signal, before shimming, matching and tun-
ing were performed. Spectra were acquired by taking 32 scans for each condition, un-
less otherwise stated. All results were processed with Bruker TopSpin™ and NMRFAM-
SPARKY.196
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7.4.8 Negative-stain electron microscopy
A 5 µL sample of 25 mg/mL protein was placed on a clean microscopic slide, before 5
µL of uranyl acetate was applied. The plate was left to air dry (1 minute) before images
were acquired using a Jeol 2010F transmission electron microscope (Ian Hands Portman).
Results were analysed using ImageJ version 1.48.197;198
Further negative-stain images were obtained at the Beckmann Lab, Genzentrum, LMU
(O. Berninghausen) using a 100kV Morgagni microscope, equipped with a side-mounted
SIS Megaview 1K CCD camera. Samples were prepared and analysed (as above).
7.4.9 Cryogenic-electron microscopy
Samples were then vitrified using a Vitrobot™ and cryo-EM data was acquired using a
120 kV SPIRIT transmission electron microscope (Tecnai) with an Eagle 2K CCD camera
(pixel size of 30 µm).
7.4.10 Surface plasmon resonance
Biacore T2000 surface plasmon resonance (SPR) and Biacore T200 instruments were used
to immobilise ligand and collect kinetic data of their interactions with analytes. Ligand
proteins were diluted in 10 mM sodium acetate (pH 5.5) and immobilised on a CM5 chip
(Biacore T2000) or an S-series CM5 chip (Biacore T200) by amine coupling using 1-Ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC), N-hydroxysuccinimide (NHS) and ethanol-
amine (Figure 7.5). A blank lane was also deactivated, allowing for subtraction of a base-
line.
Analyte proteins were then serially diluted in HEPES buffered saline (HBS) and a range
of concentrations were run over the CM5 chip lanes with an immobilised ligand and a
blank. Data was observed and edited using the Biacore evaluation software. The soft-
ware was also used to create mathematical kinetic fits to acquired data, with a 1:1 binding
model chosen. All kinetics were calculated from a range of concentrations (1.25 - 20 µM),
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Figure 7.5. Ligand immobilisation to the surface of a chip. EDC/NHS activates the carboxyl group (a) before the ligand
is covalently attached to the surface (b). Ethanolamine then deactivates the remaining esters (c). R1 = CH2 CH3, R2 =
(CH2)3 N+H (CH3)2 Cl-.
with each sample run in triplicate. Errors given correspond to one standard deviation.
7.5 Biophysical assays
The following assays were all examined using the maXis IITM (Bruker) following the pre-
viously described protocols.
7.5.1 Conversion of recombinant ACPs from apo to holo-
forms
Apo-ACPs were posttranslationally modified to holo-ACPs using a surfactin phosphopan-
tetheinyl transferase (Sfp, a phosphopantetheinyl transferase (PPTase) from B. subtilis),
MgCl2 and coenzyme A (CoA-SH). 50 µL aliquots of apo-ACPs were pipetted into a 1.5
mL Eppendorf. Samples were then diluted to final concentrations of 200 µM apo-ACP,
10 mM MgCl2, 10 µM Sfp, 0.5 mM CoA-SH and 100 mM Tris-HCl (pH 7.5) with storage
buffer. The reaction was then incubated (30 minutes, room temperature), after which con-
version was confirmed by LC-QTOF (previously described method).
147
7.5.2 Conversion of recombinant ACPs from apo to acyl-
holo-forms
A range of acyl-substrates were attached to apo-ACPs using the following method. The
type of acyl group attached to the phosphopantetheine arm was dependent on the type
of acyl-CoA used.
50 µL aliquots of apo-ACPs were pipetted into a 1.5 mL Eppendorf. Samples were then
diluted to final concentrations of 200 µM apo-ACP, 10 mM MgCl2, 10 µM Sfp, 0.5 mM
acyl-CoA and 100 mM Tris-HCl (pH 7.5). Dilutions were carried out with storage buffer.
The reaction was then incubated (2 hours, room temperature), after which conversion
was confirmed by LC-QTOF (Table 7.4.3).
7.5.3 Acyl-transfer fromM3/M4 ACP to M5
The reaction mixtures from 7.5.2 were mixed with an equimolar concentration of M5 (un-
less otherwise stated) and diluted with storage buffer to a final concentration of 50 µM of
each protein. The assays were then incubated (overnight, room temperature) and anal-
ysed by LC-QTOF (Table 7.4.3). Samples that were collected at time points before acyl-
transfer was likely to have completed were immediately frozen at −80◦ C to prevent
further transfer occurring.
7.5.4 Direct competition assay of acyl-transfer fromM3 ACP
and 4 ACP to M5
Octanoyl/decanoyl-holo-M3 ACP and M4 ACP were prepared (as described in 7.5.2).
Both reactions were mixed in equimolar amounts and diluted to contain 100 µM of each
ACP with storage buffer. M5 was diluted to 100 µM with storage buffer and equal
amounts of each sample were then mixed such that the final concentration of each ACP
and M5 was 50 µM. The sample was incubated (overnight, room temperature) and anal-
ysed by LC-QTOF (Table 7.4.3).
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7.5.5 The loading of acyl-substrates onto M5’s KS domain
and the subsequent extension of a malonyl-derived
extender unit
48 µL of the reactant from 7.5.1 was mixed with 1µL of (methyl)malonyl-CoA (20 mM)
and 1 µL of acyl-S-N-acetylcysteamine (SNAC, 20 mM). The extended product depends
both on the acyl-SNAC loaded onto the KS of M5 and the malonyl-derived extender unit
utilised by the AT of M5. The reactions were then incubated (overnight, room tempera-
ture) to test the ability of M5 to catalytically transfer and extend each of these substrates,
after which extended products were detected by LC-QTOF (Table 7.4.3).
7.5.6 KS-ACP cross-linking between ACPs and truncated
M5 constructs
Cross-linking of M3 ACP, M3 ACPT, M4 ACP, M4 ACPT and M5 ACP with both full
length and truncated M5 constructs was achieved by first attaching a ppant cross-linker
to the apo-ACP before adding M5 in a 2:1 molar ratio (ACP:M5). Each apo-ACP was trans-
ferred to a 1.5 mL Eppendorf. Attachment of a pantetheine cross-linker to the ACP was
then achieved bymixing the ACPwith the following constituents tomake a 50 µL reaction
with the final concentrations as follows: apo-ACP (140 µM) with a pantetheine-derived
KS-AT cross-linker (0.8 mM), PanK (250 µM), PPAT (250 µM), DPCK (250 µM), MgCl2 (10
µM), Sfp (500 µM) and ATP (2 mM). After incubating (2 hours, room temperature), the
increase in mass was confirmed by LC-QTOF.
The cross-linking of the pantetheine-loaded ACP to the KS of M5 was then achieved by
adding 50 µL of M5 (140 µL) to the reaction mixture, resulting in a reaction mixture con-
taining the ACP and M5 in a 2:1 molar ratio. The reaction was then incubated (overnight,
room temperature) and cross-linking was confirmed using SDS-PAGE gel electrophoresis
and LC-QTOF.
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7.5.7 AT-ACP cross-linking between ACPs and truncated
M5 constructs
Attempts at cross-linking of M5 ACP with M5 KSAT-C207A/S656C, via the AT active
site, was achieved using the same method as described in 7.5.6.
7.6 Synthesis of SNAC and pantetheine-
bound substrates
The following work was carried out by Matthew Beech, Christian Hobson, Joleen Mass-
chelein and Zhou Shanshan.
7.6.1 Synthesis of protected pantetheines
Pantetheine was synthesised by Matthew Beech using the following method.
5 g of D-pantothenic acid hemicalcium salt was mixed with 1.2 equivalents of p-toluene
sulfonic acids (pTSA) in a 1 L round bottom flask. 250 mL of acetone was added and the
flask was evacuated with argon and stirred (overnight, room temperature). The resulting
slurry was filtered over celite and acetone was removed in a vacuum, yielding a yellow
oil. The oil was dissolved in 50 mL of EtOH and washed with brine (3 x 50 mL) before
being dried over MgSO4 and concentrated in a vacuum, yielding a white solid. After dry-
ing under a high vacuum overnight a yield of 4.029 g was achieved with 89.9 % purity
(Figure 7.6).
HRMS:m/z calculated for C12H21NO5Na [M
+Na]+ = 282.1312 Da, found: 282.1309 Da.
1H NMR (500 MHz, CDCl3) δ: 7.05 (bs, 1H, H-10), 4.12 (s, 1H, H-8), 3.71 (d, 1H, 2 J = 12.0,
H-4a), 3.66-3.58 (m, 1H, H-11a), 3.56-3.48 (m, 1H, H-11b), 3.31 (d, 1H, 2 J= 12.0, H-4b), 2.65
(t, 1H, 3 J = 6.5, H-12), 1.49 (s, 3H, H-1/2) 1.45 (s, 3H, H-1/2), 1.06 (s, 3H, H-6/7), 1.00 (s,
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Figure 7.6. (R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid.
3H, H-6/7).
13C NMR (125 MHz, CDCl3) δ: 175.7 (C-13), 170.2 (C-9), 99.3 (C-3), 77.2 (C-8), 71.5 (C-4),
34.1 (C-11), 33.9 (C-12), 33.0 (C-5), 29.4 (C-1/2), 22.0 (C-6/7), 18.9 (C-6/7), 18.7 (C-1/2).
3 g of the resulting product was placed in a 250 mL round bottom flask with 1.1 equiv-
alents of carbonyldiimidazole (CDI). The flask was evacuated with argon and 50 mL of
anhydrous tetrahydrofuran was added by cannula. The reaction was stirred for one hour
before cysteamine-HCl was added. The flask was then evacuated with argon and stirred
(overnight, room temperature). The solvent was then removed by vacuum, the product
was redissolved in dichloromethane and washed with saturated NH4Cl (2 x 50 mL) and
brine (2 x 50 mL). The organic phase was dried over MgSO4 and concentrated to give an
amorphous solid. The product was then purified by thin layer chromatography (TLC) in
100 % ethyl acetate, yielding 1.701 g of product with 80 % purity (Figure 7.7).
Figure 7.7. (R)-N-(3-((2-mercaptoethyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamide.
HRMS:m/z calculated for C14H26N2O4SNa [M
+Na]+ = 341.1505 Da, found: 341.1505 Da.
1H NMR (500 MHz, CDCl3) δ: 7.01 (bs, 1H, H-10), 6.25 (bs, 1H, H-14), 4.09 (s, 1H, H-
8), 3.69 (d, 1H, 2 J = 12.0, H-4a), 3.63-3.50 (m, 2H, H-11), 3.50-3.36 (m, 2H, H-15), 3.28 (d,
1H, 2 J = 12.0, H-4b), 2.69-2.63 (m, 2H, H-16), 2.47 (dt, 2H, 3 J = 6.0, 2.0, H-12), 1.46 (s, 3H,
H-1/2), 1.42 (s, 3H, H-1/2), 1.37 (t, 1H, 3 J = 8.5, H-17), 1.04 (s, 3H, H-6/7), 0.97 (s, 3H,
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H-6/7).
13C NMR (125 MHz, CDCl3) δ: 171.1 (C-13), 170.4 (C-9), 99.2 (C-3), 77.2 (C-8), 71.5 (C-4),
42.5 (C-15), 36.2 (C-12), 34.9 (C-11), 33.0 (C-5), 29.5 (C-1/2), 24.6 (C-16), 22.2 (C-6/7), 19.0
(C-6/7), 18.7 (C-1/2).
7.6.2 Synthesis of pantetheine bound substrates
The previously synthesised pantetheine (Figure 7.6.1) was coupled to decanoic acid and
dodecanoic acid using the following procedure.
50 mg of Figure 7.6.1, 45.2 mg of EDC and substrates (32.4 mg decanoic acid or 37.6 mg
dodecanoic acid) were dissolved in dichloromethane (DCM) under argon. 56 µL of N,N-
Diisopropylethylamine (DIPEA) was added and the mixture was stirred overnight. After
dilution in 5 mL of DCM, the mixture was washed with a 1 M HClNaHCO3 solution.
The solvents were then dissolved under vacuum and dried under HI-VAC. The products
were then purified by TLC in 100 % acetate and fractions were dried under HI-VAC to
yield 15 mg (decanoic) and 24 mg (dodecanoic) of compound (Figure 7.8).
Figure 7.8. (R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl) (do)decanethioate.
(R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl)
decanethioate
HRMS:m/z calculated for C24H45N2O5SNa [M
+Na]+ = 495.2863 Da, found: 495.2863 Da.
1H NMR (500 MHz, CDCl3) δ: 6.95 (s, 1H, H-10/14), 4.01 (s, 2H, H-15), 4.79 (m, 1H,
H-8), 3.59-3.64 (d, 2H, 2 J = 12.5, H-11b), 3.57-3.30 (m, 2H, H-4), 3.24-3.19 (d, 2H, 2 J = 12.0,
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H-11a), 2.96-2.92 (t, 2H, 3 J = 6.5, H-16), 2.51-2.47 (t, 2H, 3 J = 12.5, H-12), 2.37-2.34 (t, 2H,
3 J = 6.0, H-19), 1.50 (s, 2H, H-20), 1.20-1.17 (m, H1/2/21-26),0.97 (s, H3, H-6/7/27), 0.90
(s, H3, H-6/7/27), 0.81 (t, H3, 3 J = 7.0, H-6/7/27).
13C NMR (125MHz, CDCl3) δ: 200.0 (C-18), 92.5 (C-8), 71.4 (C-4), 44.2 (C-19), 39.6 (C-12),
36.0 (C-16), 34.8 (C-5), 31.8 (C-25), 29.7-28.5 (C-20 to C-24), 25.6 (C-1/2), 22.7 (C-26), 16.9
(C-6/7).
(R)-S-(2-(3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propanamido)ethyl)
dodecanethioate
HRMS:m/z calculated for C26H48N2O5SNa [M
+Na]+ = 523.3175 Da, found: 523.3178 Da.
1H NMR (500 MHz, CDCl3) δ: 8.01 (s, 1H, H-10/14), 7.99 (s, 1H, H-10/14), 4.10 (s, 1H,
H-8), 3.87 (s, 2H, H-15), 3.71-3.69 (d, 2H, 2 J = 11.5, H-11b), 3.64-3.56 (m, 2H, H-4), 3.32-3.29
(d, 2H, 2 J = 11.5, H-11a), 3.05-3.01 (t, 2H, 3 J = 6.5, H-16), 2.61-2.56 (t, 2H, 3 J = 8.0, H-12),
2.46-2.42 (t, 2H, 3 J = 6.0, H-19), 1.61 (s, 2H, H-20), 1.29-1.27 (m, 2H, H-1/2 and H-21 to
H-28), 0.92-0.89 (t, 3H, 3 J = 7.0, H-6/7/29).
13C NMR (125 MHz, CDCl3) δ: 199.9 (C-18), 171.2 (C-13), 170.2 (C-9), 114.6 (C-3) 99.0 (C-
8), 71.4 (C-4), 44.2 (C-19), 39.6 (C-12), 38.6 (C-11), 36.0 (C-15), 34.8 (C-16), 33.0 (C-5), 31.9
(C-27), 29.8-28.4 (C20-26), 25.6 (C1/2), 22.7 (C28), 18.9 (C6/7), 18.7 (C6/7), 14.1 (C-29).
7.6.3 Deprotection of the SNAC / pantetheine-bound sub-
strates
The protected pantetheines (7.6.2) were diluted in 0.5 mL of tetrahydrofuran (THF) and
10 mL of rubidium fluoride (RBF). 0.5 mL of H2O and 1 mL of acetic acid were added and
the mixture was stirred (72 hours). Solvents were removed under vacuum at 45 ◦C and
the compound was purified by TLC in 5 %methanol in DCM. The removal of solvent un-
der vacuum yielded 6.5 mg (decanoyl pantetheine) and 58 µg (dodecanoyl pantetheine,
Figure 8.2).
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Figure 7.9. (S)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) (do)decanethioate.
(S)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) decanethioate
HRMS:m/z calculated for C21H40N2O5SNa [M
+Na]+ = 455.2550 Da, found: 455.2553 Da.
1H NMR (500 MHz, CDCl3) δ: 7.32 (s, H1, H-8/12), 6.23 (s, 1H, H-7), 5.23 (s, H1, H-
1), 3.93 (s, H1, H-3/6), 3.52-3.47 (m, 2H, H-2), 3.42 (s, H1, H-13), 3.35-3.27 (m, 2H, H-9),
3.01-2.89 (m, 2H, H-14), 2.52-2.48 (t, 2H, 3 J = 7.5, H-10), 2.37-2.33 (t, 2H, 3 J = 7.0, H-17),
1.61-1.52 (m, 2H, H-18), 1.26-1.17 (m, 2H, H-19 to H-24), 0.83-0.80 (m, 3H, H-4/5/25).
13C NMR (125 MHz, CDCl3) δ: 14.1 (C-27), 20.4 (C-6/7), 21.7 (C-6/7), 22.7 (C-26), 25.6
(C-20), 28.3-29.3 (C-21 to C-24), 31.8 (C-25), 35.2 (C-16), 35.6 (C-15), 39.4 (C-11), 39.7 (C-12),
44.2 (C-19), 70.9 (C-4), 77.3 (C-8), 171.7 (C-13), 173.6 (C-9), 200.5 (C-18).
(S)-S-(2-(3-(2,4-dihydroxy-3,3-dimethylbutanamido)propanamido)ethyl) dodecanethioate
HRMS: m/z calculated for C23H44N2O5SNa [M
+Na]+ = 483.2863 Da, found: 483.2863 Da.
1H NMR (500 MHz, CDCl3) δ: 7.37(bs, 1H, H-8), 6.17 (bs, 1H, H-12), 4.02 (s, 1H, H-6),
3.62-3.58 (m, 1H, H-4,H-9), 3.55-3.48 (m, 1H, H-2/13), 3.11-2.99 (m, 2H, H-14), 2.61-2.57 (t,
2H, 3 J = 7.0, H-10), 2.45-2.42 (t, 2H, 3 J = 6.0, H-17), 1.70-1.63 (m, 2H, H-18), 1.28-1.23 (m,
16H, H-19 to H-26), 1.05 (s, 3H, H-4/5), 0.95 (s, 3H, H-4/5), 0.89-0.92 (t, 3H, 3 J = 7.0, H-27).
13C NMR (125 MHz, CDCl3) δ: 200.5 (C-18), 173.5 (C-13), 171.7 (C-9), 77.3 (C-8), 71.0
(C-4), 44.2 (C-19), 39.7 (C-12), 35.6 (C-11), 35.1 (C-15), 32.0 (C-17), 28.3-29.6 (C-21 to C-26),
25.7 (C-20), 22.7 (C28), 21.7 (C-6/7), 20.4 (C-6/7), 14.1 (C-29).
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7.6.4 Production of SNACs
The following SNAC-bound substrates were provided by various members of the Challis
group. All NMR assignments and mass spectrometry data were obtained by the group
members who produced the corresponding substrates.
S-(2-acetamidoethyl) 5-methyl-3-oxohexanethioate
HRMS: m/z calculated for C11H19NO3SNa [M
+Na]+ = 268.0978 Da, found: 268.0985 Da.
1H NMR (400 MHz, CDCl3) δ: 12.55 (br s, 1H, O-H), 6.23 (br s, 1H, N-H), 5.40 (s, 1H,
H-5), 3.65 (s, 2H, H-5’), 3.42 (t, 2H, 3 J = 6.0, H-6), 3.05 (t, 2H, 3 J = 6.0, H-7), 2.37 (d, 2H, 2 J
= 7.0, H-3), 2.11 (m, 1H, H-2), 1.99 (br, s, 2H H-3), 1.94 (s, 3H, H-10), 0.89 (d, 6H, 2 J = 6.5,
H-1).
13C NMR (100 MHz, CDCl3) δ: 194.08 (C-4’), 176.54 (C-6), 170.51 (C-9), 170.36 (C-9’),
100.04 (C-5’), 57.45 (C-5), 52.10 (C-3), 43.95 (C-3’), 39.74 (C-8’), 39.04 (C-8), 29.04 (C-7),
27.67 (C-7’), 26.33 (C-2), 24.23 (C-10), 22.29 (C-1).
S-(2-acetamidoethyl) 3-oxooctanethioate
HRMS: m/z calculated for C12H21NO3SNa [M
+Na]+ = 282.1134 Da, found: 282.1147 Da.
1H NMR (400 MHz, CDCl3) δ: 12.59 (br s, 1H, O-H), 6.02 (br s, 1H N-H), 5.45 (s, 1H,
H-7’), 3.68 (s, 2H, H-7), 3.48-3.42 (m, 2H, H-10), 3.09-3.05 (m, 2H, H-9), 2.51 (t, 2H, 3 J = 7.5,
H-5), 2.16 (t, 2H, 3 J = 7.5, H-5’), 1.96 (s, 3H, H-12), 1.58 (q, 2H, 5 J = 7.0, H-4), 1.31-1.24 (m,
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4H, H-2/3), 0.90-0.86 (m, 3H, H-1).
13C NMR (100 MHz, CDCl3) δ: 194.24 (C-6’), 177.63 (C-8), 170.41 (C-11), 99.09 (C-7’),
57.14 (C-7), 43.37 (C-5), 39.86 (C-5’), 39.14 (C-10), 34.82 (C-10’), 31.19 (C-9’), 31.07 (C-9),
29.17 (C-3), 27.78 (C-3’), 25.86 (C-4’), 23.11 (C-12), 23.05 (C-4), 22.32 (C-2), 22.28 (C-2’),
13.82 (C-1).
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Constructs
All constructs contain the followingN-terminalHis-Tag: MHHHHHHGKPIPNPLLGLDSTENLYFQGIDPFT
QMNM3 ACP (Dr. Orestis Lazos)
LLDLVTTTVAEVLGHAGTDGIDADRGLLAMGFDSLTAVEFRNRLAAETGLRLPSTLVFNHPTPGAIAEFL
RAQLAPEPTDELDRLAADLSTMDPERQAAVLGRMAELLHKWNTNGTGNGASADLDSLSDEELFDALD
EELGQR
QMNM3 ACPS
LLDLVTTTVAEVLGHAGTDGIDADRGLLAMGFDSLTAVEFRNRLAAETGLRLPSTLVFNHPTPGAIAEFL
RAQLAPEPTD
QMNM4 ACP (Dr. Orestis Lazos)
LLIDVVRGHVATVLGHTDPDTIPTEKAFKELGFDSLTAVELRNRLTAATGLRLPATLVFDHPTLAGLAGYM
RAELAPRTEEPDPASAVLERLAELEEALAGLSDPRIADRLRELLAVAGGTDPGLGSASADELFDFIDGKLG
RKVETA
QMNM4 ACPS
LLIDVVRGHVATVLGHTDPDTIPTEKAFKELGFDSLTAVELRNRLTAATGLRLPATLVFDHPTLAGLAGYM
RAELAP
QMNM5 ACP (residues 1199-1292 of M5)
ATGAEQEQLLTELVRFHASDVLGHASPEAIGVEDSLLDHGFSSFAALELSNRLQAASGVQIPPVAIYDQPT
LGAVITHLRDALAAEPS
QMNM5 KS (residues 1-444 of M5)
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A mutation was carried out on the KS active-site (C207A).
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVE
QMNM5 KSATS (residues 1-888 of M5)
Mutations were carried out on the KS active-site (C207A) and the AT active-site (S656C).
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGAR
QMN KSAT∆283 (residues 1-915 of M5)
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
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ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VD
QMN KSAT∆136 (residues 1-1062 of M5)
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAEL
QMN KSAT∆72 (residues 1-1126 of M5)
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
171
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVR
EALAPL
QMN KSAT∆60 (residues 1-1138 of M5)
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVR
EALAPLDELTAMVFVFTS
QMN KSAT∆38 (residues 1-1160 of M5)
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MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVR
EALAPLDELTAMVFVFTSATRSPAQASATAWARRRGAVVV
QMN KSAT∆21 (residues 1-1177 of M5)
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVR
EALAPLDELTAMVFVFTSATRSPAQASATAWARRRGAVVVVVVAWDGVAPSAVGLVLRQG
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QMNM5 KSAT (residues 1-1198 of M5, Dr. Matthew Jenner)
Mutations were carried out on the KS active-site (C207A) and the AT active-site (S656C).
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVR
EALAPLDELTAMVFVFTSATRSPAQASATAWARRRGAVVVVVVAWDGVAPSAVGLVLRQGAAAPDVVAEL
SASVPAPAVAP
QMNM5 (Dr. Orestis Lazos) KS-AT-ACP
Mutations were carried out on the KS active-site (C207A) and the AT active-site (S656C).
MSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEPIAVVAMSCRYPHGVTSPEELWELVASGRDAIA
DFPADRGWPADVYDPDPDRRDRPHAGGFLYDAADFDPGFFGISPREAPAIDPQQRLLLEIAWEAFERAGI
DAESVRGSDTGVFTGVMYGDYGSRLQDRAPQGYESYLGNGSAGSIASGRVAYTFGLEGPAVTIDTACSSSL
VALHLAVQALRQGDCSLALAGGVTVMATPMVFTEFDRQRGLSADGRCKSFAAAADGTGFAEGAGLLLL
ERLSDARRHGHPVLGLVRGTAVNQDGASNGLTAPNGPSQERVIKQALENARVTPSEVDAVEAHGTGTTL
GDPIEAQALLATYGKARGEKPLYLGSIKSNIGHTQAAAGVAGVIKMIMAMRHGELPRTLHVDAPNPLVD
WASGGVSLLTEPAKWQQNGHPRRAGVSSFGISGTNAHVILEQAPPVEPASEPCVAPGPVPWVLSAKSPAA
VQGQAERLLAHLTLNPGLTVADVGHSLATTRTSFSHRAVVFGDRQEELVKGLSGLAHGTPATNLVQGRAT
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GGKTAFVFTGQGSQRPGMGRQLYATYPVFTAELDRVCALFDGLLDRPLLPILFAEPRTPEAALLNRTAYTQ
VALFALETALYRLVESYRVRPSFVAGHSIGELTAAHVAGVLSLEDACVLVAARGRLMESARDDGAMLAIEA
PESAVTPLLDASVSLAAVNGPNAVVLAGDLERVLAIGAEFKAQGVRTKRLTVSHAFHSAHLDPMLDEYRR
IARGLSYSAPRIPVVSTVTGEVADELTSPEYWVRQVRQPVRFLDGMRTLYSSGVRTFVEIGPDAVLAPAMQA
CVPEVDHGVIPALTSRRSEPRTLVTALAKAHVRGVPVDWSAGFSGARRVDLPTYAFQRSRYWLDPEAPSAQ
VDLASAADVLGLTEVQRATLAAWQRRHTWAHRKTWRPLRTVPSPPGTWLVPSGPDRLVEVLRERGAQVV
TAGNAPVDGVLTFDEVDHPAPVWLLTSDADPGYACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPE
VFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVR
EALAPLDELTAMVFVFTSATRSPAQASATAWARRRGAVVVVVVAWDGVAPSAVGLVLRQGAAAPDVVAEL
SASVPAPAVAPDNRLLAATGAEQEQLLTELVRFHASDVLGHASPEAIGVEDSLLDHGFSSFAALELSNRLQA
ASGVQIPPVAIYDQPTLGAVITHLRDALAAEPS
QMNM5 KRD-A (residues 960-1198 of M5)
WLVPSGPDRLVEVLRERGAQVVTAGNAPVDGVLTFDEVDHPAPVWLLTSDADPG/YACDHLVHLPTSPT
DETWERLVDALGSAEPRLAIRGPEVFAEHLERAELDGDWWPDGPVLITGDDELSSWAARWFEEQGVAVV
AEAGPSLAAVVQVVPPEWTPAEVREALAPLDELTAMVFVFTSATRSPAQASATAWARRRGAVVVAWDGV
APSAVGLVLRQGAAAPDVVAELSASVPAPAVAP
QMNM5 KRD-B (residues 1014-1198 of M5)
YACDHLVHLPTSPTDETWERLVDALGSAEPRLAIRGPEVFAEHLERAELDGDWWPDGPVLITGDDELSSW
AARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVREALAPLDELTAMVFVFTSATRSPAQASATAWAR
RRGAVVVAWDGVAPSAVGLVLRQGAAAPDVVAELSASVPAPAVAP
QMNM5 KRD-C (residues 1063-1198 of M5)
DGDWWPDGPVLITGDDELSSWAARWFEEQGVAVVAEAGPSLAAVVQVVPPEWTPAEVREALAPLDELT
AMVFVFTSATRSPAQASATAWARRRGAVVVAWDGVAPSAVGLVLRQGAAAPDVVAELSASVPAPAVAP
QMNM5 KRD-D (residues 1103-1198 of M5)
LAAVVQVVPPEWTPAEVREALAPLDELTAMVFVFTSATRSPAQASATAWARRRGAVVVAWDGVAPSAVG
LVLRQGAAAPDVVAELSASVPAPAVAP
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QMNM3 ACPdd-M5 ddKS
APEPTDELDRLAADLSTMDPERQAAVLGRMAELLHKWNTNGTGNGASADLDSLSDEELFD
ALDEELGQRGNGRRMSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEP
QMNM4 ACPdd-M5 ddKS
APRTEEPDPASAVLERLAELEEALAGLSDPRIADRLRELLAVAGGTDPGLGSASADELFD
FIDGKLGRKVETAMSTGPTEQKLLDYLKWVTTDLDRTRDQLLALEEKASEP
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Known genes from theQMNbiosynthetic
cluster
Table 8.1. The QMN gene cluster and the proposed functions of encoded proteins.
Gene name Length (bp) Proposed function of encoded protein
qmnB 1,413 propionyl-CoA carboxylase
qmnC 753 TE II
qmnD4 966 2-oxoacid dehydrogenase/AT
qmnA1 17,772 PKS (KSQ-AT-ACP-KS-AT-DH-KR-ACP-
KS-AT-DH-KR-ACP-KS-AT-DH-KR-ACP)
qmnA2 5,313 PKS (KS-AT-DH-KR-ACP)
qmnA3 3,876 PKS (KS-AT-KRD-ACP)
qmnE 1,236 unknown
qmnF 1,488 unknown
qmnRg1 255 regulator
qmnG 1,599 PQQ-dependent dehydrogenase
qmnH 1,128 Proposed Diels Alderase
qmnI 1,044 unknown
qmnJ 483 unknown
qmnRs1 1,176 transporter
qmnRs2 681 transporter
qmnK 1,056 unknown
qmnL 456 unknown
qmnM 657 unknown
qmnN 390 unknown
qmnRg2 1,347 regulator
qmnRg1 666 regulator
qmnD5 1,029 3-oxoacyl-ACP synthase III (KS)
qmnD1 1,839 glyceryltransferase/phosphatase
qmnD2 213 ACP
qmnD3 843 2-oxoacid dehydrogenase/AT
qmnO 1,209 cytochrome P450
qmnRg4 2,805 regulator
qmnRg5 2,463 regulator
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NMR andmass spectra for the production
of decanoyl- and dodeconoyl-pantetheine
Figure 8.1. Mass spectra of each step in decanoyl- and dodecanoyl-pantetheine synthesis. (a) Protected pantothenic
acid, (b) protected pantetheine, (c) protected decanoyl pantetheine, (d) protected dodecanoyl-pantetheine, (e) depro-
tected decanoyl-pantetheine, (f) deprotected dodecanoyl-pantetheine.
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Figure 8.2. 1H NMR analysis of decanoyl- (above) and dodecanoyl-pantetheine (below).
179
Sequence alignments
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Figure 8.3. Sequence alignment of QMN M5’s linker region with other AT-ACP regions of spirotetronate PKS final
modules.
Mass spectra
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Figure 8.4. Mass spectra for overproduced proteins characterised in chapter 2.
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